The Effects of Atypical Protein Kinase C on TGFβ Signalling by Gunaratne, Adrian D
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
3-24-2014 12:00 AM 
The Effects of Atypical Protein Kinase C on TGFβ Signalling 
Adrian D. Gunaratne 
The University of Western Ontario 
Supervisor 
Dr. John Di Guglielmo 
The University of Western Ontario 
Graduate Program in Pharmacology and Toxicology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Adrian D. Gunaratne 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Cancer Biology Commons 
Recommended Citation 
Gunaratne, Adrian D., "The Effects of Atypical Protein Kinase C on TGFβ Signalling" (2014). Electronic 
Thesis and Dissertation Repository. 1975. 
https://ir.lib.uwo.ca/etd/1975 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
THE EFFECTS OF ATYPICAL PROTEIN KINASE C ON TGF SIGNALLING 
 
(Thesis format: Integrated Article) 
 
 
 
by 
 
 
 
Adrian Gunaratne  
 
 
 
 
Graduate Program in Physiology and Pharmacology 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Doctor of Philosophy 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Adrian Gunaratne 2014 
 
 
 ii 
 
 
Abstract 
The transforming growth factor beta (TGFβ) signalling pathway is an essential 
regulator of many cellular processes including epithelial growth control, epithelial to 
mesenchymal transition (EMT), apoptosis, and the establishment of developmental fate. 
Alterations in TGF signalling patterns are associated with various pathological disorders 
such as fibrosis and cancer. In recent years it has become clear that regulation of TGF 
signalling is dependent on the trafficking and endocytosis of the TGF receptors, however, 
the factors that control these processes are still under investigation. 
 In this thesis, I examined the role of Protein Kinase C (PKC) in the regulation of 
TGF signalling pathways and found that the Atypical PKC isoforms (aPKC; a subgroup of 
the PKC family) indeed can alter TGF receptor signalling. My work has shown that the 
modulation of aPKC expression or activity using inhibitors and/or small interfering RNA 
(siRNA) prolongs the temporal phosphorylation of the downstream transcription factor 
Smad2 through altered receptor membrane trafficking. Furthermore, I showed that aPKC 
activity and expression alters the phosphorylation and degradation of Par6, which in turn 
affects TGF induced EMT and migration. Finally, I examined global gene expression 
changes in aPKC silenced cells - and related these effects to altered Smad nuclear 
accumulation. Notably, we also found that these cells demonstrate enhanced p38 MAPK 
signalling, which sensitizes them to TGF induced apoptotic response.    
In conclusion, I found that aPKC isoform activity and expression is intricately linked 
to the regulation of various TGF receptor signalling pathways that control gene 
expression, EMT, and apoptosis.  
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1 Introduction 
1.1 Introduction to the TGFpathway  
The transforming growth factor beta (TGF) signalling pathway represents a class 
of molecules that are essential regulators of embryonic development and tissue 
homeostasis. TGF regulates diverse cellular processes including cell differentiation, 
proliferation, migration, apoptosis, and cell plasticity.  
Given the importance of TGF signalling in tissue homeostasis, aberrant 
signalling leads to various pathologies and disorders including diseases of immunity and 
inflammation, cancer, and fibrosis. Paradoxically, TGF can both inhibit, and promote 
cancer, as it acts as a tumour suppressor in the early stages of cancer development, but a 
tumour promoter in late stage cancers.  
It has been over 30 years since TGF was first discovered as a multifunctional 
cytokine[1], and although the general pathways surrounding TGF have been identified, 
it has long been known that the contextual nature of TGF hints at a pathway more 
complicated than the sum of its seemingly simple parts. Since its discovery, researchers 
have uncovered that the pleiotropic nature of TGF is controlled by a network of 
regulators along various points in the pathway that control the activity and outcome of 
TGF signalling; In turn, how this pathway and its various components are regulated, can 
dictate how cells respond to TGF signals.        
Thus, knowledge of the mechanisms that govern the regulation and the signalling 
of this incredibly powerful system are important to increase our understanding of animal 
embryo development, tissue homeostasis, and diseases such as cancer.  
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1.1.1 TGFligands 
The TGFβ superfamily, which includes over 30 cytokine members, are involved 
with the binding and the activation of ser/thr kinase receptors to mediate signalling 
cascades and transcriptional events that control cellular homeostasis and metazoan 
development (reviewed in [2-7]). These structurally related cytokines are characterized 
by 6 conserved cysteine residues and the genes are encoded by 42 open reading frames in 
the human genome [8]. The superfamily is further divided into 2 major subfamilies based 
on sequence similarities and the downstream pathways they activate: specifically the 
TGFActivin/Nodal subfamily and the BMP/GDF/MIS (Bone morphogenetic protein, 
growth and differentiation factor, Muellerian inhibiting substance) subfamily [9].  
TGF was the first discovered member of the superfamily, and is often 
considered the prototype. There are three TGF isoforms in mammals: TGF1, TGF2 
and TGF3. Each isoform is encoded from a different gene, although all activate the 
same receptor system [6]. TGF1 is the major isoform in adults, as its expression is the 
most predominant and ubiquitous, although all three isoforms are expressed during 
development [10, 11]. Of the three ligands TGF1 is also the most frequently upregulated 
in tumor cells and is often the focus of TGF studies in tumorigenesis [3, 12, 13]. 
 TGF ligands are homo-dimeric proteins with each monomer forming several 
extended -strands that interlock through three intrachain disulfide bonds. These 
disulfide bridges form a tight structure common to TGF ligands known as the “cysteine 
knot” [14].  The dimer is stabilized through hydrophobic interactions and also by an 
inter-subunit disulfide bond [14].  
TGF ligand is secreted as an inactive latent complex with two pro-segment 
peptides [15]. The pro-peptide is called the latency-associated protein (LAP) and TGF 
bound to LAP is not recognized by the TGF receptors. LAP also links TGF 
homodimers to latent TGF-binding proteins (LTBPs) through direct disulfide bonds to 
LAP. LTBPs can target the TGF-LAP complex to the cell surface for activation or to the 
extracellular matrix for storage [16-18]. This latency complex mechanism safeguards 
against inadvertent activation and allows for sequestration in the extracellular matrix 
4 
 
(ECM) [3, 6, 7]. Importantly, sequestration of ligand in the ECM allows for a reservoir of 
readily available ligand without the need for synthesis [17, 18].  
The regulated activation process of TGF involves preferential cleavage and 
degradation of the TGF prosegments by activating molecules and proteases. Latent 
TGF can be activated by proteases and ECM proteins such as matrix metalloprotease 2 
(MMP2), matrix metalloprotease 9 (MMP9), plasmin and thrombospondin [19-22]. It is 
important to note that these proteases are often expressed in malignant cells and are 
highly active at sites of cell migration and invasion – giving indication that the activation 
of TGF plays a role in these processes [21, 22].  
Once TGF ligand is activated, it mediates downstream transcriptional events 
through the binding and activation of the TGF receptors.  
 
1.1.2 TGFreceptors 
TGF ligands bind and activate a family of transmembrane proteins known as the 
TGF receptors. There are two major TGF receptor kinase subtypes in the superfamily 
categorized by their structural and functional properties: type I receptors and type II 
receptors. Type I and type II receptors are structurally related glycoproteins consisting of 
a N-terminal extracellular ligand binding domain, a transmembrane domain, and a ser/thr 
kinase domain near the C-terminus [6, 23, 24]. Together, these receptors mediate 
intracellular signals upon activation and are crucial to the mediation of TGF stimulated 
responses.  
There are seven type I and five type II receptors in the human genome, all of 
which mediate TGF signalling [25] (Figure 1.1). The type II receptors consist of: 
ActRII, ActRIIB, TRII, BMPRII and AMHRII [6]. The seven type I receptors were 
originally systematically classified as the activin receptor-like kinases (ALK), thus 
named ALK1-7. As the physiological ligands of the ALK receptors became known, more 
descriptive names were introduced [6]. For example, the Type I TGF receptor (TRI) in 
the prototypical TGF pathway is also known as ALK5 [26, 27].   
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At the cell surface, type II receptors form dimers that bind TGF ligand. Ligand 
binding promotes the binding of type I receptor dimers, thus forming an activated 
ligand/heterotetrameric receptor signalling complex [6, 7]. Classical TGF signalling 
involves type II receptors (TRII) phosphorylating TRI, thereby activating it. Active 
TRI in turn phosphorylates intracellular signalling mediators such as Smads, which 
regulate the transcription of TGF target genes to mediate cellular response (Figure 1.2) 
[23]. 
TRII is a constitutively active ser/thr protein kinase which is found on the cell 
surface as a homodimer in the presence or absence of ligand. TGF ligand enhances the 
formation of heteromeric complexes of TRII homodimers and TRI homodimers 
(reviewed in [2, 28]). Interestingly, overexpression of TRI and TRII can also promote 
the formation of the heteromeric complex without the addition of ligand [29]. Once TRI 
and TRII are in a heteromeric complex, the constitutively active TRII 
transphosphorylates TRI on a unique glycine-serine sequence termed the “GS domain”. 
The GS domain is a thirty amino acid region adjacent to the kinase domain of TRI 
containing a characteristic SGSGSG sequence, and is critical for proper TGF signalling 
[23]. In the basal state, the GS domain of TRI presses against the catalytic center of the 
kinase domain – thereby holding TRI inactive [30]. TRII phosphorylation of the GS 
domain triggers the activation of TRI [30]. The phosphorylated GS domain also acts as 
a docking site for “Smads” the canonical intracellular mediators of TGF signals and 
mutations of serine and or glycine residues in the TRI GS domain can impair TGF 
signalling potential [31].  In addition to the unique GS domain, TRI and TRII have 
several other key differences. TRI has a shorter extracellular domain than TRII and 
does not bind ligand independently [2, 32].  TRII also possesses a ser/thr rich 
intracellular tail, which is not found in TRI [28]. Furthermore, unlike TRII, TRI 
kinase activity is not constitutively active. However, mutational studies have discovered 
that mutation of threonine 204 to aspartic acid locks the kinase in an active state and can 
transduce TGF signals in the absence of ligand [31]. 
A third receptor type, termed the type III receptor, assists in TGF signalling by 
facilitating the presentation of ligand to the type II receptor [33, 34]. There are two type 
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III receptors, known as endoglin, and betaglycan (also referred to as TRIII).  These 
membrane anchored receptors do not have enzymatic activity and are considered 
accessory receptors as TGF signals can still be propagated in their absence [6]. 
Betaglycan can bind all three TGF ligand isoforms with high affinity [35, 36], but is 
most evidently important with TGF2 ligand, which has a low intrinsic affinity for 
binding TRII in the absence of betaglycan [36]. Unlike betaglycan, which shows a 
greater range of expression, endoglin is primarily expressed in endothelial cells, and 
interestingly, does not bind TGF2 [37-39]. Although, thought of as accessory receptors 
that can aid in signalling, type III receptors can also inhibit TGF signalling potential.  
For example, betaglycan’s extracellular domain can be released from the membrane; this 
soluble betaglycan can thereby sequester TGF ligand and inhibit TGF signalling [40]. 
Thus, the exact role of type III receptors is complicated as they can both enhance and 
reduce the signalling potential of TGF isoforms in varying contexts. 
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Figure 1.1.  TGF superfamily signalling components 
The core components of various TGF pathways (vertebrate) are shown in this diagram. 
TGF ligands bind type II receptors, which bind and phosphorylate type I receptors. 
Type I receptors phosphorylate corresponding R-Smads, which bind the common Smad 
(Smad 4) to form a transcriptional complex. I-Smads can inhibit R-Smad signalling by 
competitively binding to type I receptors thereby excluding R-Smads from 
phosphorylation. Shown in bold is the TGF pathway studied in this thesis.  
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1.1.3 Smads  
The Smad family of proteins are the originally identified substrates of the type I 
receptor family and are essential in the co-ordination and regulation of the TGF signal 
transduction process. The Smads were first identified as the gene products of the 
Drosophila MAD gene (Mothers against Decaplentaplegic [DPP]) and the C. elegans 
Sma gene [41-43].  Smads are ubiquitously expressed during development and in all adult 
tissues [44, 45] and the deregulation of Smads are associated with numerous cancers 
(reviewed in [12, 46]). Smads have two highly conserved “Mad Homology” (MH) 
domains: an N-terminal MH1 domain and a C-terminal MH2 domain, which are attached 
by a proline rich “linker” region [6, 23]. 
There are eight mammalian Smads divided into three functional groups: the 
receptor regulated Smads (R-Smad), the common-Smad and the inhibitory Smads (I-
Smad) (Figure 1.1). Upon receptor activation, the type I receptor binds and 
phosphorylates R-Smads, which then oligomerize with the co-Smad to regulate 
transcriptional events at the nucleus. Alternatively, I-Smads can bind the activated 
receptor, thereby blocking R-Smad binding, and subsequently recruiting ubiquitin ligases 
to target the receptor complex for degradation.  
The receptor regulated Smads (R-Smads) consists of Smad1, Smad2, Smad3, 
Smad5 and Smad8. Smad2 and Smad3 are involved in the TGF/Activin pathways, 
whereas Smad1, Smad5 and Smad8 participate in the BMP signalling pathway (Figure 
1.1) [2, 23]. 
The specificity of the various R-Smad and type I receptor interactions is mediated 
by the “L45 loop” in the kinase region of type I receptor and the L3 loop in the MH2 
domains of R-Smads [47].  In the classical TGF pathway, the type I receptor is TRI, 
the primary R-Smad is Smad2, and the I-Smad is Smad7. The phosphorylated GS region 
of activated TRI acts as a docking site for Smad2. This interaction occurs via a 
positively charged surface patch present in the Smad2 MH2 domain [48, 49] and 
mutations in this basic patch of Smad2 limit its binding and activation by TRI [50].     
R-Smads are directly activated by type I receptors through phosphorylation. R-
Smads contain an evolutionarily conserved SSXS motif in their MH2 domain, and the 
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two most C-terminal serine (S) residues become directly phosphorylated by type I 
receptors [6, 23, 51]. Phosphorylated Smad2 dissociates from TRI, and the 
phosphorylated SXS region of Smad2 binds to a positively charged surface pocket on the 
MH2 domain of the co-Smad, Smad4 [23]. The R-Smad-Smad4 heteromeric complex 
then translocates to the nucleus where it binds to promoters of TGF target genes, or 
interacts with various co-activators or co-repressors that ultimately control TGF specific 
transcriptional programs [6, 7]. 
Unlike the R-Smads and co-Smads, which carry TGF signals to the nucleus, I-
Smads (Smad 6 and Smad7) act antagonistically to reduce TGF signal transduction [6, 
7]. Smad7 primarily functions in the TGF/Activin and BMP pathways, whereas Smad6 
preferentially functions in the BMP pathway. The MH1 domains of I-Smads show little 
similarity to the MH1 domains of the R-Smads, but the MH2 domains of R-Smads, co-
Smad and I-Smads are homologous. However, unlike the R-Smads, the I-Smads do not 
contain the characteristic C-terminal SSXS phosphorylation sequence. Lacking the ability 
to be phosphorylated, this allows for I-Smads to stably interact with an activated receptor, 
thereby antagonizing signalling by competing with R-Smads for activated receptor 
binding [6, 7]. Furthermore, I-Smads mediate the interaction between the receptors and 
Smurf 1 and Smurf2 (Smad ubiquitination regulatory factors), which are E3 ubiquitin 
ligases that ubiquitinate and target the receptors for degradation, thereby suppressing 
further TGF signalling [52, 53].  
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Figure 1.2.  Classical TGF receptor activation and signalling 
TGF signalling is initiatied at the cell surface when the TGF type II receptor (TRII) 
binds TGF ligand. Ligand binding promotes the binding of the TGF type I receptor 
(TRI), leading to the formation of an activated ligand/heterotetrameric receptor 
signalling complex. TRII activates TRI by phosphorylating it on its GS domain. The 
active type I receptor in turn phosphorylates intracellular signalling mediators such as 
Smad2, which stimulates the binding of Smad4 to the R-Smad. Smad2-Smad4 
association creates a transcriptional unit that accumulates in the nucleus to regulate the 
transcription of TGF target genes. The activated TGF receptors can also activate 
various Non-Smad signalling pathways. 
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1.1.4 Pleiotropic effects of TGF 
The effects exerted by TGF signalling have long been known to be cell and 
context dependent (reviewed in [5, 12, 54]. In mature tissues, TGF has multiple roles 
that ultimately lead to homeostasis. For example, TGF stimulates fibroblasts of the 
stroma to grow and deposit extra cellular matrix proteins; TGF inhibits the growth of 
endothelial cells and controls their morphogenesis; TGF can inhibit cells of the immune 
system by inhibiting T-cell proliferation and natural killer cell function; and in the 
epithelium, TGF controls cell growth through stimulating cell cycle arrest, apoptosis, 
and adhesion (Figure 1.3) (reviewed in [12]). Given the important homeostatic role for 
TGF signalling, its deregulation leads to various pathologies. For example, aberrant 
TGF signalling is a hallmark of many epithelial derived cancers [3, 55], and drives 
tumour progression. Normally, TGF acts as a tumour suppressor by controlling the 
growth of the epithelium, but in many tumours TGF undergoes a role switch and 
becomes a cancer promoting metastatic agent [3, 4, 55-58]. The growth suppressive 
function of TGF was originally described to be through the phosphorylation of RB 
(retinoblastoma protein) [59]. RB functions as a cell cycle gatekeeper, and in its 
underphosphorylated state, prevents cells from entering into mitosis from the G1 
checkpoint of the cell cycle [60]. Interestingly, TGF arrests cells in the G1 phase of the 
cell cycle through the prevention of RB phosphorylation thereby leading to growth 
suppression [59]. Phosphorylation of RB occurs through cyclin dependent kinases CDK4 
and CDK6 [60]. TGF stimulation leads to the upregulation of the CDK inhibitors p15 
and p21, which prevent the actions of CDK4 and CDK6 thereby preventing RB 
phosphorylation and the ultimately stimulating growth arrest [5, 12]. Other mechanisms 
of growth arrest include the TGF induced repression of growth stimulatory transcription 
factors including Myc, and members of the ID family [5, 12, 54]. Thus, although the 
mechanisms can differ among various cell types, TGF normally causes growth arrest in 
mature epithelium, maintaining it in a homeostatic state.  
In addition to controlling epithelial cells through a cytostatic program, TGF can 
also stimulate apoptosis to maintain homeostasis. Apoptosis is a form of programmed cell 
death and is important for normal cell turnover; however, deregulation of apoptosis is 
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also involved in various pathological disorders (reviewed in [61]). Apoptotic signalling 
can be classified into extrinsic (via death receptor), and the intrinsic (mitochondrial) 
pathways, however, each pathway can influence the other. Activation of either pathway 
leads to the cleavage of a group of cysteine proteases called caspases, which execute the 
apoptotic program to result in DNA fragmentation, chromatin condensation, protein 
degradation, and membrane blebbing, which leads to the formation of cell fragments 
called apoptotic bodies. These apoptotic bodies are subsequently engulfed by phagocytic 
cells such as macrophages [61]. Because apoptotic bodies do not release the cellular 
contents into the surrounding interstitial tissue, an inflammatory response is not triggered 
[61]. The extrinsic pathways that trigger apoptosis utilize transmembrane death receptors 
which most often include members of the tumor necrosis factor (TNF) receptor gene 
superfamily [62]. The best characterized of these are the Fas ligand/Fas receptor complex 
and the TNF-/TNFR1 models. Activation of these receptors by their ligands leads to the 
recruitment of cytoplasmic adaptor proteins to form a death-inducing signalling complex 
(DISC) [63]. DISC ultimately triggers the activation of caspases through cleavage [61]. 
The intrinsic apoptosis pathway involves non-receptor mediated signals that cause 
changes in the inner mitochondrial membrane that disrupt membrane potential resulting 
in the release of normally sequestered pro-apoptotic proteins into the cytosol [61]. 
TGF has been reported to operate in both apoptotic pathways. For example, 
TRII can interact directly with the pro-apoptotic adapter protein DAXX, a member of 
the Fas pathway, which leads to the activation of JNK and the induction of apoptosis of 
epithelial cells [64]. Furthermore, TGF can also operate in the intrinsic pathway through 
its transcriptional induction of DAPK (death associated protein kinase) [65]. DAPK can 
regulate cytochrome C release from mitochondria, and ultimately apoptotic response 
[65].   
Thus, the cytostatic and apoptotic actions of TGF signalling make it a clear 
regulator of cellular and tissue homeostasis. Deregulation of various components of the 
TGF pathway often lead to diseases of hyperproliferation, such as cancer.   
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Figure 1.3.  The multi-functional nature of TGF. 
TGF signalling has cell type and context-specific effects. TGF has an important role in 
controlling the growth homeostasis of the epithelium by regulating cell-cycle arrest and 
apoptosis. Whereas in fibroblasts, TGF stimulates ECM production and proliferation, 
important aspects of tissue repair. However, as tumours progress, the growth inhibitory 
aspects of TGF are lost, and then TGF signalling can stimulate EMT, migration, and 
invasion, thereby facilitating tumour progression.    
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1.2 Regulation of TGF signal transduction  
      It has become clear that the complex nature of TGF responses is partly 
related to the regulation of TGF receptor signalling. The importance of this regulation is 
highlighted by the complex roles of TGF in development, and the detrimental 
consequences of aberrant TGF signalling in various diseases such as cancer and fibrosis. 
Much work has been devoted to understanding the mechanisms that govern the regulation 
of TGF receptor signalling, however, many questions still remain to be addressed.  
 
1.2.1 Endocytosis and membrane trafficking  
Endocytosis of cell surface receptors has been shown to be an important 
regulatory event. Endocytosis refers to the process by which membrane associated 
molecules are taken into the cellular environment through internal membrane 
compartments (reviewed in [66]).  This process involves the invagination of the plasma 
membrane to encapsulate the cargo, followed by budding from the membrane, and the 
formation of an intracellular vesicle containing the internalized molecules. Importantly, 
endocytosis of cell surface receptors can modulate signalling processes by spatially 
removing receptors from accessing extracellular ligand, but also opens complex avenues 
of signalling or down-regulation pathways depending on the intracellular itinerary of the 
cargo. Thus, how receptors are trafficked in the cell, can determine whether receptors are 
down-regulated or whether they can continue signalling.     
Interestingly, modulation of TGF receptor activity is controlled by the 
endocytosis and trafficking of the TGF receptors. Cell surface TGF receptors are 
dynamic and are constitutively being internalized via “clathrin dependent” and 
“membrane raft- dependent” endocytosis. Furthermore, clathrin-dependent endocytosis 
positively influences signalling and propagates TGF Smad signalling, whereas 
membrane raft-dependent endocytosis results in receptor degradation and signal 
termination [67, 68].  
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1.2.2 Classical clathrin-dependent endocytosis 
Clathrin-dependent endocytosis is a conserved mechanism which is responsible 
for the cellular internalization of pathogens, antigens, nutrients, growth factors and many 
receptor types (reviewed in: [66, 67, 69]). The defining feature of this endocytic pathway 
involves the recruitment of soluble clathrin from the cytoplasm to the plasma membrane. 
The clathrin triskelia aggregate at the membrane and create a polygonal lattice to form an 
invagination referred to as a “clathrin-coated pit”.  Clathrin binding adaptor proteins, 
such as adaptor protein 2 (AP-2), promote the clathrin polymerization as well as bind 
other cargo proteins to facilitate their endocytosis. AP-2 as well as Eps15 (epidermal 
growth factor substrate 15) facilitates the formation of the clathrin lattice, leading to an 
increase in the plasma membrane curvature and creating the pit. The clathrin-coated pit 
pinches off from the plasma membrane to form a “clathrin-coated vesicle”. This process 
is dependent on Dynamin, a GTPase that promotes the scission of the clathrin coated pit 
into a newly formed intracellular vesicle. Following endocytosis, the newly formed 
vesicles are uncoated, and then become ‘early endosomes’. The early endosome is an 
important intracellular compartment that acts as a key sorting facility for the proteins it 
contains. The vesicular cargo can be sorted into recycling endosomes, which return to the 
cell surface, or can be trafficked to late endosomes where they are furthered targeted to 
the lysosome for degradation. Interestingly, these sorting and trafficking events can be 
directed by post-translational modifications of the cargo, such as ubiquitination, 
phosphorylation, or the interaction with specific proteins [69]. Furthermore, these 
directed trafficking events are controlled by a large family of small GTPases called the 
Rab GTPases. Rab GTPases are Ras-like small G-proteins that are tightly associated with 
membranes, molecular motors, and vesicular coat components and their activity controls 
endocytosis, trafficking, and exocytosis by regulating the processes of docking, fusion, 
and tethering between vesicular compartments [66, 67]. The different endosomal 
compartments are associated with distinct Rab GTPase function, and specific Rabs are 
often experimentally used as markers of specific compartments. For example, Rab4 and 
Rab5 are localized and enriched in the early endosome, Rab 4 and Rab 11 are enriched in 
recycling endosomes, and Rab7 and Rab 9 are enriched in late endosomes [66].                   
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As with specific Rabs, the early endosome is also characterized by specific early 
endosome proteins containing a unique “FYVE” domain (Fab1, YOTB, Vac1, EEA1). 
The FYVE domain binds these proteins to the membrane lipid phosphatidylinositol-3-
phosphate (PtdIns3P), which is highly enriched in the early endosome. FYVE domain 
proteins are thought to facilitate endosomal trafficking dynamics. For example, the early 
endosome marker EEA1 (early endosome antigen-1), is a FYVE domain containing 
effector of Rab5 that helps control early endosomal fusion [66, 67]. Thus, protein-protein 
interactions, as well as various protein-lipid interactions within endosomal compartments 
are important in guiding the sorting of intracellular cargo following clathrin-mediated 
endocytosis.  
 
1.2.3 Non-classical endocytosis: Membrane-rafts 
Clathrin-independent endocytosis is also a common mode of internalization for a 
number of molecules from the extracellular environment. Clathrin-independent 
endocytosis routes are sensitive to cholesterol depletion, pointing to the importance of 
membrane rafts (sometimes also called lipid rafts).  Membrane rafts are liquid ordered 
membrane microdomains that are discrete from clathrin-coated pits. They are 
characterized by portions of the plasma membrane that have a very distinct lipid 
composition: they are rich in cholesterol, glycosphingolipids, and 
glycosylphosphatidylinositol-anchored (GPI) proteins [67, 70]. This unique composition 
makes membrane rafts less fluid and more rigid than non-raft areas of the plasma 
membrane [71]. Interestingly, these properties allow membrane rafts to create platforms 
that recruit and/or exclude specific lipids and proteins and thus can segregate cell surface 
components from the rest of the plasma membrane, allowing for another mechanism of 
endocytosis and protein trafficking [67, 71].  Interestingly, membrane raft-mediated 
endocytosis seems to be especially important for proteins that contain a GPI anchor [72, 
73]. The spingholipids and cholesterol in membrane rafts tether GPI-anchored proteins by 
binding to the acyl chain on the GPI-anchor [74]. Another mechanism linking cell surface 
molecules to membrane rafts are through interactions with raft resident proteins such as 
caveolin, flotillin and annexin [67, 70, 73, 74]. 
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Membrane rafts important to the regulation of the TGF pathway are “caveolae”. 
Caveolae are a subset of membrane rafts that are morphologically identifiable as flask-
like invaginations of the plasma membrane approximately 60-80 nm in diameter [66, 70, 
72, 75]. Caveolae, like membrane rafts, are rich in cholesterol and sphingolipids, but they 
are also highly enriched in a type of protein called the caveolins [76]. There are three 
types of caveolins: caveolin-1, caveolin-2, and caveolin-3. Caveolin-2 is only found 
expressed in muscle cells, whereas caveolin-1 and 2 show widespread cellular 
expression. However, caveolin-1 (cav-1) is the most important for the formation of 
caveolae in most cells and cav-1 knockout mice lack caveolar structures [77, 78].  
Caveolae form through the oligomerization of cav-1 proteins and their association with 
cholesterol molecules [67, 79]. Similar to clathrin-mediated endocytosis, protein-protein 
interactions with constituents of membrane rafts, such as cav-1, can regulate entry into 
caveolae and control the endocytosis of molecules into these intracellular compartments. 
Caveolae-dependent endocytosis has been shown to be important for the internalization 
of various nutrients, viruses and cell surface receptors, including various GPCRs, RTKs 
and TGF receptors [67-70, 79, 80].  
 
1.2.4          Endocytic trafficking regulates TGF receptor activity 
Interestingly, TGF induced signalling events are intricately linked to the 
trafficking of TGF receptors (Figure 1.4) [68, 81-86]. TGF receptors are constitutively 
internalized via both membrane raft-dependent and clathrin-dependent endocytosis, and 
the   specific trafficking of the TGF receptors, was determined to dictate whether the 
TGF signal would be propagated or degraded [68]. In this study, Di Guglielmo et al. 
report that the inhibition of clathrin-dependent endocytosis using Eps15 or Dynamin 
dominant negative mutants blocked the ability of TGF receptors to access the early 
endosome, and increased their propensity to access caveolae. Similarly, using a 
cholesterol depletion technique, which inhibits membrane-raft dependent endocytosis, 
receptors were less likely to access caveolae and found more in the early endosome. This 
interesting finding indicated that TGF receptors could internalize from the cell surface 
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at least two ways: via clathrin coated pits into the early endosome or via membrane rafts 
into caveolae – and these processes could be manipulated by altering trafficking 
machinery. It is interesting to note that because the TGF receptors are constitutively 
being internalized, ligands in this system do not regulate trafficking events, but instead, 
stabilize heterotetrameric interactions between the Type I and II TGF receptors [68]. 
Internalization of activated receptor complexes into distinct endocytic compartments, 
such as the early endosome or caveolae, serves to bring the receptors to distinct Smads 
and Smad associated proteins associated with each particular compartment. Moreover, 
the fate of the receptors and ultimately the TGF signal, was related to the subcellular 
compartment that the receptors accessed. Receptors accessing the early endosome were 
more likely to phosphorylate Smad2 and propagate TGF signalling, whereas receptors 
accessing caveolae were more likely to be targeted for degradation (Figure 1.4) [68]. This 
finding was particularly interesting, as classically the internalization of various 
membrane receptors into the early endosome was thought to solely be a mechanism by 
which signalling is reduced or for the down regulation of receptors. However, it is now 
known that endosomes can be highly specific signalling platforms for various receptors 
(reviewed in [69]) and this was true of the TGF receptors.  
Di Guglielmo et al. found that TGF receptors that internalized into the early 
endosome via clathrin promoted TGF signalling through the enhanced activation of 
Smad2 [68]. TGF receptors are pulled into the early endosome through clathrin-
mediated endocytosis due to a direct protein-protein interaction of a dileucine motif in 
TRII with the clathrin adaptor protein AP-2 [82]. The early endosome, is enriched in an 
anchoring protein called SARA (Smad Anchor for Receptor Activation), which functions 
to spatially facilitiate the phosphorylation of R-Smads by activated TGF receptors [87]. 
Like many other early endosome proteins, SARA contains a FYVE domain, which binds 
to PtdIns3P, a membrane lipid enriched in early endosomes [7, 87]. SARA binds the R-
Smads (Smad2 and Smad3) via their MH2 domain, and the carboxy terminal domain of 
SARA binds to the activated TGF receptor complex, effectively bridging the receptor 
and R-Smads [87]. SARA preferentially binds non-phosphorylated forms of Smad2, and 
it is thought that the activated receptor complex, which is formed at the plasma 
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membrane, is captured by SARA in the early endosome, and then presents the bound R-
Smad to the receptor for phosphorylation [7].  Once Smad2 is phosphorylated, it 
dissociates from SARA, and then binds Smad4, leading to nuclear translocation and the 
initiation of transcription [87, 88]. This idea that TGF receptors access R-Smads at the 
early endosome greatly implicates trafficking events in controlling the intensity and 
duration of Smad phosphorylation. Indeed, maximal signal transduction is dependent on 
TGF receptors reaching the early endosome [89]. More specifically, in this study the 
authors show that although TGF receptors can still phosphorylate Smad2 when clathrin-
mediated endocytosis is inhibited, endocytosis was required for Smad2 to fully 
translocate to the nucleus and mediate transcription [89]. Furthermore, over expression of 
SARA mutants that lack the FYVE domain mislocalizes Smad2 and inhibits Smad2 
phosphorylation and gene transcription [87].  These interesting finding suggests that there 
is an important spatial regulation of the R-Smad activation and translocation process. 
Furthermore, these reports identify an important regulatory role for trafficking and the 
spatial organization of TGF receptors and Smads in executing TGF dependent 
transcription. Indeed ongoing work seeks to uncover the pathways, and proteins that 
control these regulatory endocytic processes and ultimately the TGF signal.  
In addition to being internalized by clathrin-mediated endocytosis, TGF 
receptors can undergo membrane-raft mediated endocytosis, which targets them to a 
caveolin positive vesicle [67, 68]. The cytoplasmic tail of TRI contains a caveolin-
binding motif, which facilitates its interaction with the scaffolding domain of caveolin-1, 
and this interaction ultimately targets receptors to caveolae [85]. In contrast to the early 
endosome, the cav-1 positive endosome facilitates the interaction of Smad7 instead of 
Smad2 with the activated receptors [68]. As mentioned, Smad7 is an inhibitory Smad, 
and has an antagonistic role in TGF signalling. More specifically, it sterically prevents 
the interaction of Smad2 with TRI through competitive binding thereby preventing its 
activation and subsequent binding to Smad4 [90, 91]. Furthermore, it acts as an adaptor 
protein for the ubiquitin ligase Smurf2 that targets the activated receptor complex for 
degradation through ubiquitination [92]. Ubiquitin is a small 76 amino acid protein that is 
covalently added to lysine residues of proteins by ubiquitin ligases, which catalyze this 
post-translational modification. Poly-ubiquitin chains can target proteins for degradation 
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by the proteasome and can also regulate trafficking events to the lysosome [93]. 
Ubiquitin mediated protein degradation controls the turnover and stability of various 
proteins including many cell surface receptors [93]. Interestingly, ubiquitin itself has 
seven lysine residues to which further ubiquitin molecules can be attached. Mono-
ubiquitination and Lys-63 linked polyubiquitination are known to be important regulators 
of the localization and/or function of proteins, whereas Lys-48 linked polyubiquitination 
of proteins is a signal for proteasomal degradation [93, 94]. Ubiquitination is facilitated 
by a multi-enzyme cascade consisting of E1, E2, and E3 ligases (reviewed in [93]). E1 
enzymes activate ubiquitin for conjugation, E2 enzymes are ubiquitin conjugating 
enzymes, and E3 are ubiquitin protein ligases which transfer the ubiquitin chain to the 
target lysine residue [93]. Smurf2 is a HECT-domain (Homologous to the E6-AP 
Carboxyl Terminus) E3 ubiquitin ligase, which like other protein members of this class, 
can directly target ubiquitin to specific substrates. Smurf2 is normally nuclear, but its 
binding to Smad7 induces export and stable interaction with the activated TGF receptor 
complex [92]. Smurf2 then ubiquitinates the TGF receptor-Smad7 complex which leads 
to their targeted degradation through proteasomal and lysosomal pathways [92]. Thus, 
TGF receptor internalization via membrane rafts into cav-1 positive compartments 
seems to be an important negative regulator of TGF induced Smad signalling.  Indeed, 
receptor trafficking and ubiquitination acts as a tight control mechanism for TGF 
receptor degradation, and subsequently the availability of active receptor complexes.  
It has become clear that the method of receptor internalization influences the 
magnitude, duration and efficiency of TGF signal transduction. More specifically, 
trafficking of the TGF receptors into SARA enriched early endosomes facilitates 
signalling whereas trafficking into cav-1 positive vesicles targets the receptor complex 
for degradation through the interactions of Smad7 and Smurf2 (Figure 1.4). Thus, the 
early endosome acts as a signalling platform for the TGF receptors that effectively 
sequesters the receptor away from cav-1 and raft mediated endocytosis and also promotes 
the access of the substrate Smad2 through its enriched levels of SARA. 
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Figure 1.4.  Endocytosis and trafficking control TGF receptor activity 
Activated TGF receptors internalize via clathrin coated pits into the early endosome to 
facilitate downstream signalling. In the early endosome, SARA presents Smad2 to the 
activated receptor complex. TRI phosphorylates Smad2 , which stimulates the 
dissocation from SARA and the subsequent interaction with Smad4. This Smad complex 
translocates to the nucleus to activate TGF target genes. Alternatively, receptors 
internalize into caveolin-positive vesicles and interact with the inhibitory Smad7 leading 
to subsequent Smurf dependent ubuiqitination and degradation of the receptors. Thus, the 
function of these internalization pathways is dictated by the resident proteins associated 
with each compartment, and altered trafficking and internalization of TGF receptors can 
alter TGF signalling outcomes. 
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1.2.5 Regulation of Smads 
As mentioned above, R-Smads are direct targets of ligand bound TGF receptors, 
and are the key regulators of TGF transcriptional response.  Generally, in quiescent 
cells, Smad2 localizes primarily in the cytoplasm, I-Smads are primarily nuclear, and 
Smad4 resides in both the nucleus and cytoplasm [6]. Upon phosphorylation, Smad2 
forms a heteromeric complex with Smad4 and this complex accumulates in the nucleus 
where it regulates transcription. Once TGF signalling is terminated, R-Smads are 
rapidly dephosphorylated by PPM1A in the nucleus and exported back to the cytoplasm 
[95, 96]. Although, classically Smads accumulate in the nucleus following TRI 
mediated phosphorylation, it is also clear that R-Smads undergo dynamic shuttling to and 
from the nucleus allowing for a mechanism to constantly “sense” activated TGF 
receptors (reviewed in [23, 97, 98]). Subsequently, the subcellular localization of Smads 
is also controlled by various mechanisms, partly owing to the presence of distinct nuclear 
localization sequences (NLS) and nuclear export sequences (NES) [97].  
Although small molecules can passively diffuse into the nucleus, proteins larger 
than 40 kDa (such as Smads) must be actively transported across the nuclear membrane 
through the nuclear pore complex (NPC) (reviewed in [99, 100]). The classical nuclear 
import pathway across the NPC involves the aid of a complex of two receptor transporter 
proteins, importin- and importin-. Importin- acts as an adaptor that recognizes and 
binds the characteristic basic residues (arginine and lysine) in the NLS of target proteins. 
Importin- binds importin--tethered cargo and the entire complex can enter the nucleus 
through its interactions with nucleoporins, which are proteins that constitute the nuclear 
pore complex (reviewed in [101]). Target proteins can also bind directly to importin-, or 
directly to nucleoporins to permit their nuclear entry. Similarly, nuclear export is largely 
dependent on the export transporter CRM1 (chromosome region maintenance 1) also 
sometimes referred to as exportin-1 [100, 101]. CRM1 binds to the leucine rich NES, and 
then interacts with nucleoporins to permit transport back into the cytosol [100]. However, 
cargo can also bind nucleoporins directly to permit their export.         
The MH1 domain of all Smads contains a conserved NLS, however, the nuclear 
import of Smad2 occurs independently of Importin-[102]. Instead, nuclear shuttling of 
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Smad2 is dependent on a direct interaction of the MH2 domain of Smad2 with 
nucleoporin proteins. Smad2 directly interacts with CAN/Nup214, a nucleoporin protein 
that resides on the cytosolic side of the NPC, which facilitates the entry of Smad2 into the 
nucleus [102]. On the nuclear side of the NPC, Smad2 can bind the nucleoporin Nup153, 
which facilitates its export from the nucleus [102]. Interestingly, the residency of Smad2 
in the nucleus or the cytosol is dependent on cytosolic or nuclear interacting proteins that 
can act as retention factors. For example, SARA (an endosomal protein) competes with 
CAN/Nup214 for binding to hydrophobic patches in the MH2 domain of Smad2 [103]. 
Because receptor mediated phosphorylation of Smad2 decreases its affinity for SARA 
[88], this may enhance the ability of Smad2 to bind CAN/Nup214 and thus nuclear 
transport. Once in the nucleus, Smad2 then interacts with transcriptional co-factors, 
which retain it in the nucleus. Consistent with this idea, expression of the Smad binding 
domain of SARA, reduces nuclear accumulation of the Smad MH2 domain [88], whereas 
Smad2 nuclear accumulation is promoted through the expression of the Smad binding 
nuclear transcription factor FoxH1 [102, 104]. Phosphorylated forms of Smad2 are 
retained in the nucleus more efficiently than unphosphorylated forms, indicating that 
phosphorylation increases the association of transcription co-factors and Smad4 binding 
[23].  Moreover, although the MH1 domain of R-Smads can bind DNA, this intrinsic 
DNA binding affinity is relatively low and Smad mediated transcription requires other 
DNA binding transcription factors in a complex with Smads [98]. Thus, the idea that 
Smad2 can constantly shuttle to and from the nucleus emerges as a mechanism by which 
the Smads can constantly monitor the activity status of the TGF receptors – where 
regulatory factors such as SARA retain it in the cytoplasm, and nuclear partners retain it 
in the nucleus for TGF mediated transcription. 
Interestingly, the nuclear import of Smad4 follows a more classical nature. Smad4 
contains a NLS in its MH1 domain, which unlike Smad2, does interact with importin-
. Smad4 has two NESs, one is located in its MH1 domain and the other in its 
linker region, and nuclear export is mediated by CRM1 [97, 105-107].  Smad4 
accumulates in the nucleus through its association with R-Smads, however, evidence for 
Smad4 shuttling independent of ligand was provided when it was discovered that 
mutations in the NLS reduces nuclear entry, whereas mutations of the NES promote 
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nuclear accumulation [105-107]. Upon ligand stimulation, the Smad4 NES is masked by 
the interaction of Smad4 with the phosphorylated R-Smad, which allows Smad4 to 
accumulate in the nucleus [95, 106]. Smad4 dissociates from R-Smads once R-Smads are 
dephosphorylated, and both are exported from the nucleus to the cytoplasm [95]. If TGF 
receptors are still active, R-Smads are phosphorylated, bind Smad4, and return to the 
nucleus. 
Thus, constant nucleo-cytoplasmic shuttling of Smads is a key feature of TGF 
signalling. The continuous cycles of receptor mediated phosphorylation in the cytoplasm, 
and rapid nuclear dephosphorylation allows for a constant sensing mechanism that 
detects the activation status of the receptors, and allows for proper termination in the 
absence of ligand or receptor termination. 
Interestingly, other signalling pathways can also converge on Smad signalling to 
regulate its activities. As mentioned, Smads consist of an MH1 domain and an MH2 
domain separated by a “linker” region. As mentioned above, the MH1 domain is involved 
in DNA binding, and the MH2 domain is involved in binding other protein partners, such 
as activated receptors, cytoplasmic retention factors, nucleoporins, and nuclear proteins 
involved in transcription such as co-factors. The linker region in between the MH1 and 
MH2 domains is variable among the Smads, and has been shown to have various 
regulatory functions (reviewed in [108]). Interestingly, several ser/thr kinases have been 
discovered to phosphorylate the Smad linker region. For example, all three members of 
the mitogen activated protein kinase pathways (MAPK), including extracellular-signal 
related kinase (ERK), Jun N-terminal kinase (JNK) and p38 kinase have all been shown 
to phosphorylate Smads in the linker [108]. Initially, ERK was found to phosphorylate 
the R-Smads 1, 2 and 3 on multiple residues in the linker region and this effectively 
reduced the ability of R-Smads to accumulate in the nucleus in response to TGF [109, 
110]. This became an interesting topic, as a properly timed nuclear exclusion of R-Smads 
through linker phosphorylation was shown to be quite important for early embryonic 
developmental processes (reviewed in [111]). More specifically, R-Smad linker 
phosphorylation by MAPK, and subsequent attenuation of TGF-Smad signalling, 
deprives the ability of the ectoderm to become mesoderm, and was also shown to be 
important to promote the neural differentiation and dorsalization of the mesoderm in 
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Xenopus frog embryos [112, 113].    Smad linker phosphorylation has also been shown to 
play a role in oncogenic progression. Many cancer cells are often transformed by 
oncogenic Ras, which activates mitogenic signalling by ERK, and thus enhances 
proliferation. Normally, TGF signalling can override the proliferative effects of 
mitogenic Ras signalling in epithelial cells – however, it was discovered that oncogenic 
Ras signalling to ERK can antagonize TGF tumour suppressive effects through Smad 
linker phosphorylation and nuclear exclusion [110]. However, although these initial 
reports describe Smad linker phosphorylation by ERK leading to nuclear exclusion, since 
then multiple studies have also reported that linker phosphorylation (by various kinases) 
can also enhance TGF-dependent transcription [114-117] – seemingly two completely 
opposite effects. Furthermore, in addition to MAPK members, multiple other kinases 
such as GSK-3, CDKs, CAMK, and ROCK, have been shown to phosphorylate the Smad 
linker region regulating various processes in various cell types, indicating that the role of 
Smad linker phosphorylation is significantly more complicated than initially anticipated 
[108]. Clearly, linker region phosphorylation does have the ability to modify TGF 
signalling, but the exact mechanisms and outcomes in varying contexts are still unclear 
and are currently still being investigated.   
 
1.3 Protein Kinase C  
1.3.1 The Protein Kinase C Family 
Protein kinase C (PKC) consists of a family of ser/thr kinases involved in diverse 
cellular processes, including cell proliferation, migration, differentiation, apoptosis, 
neurotransmission, signal transduction and cell polarity (reviewed in [118-124]).  The 
PKC family consists of at least 10 members divided into three subgroups based on their 
structure and their requirements for activation: the classical PKCs (cPKC), the novel 
PKCs (nPKC) and the atypical PKCs (aPKC) (Please see Figure 1.5) [118-124].     
Classical PKCs () require calcium and diacylglycerol (DAG) for 
activation, novel PKCs () require DAG, and atypical PKCs (and) are 
independent of DAG or calcium [119-123, 125]. All PKCs also utilize phosphatidylserine 
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as a co-factor for activation [126, 127]. PKC isoforms contain an N-terminal regulatory 
region, and a C-terminal kinase domain.  Within the regulatory region lies an N-terminal 
psuedosubstrate domain which binds and autoinhibits the kinase domain of the enzyme 
by mimicking PKC substrate sequences and occupying the substrate binding site [124].  
The cPKCs contain two cysteine rich domains. One is termed the C1 domain, 
which binds DAG and other phospholipids, the other is termed the C2 domain which 
binds calcium. The nPKCs have a C1 domain but no functional C2 domain, resulting in 
their calcium insensitivity. These two groups can also be activated by phorbol myristate 
acetate PMA, which mimics endogenous DAG [128]. The aPKCs lack a C2 domain and 
their C1 domain is truncated and does not bind DAG (or PMA) – thus rendering them 
insensitive to calcium or DAG [129, 130]. Instead, aPKCs can be activated by other lipid 
components such as phosphatidylinositols, phosphatidic acid, arachidonic acid and 
ceramide or by kinases such as PI3K (phosphatidylinositol 3 kinase) or PDK1 (3’PI-
dependent kinase 1) [131-136].  
Numerous extracellular signals control the activity status of the various PKC 
isoforms, which in turn affect the activity of transcription factors, enzymes, cytoskeletal 
proteins, and cellular receptors. Classically, PKCs are activated through cell surface 
receptors that trigger intracellular signalling pathways. G-protein coupled receptors 
(GPCRs) and receptor tyrosine kinases (RTKs) activate PKC through signalling pathways 
that produce second messenger molecules such as calcium and DAG [124].  For example, 
the activation of GPCRs by their extracellular ligands regulates the activity of 
intracellular G-proteins, some of which can lead to the activation of phospholipase C  
(PLC). PLC triggers the production of inositol 1,4,5 triphosphate (IP3) and DAG. IP3 
triggers increases in the intracellular levels of calcium, whereas DAG activates both 
cPKCs and nPKCs. In addition to GPCRs and RTKs, more recently TGF ser/thr kinase 
receptor activity has also been shown to lead to PKC activation [137].  Additionally, 
other proteins and lipids can influence the regulation of PKCs. For example, arachidonic 
acid and similar fatty acids are also known to activate PKC [138]. Furthermore, the 
localization of several PKC isoforms to specific subcellular destinations can be altered 
through their interactions with RACK proteins (receptors for activated C kinase) which 
act as escorts to specific areas of the cell [118].  
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In the basal state, PKCs localize mainly to the cytoplasm in a folded inactive 
structure. The N-terminal pseudosubstrate domain folds over to bind to the C-terminal 
catalytic domain of the PKC thereby holding PKC inactive. When intracellular levels of 
calcium and DAG increase, PKC translocates to the plasma membrane where it can bind 
these second messengers, which ultimately cause the pseudosubtrate domain to dissociate 
from the kinase domain. This allows PKC to interact with and phosphorylate its 
substrates, thereby triggering downstream signalling cascades[124].       
Various studies have shown that many PKC isoforms are expressed in virtually all 
tissue and cell types, and that expression is developmentally regulated and is related to 
the differentiation status of a tissue (reviewed in [139-141]). Originally it was difficult to 
attribute specific functions to specific PKC isoforms, due to the similar activator 
requirements and substrate specificities of the various PKCs in vitro. However, genetic 
manipulations of specific isoforms have identified PKC isoform specific functions, 
making it clear that PKCs can execute unique and non-redundant functions within the 
cell. Consistent with this, PKC isoforms show different subcellular localization, tissue 
distribution, and binding partner specificity, which all contribute to their differential 
activations and specified functions [121, 142, 143].  
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Figure 1.5.  Schematic representation of the PKC family 
Most of the PKC isoforms have 4 conserved domains (C1-4) that form the diacylglycerol 
(DAG), calcium, ATP and substrate binding sites. All PKCs also have a pseudosubstrate 
region (PS) which autoinhibits kinase activity by binding to the substrate binding region 
of the inactive enzyme. Both novel and atypical PKCs lack amino acids in the C2 region 
to bind calcium.  Atypical PKCs have only 1 cysteine-rich motif, and no detectable DAG 
binding sites.  aPKCs also contain a Phox-Bem 1 (PB1) motifs that are protein-protein 
interaction domains and will bind to proteins such as Par6. 
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1.3.2  Protein Kinase C and Membrane Trafficking/Endocytosis 
Upon activation, PKCs regulate signalling pathways that control various cellular 
functions. In particular, PKCs can regulate the endocytosis, membrane trafficking, and 
desensitization of various receptors. Although the mechanisms are still being uncovered, 
PKC isoforms may be central in controlling the vesicular trafficking of various 
transporters, receptors and other plasma membrane proteins (reviewed in [118]).  For 
example, the activation of various GPCRs can lead to the activation of PKCs which 
initiate downstream signalling events, however, PKCs can also phosphorylate the GPCRs 
themselves. PKCs can phosphorylate residues within the cytoplasmic loops and C-
terminal domains of many GPCRs initiating their desensitization, endocytosis and 
sometimes degradation [118, 144-147]. Furthermore, it is well known that endocytosis of 
GPCRs can be further facilitated by the binding of the signal terminator adaptor proteins 
beta-arrestins to these phosphorylated residues [147, 148].   Internalized receptors can be 
recycled back to the plasma membrane through either a fast recycling pathway, or they 
may reside in endosomes for an extended period of time before undergoing a slow 
recyclying, or degradation [148]. Interestingly, roles have emerged for PKCs in both of 
these pathways thereby implicating PKCs as important mediators of intracellular receptor 
traffic [146, 149, 150]. The intracellular itinerary of proteins following PKC-activated 
internalization of receptors can vary. For example, H+/K+ ATPase ion pumps exhibit 
decreased recycling and activity, whereas -integrin receptors exhibit increased recycling 
to the cell surface and enhanced activity [151, 152]. Interestingly, the atypical PKCs 
(aPKCs) can stimulate the translocation of EGF receptors to late endosomes through the 
association of aPKC to the late endosome sequestering protein p62 [153]. The atypical 
PKC isoforms constitute a unique class of PKCs, and interestingly one member (PKC) 
has been implicated in TGF processes previously [154, 155].    
 
1.3.3 Atypical Protein Kinase C 
The atypical PKCs (aPKC), which consists of PKCis the mouse homolog) 
and PKC are a unique set of PKCs that do not require DAG, phosphatidylserine, or 
30 
 
calcium for their activation [156]. This distinctive characteristic is largely due to a unique 
regulatory domain [125, 157] at the NH2 terminus, which lacks a DAG or calcium 
binding motif [121, 158]. aPKC plays a critical role in establishing both front-rear and 
apical-basal cell polarity through its interaction with the polarity complex Par6, Par3, 
cdc42 and Rac1 [155, 159-161]. PKC and PKC share a 72% sequence homology at the 
amino acid level [162], however, they may have some diverging functions. The most 
striking example of this is that PKC knockout is embryonic lethal, whereas PKC 
knockout mice develop normally, although with immunological deficits [130, 158, 163]. 
It still remains unclear whether the critical role of PKC/ in mouse development is 
related to the establishment of cell polarity, or to some other critical embryonic function. 
Interestingly, a third atypical isoform of aPKC, termed PKM, was discovered to be 
expressed in the brain and is known to be important in long term potentiation (LTP) 
maintenance and memory [164-167]. This brain specific isoform was originally thought 
to be a cleavage product of full length PKC, as PKM is essentially the kinase domain 
of PKC and thus lacks an autoinhibitory regulatory domain. However, this constitutively 
active kinase was later shown to be an alternatively transcribed mRNA in the brain 
through an internal promoter within the PKC gene and not a proteolytic product [168]. 
Classical mechanisms of activation of aPKCs consist of two main events: release 
of pseudosubstrate inhibition and phosphorylation of the aPKC kinase domain on Thr-
410 by PDK1 and Thr-560 by other unknown kinases or possibly autophosphorylation  
(reviewed in [130]). As mentioned, unlike the other PKCs, which are released from 
pseudosubtrate inhibition by DAG, the aPKCs are activated by other lipid components 
such as phosphatidylinositols, phosphatidic acid, arachidonic acid and ceramide. PIP3 
appears to be a major activator of aPKC as its formation contributes to the direct 
modulation of aPKC pseudosubstrate inhibition and also by activating PDK1 which then 
phosphorylates the aPKC kinase domain [130].   Furthermore, direct interacting proteins 
can regulate aPKC function. For example, prostate apoptosis response-4 (Par-4) can 
interact with regulatory domain of aPKCs and inhibits their activities [169]. Furthermore, 
the polarity complex protein Par3 (also known as ASIP; aPKC-specific interacting 
protein) interacts with the kinase domain of aPKCs and inhibits their activity [170]. 
Another polarity protein, Par6, interacts with aPKC along with Par3 to form the polarity 
31 
 
complex. In this complex, aPKC is held inactive until an active form of Cdc42 binds 
Par6, thereby leading to activation of aPKC, and phosphorylation of target proteins that 
drive the establishment of cell polarity [171, 172].  aPKCs have been implicated in 
functioning in numerous other intracellular signalling pathways including MAPK, NFB, 
TGF, and Rac1 (reviewed in [130, 163, 172]) and are becoming increasingly important 
targets in human pathologies.   
 
1.3.4    aPKC in cancer 
Early in the 1980s, PKCs were discovered to be the major intracellular receptor of 
the tumour-promoting phorbol esters, which stimulated a massive effort to define roles of 
PKCs in oncogenesis [121, 173]. Although variations in PKC localization, activity, 
phosphorylation, and/or expression have been documented in virtually all tumour types, 
aPKCs have garnered considerable attention in cancer biology, as the atypical PKC is 
considered to be a human oncogene (reviewed in [158, 174]. 
Interestingly, it is possible that aPKC isoforms have cell and tissue specific roles 
in cancer. For example, increased PKC expression has been documented in bladder, 
hepatocellular, and head and neck carcinomas [175-177]. Similarly, PKC overexpression 
has been reported in breast, ovarian, and liver cancers [178-180] and has been implicated 
in glioma proliferation and invasion [181-184]. Furthermore, PKC is reported to be 
oncogenic in non-small cell lung cancer (NSCLC) and elevated expression is correlated 
with poor prognosis in NSCLC patients [157, 158, 160, 185-187]. Between the two 
isoforms, PKC has garnered the most attention with respect to cancer as ithas been 
implicated in the promotion of carcinogenesis in vivo and in vitro and is accepted by 
some as the first PKC to be a human oncogene [158]. For example, six non-small cell 
lung cancer cell (NSCLC) lines (A549, H1299, H292, ChaGoK1, Sk-Mes1 and H520) 
have elevated expression of PKC compared to non-transformed lung epithelial cells 
(HBE4). In NSCLC immunohistochemistry studies show that overexpression of PKCis 
confined to lung tumour cells with little to no expression present in adjacent stroma 
[160]. The elevation of PKCexpression in NSCLC patients is predictive of poor 
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outcome: patients with early stage lung cancer and high PKCexpression are more than 
10 times likely to die from the disease than those with low PKC. A similar trend is 
evident in patients with increased PKC DNA copy number and ovarian cancer [178].  
Increased PKCexpression is also correlated with increased cyclin E expression in 
ovarian cancers, and is implicated with increased proliferation, defects in cell polarity, 
and overall decreased survival [178].  Expression of a kinase deficient mutant 
(kdPKCin human A549 lung adenocarcinoma cells results in a loss of anchorage 
independent growth, but does not affect adherent cell growth, which suggests that 
PKCis essential to driving transformed growth [186].  This effect is also apparent in 
vivo, as nude mice challenged with NSCLC cells expressing kdPKC displayed a 
reduction in tumourigenicity as compared to mice challenged with wild-type NSCLC 
tumours [186]. Aurothiomalate (ATM), a gold compound that has been used in the past to 
treat rheumatoid arthritis, has been found to be a potent inhibitor of the PB1 interaction 
between PKCand Par6 [187]; Inhibiting this interaction is thought to inhibit transformed 
growth of tumours by targeting the PKC-Par 6 interaction and at the time of writing, has 
currently passed phase 1 clinical evaluation for use in non-small cell lung cancer [188]. 
An earlier study highlighted the pro-apoptotic effects of ATM on aggressive prostate 
cancer cells by the activation of ERK and p38 MAP kinases [189] indicating that the 
interaction of aPKC with Par6 may be important for survival of aggressive tumour cells. 
aPKCs are also considered survival genes, and several studies have highlighted the 
oncogenic characteristics of PKC in NSCLC, ovarian, colon, breast, and pancreatic 
cancers [157, 160, 185-187, 190, 191], and thus aPKCs may be a viable therapeutic target 
for various human cancers. Interestingly, aPKC is linked to various TGF pathways 
through direct interactions of TRI binding partners such as the polarity complex protein 
Par6, and the E3 ubiquitin ligase TRAF6 (Figure 1.6) [5, 192, 193]. Although connected, 
whether aPKCs alter TGF receptor functions and their corresponding signalling 
pathways remains to be elucidated. 
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Figure 1.6.   Potential roles for aPKC in TGF pathways 
The aPKC has been shown to associate with the TGF receptors through the scaffolding 
polarity protein Par6. This interaction occurs via PB1 domains contained on both aPKC 
and Par6. Importantly, PKC and Par6 can also bind Smurf1, an ubiquitin ligase that can 
target proteins for degradation.  aPKC can also directly bind TRAF6, a component of the 
TGF-p38MAPK pathway, and p62, another PB1 domain containing scaffold protein. 
Although, aPKC has been linked to the TGF receptors, its role in TGF signalling is not 
understood.  
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1.4 Par6 and the polarity complex 
1.4.1 Cell Polarity 
Higher order organisms consist of various specialized cell types that can execute 
specific functions. For example, neurons have long axons and make hundreds of 
connections with other cells to create a complex signalling network that can transmit 
information to peripheral regions of the body. Alternatively, one function of epithelial 
cells is to regulate and limit the transport of molecules to inner tissues, thereby creating a 
physiological and mechanical barrier from the outside environment.  This asymmetry of 
cellular function is called ‘cell polarity’ and is created by conserved signalling pathways 
that create asymmetric distribution of constituents within the cell. Cell polarity can refer 
to the antero-posterior polarity critical for asymmetric cell division during development, 
apical-basal polarity of epithelial cells, front-rear polarity seen in polarized migrating 
cells, or axon formation from naïve neurites seen in neurons (reviewed in [172]). 
Interestingly, these seemingly very different cell polarity processes are controlled by a set 
of evolutionarily conserved proteins involving Par6 and aPKC. There are 6 Par genes, 
Par1 and Par4 are ser/thr kinases, Par2 is a RING-finger protein, Par3 and Par6 are PDZ-
domain-containing scaffold proteins, and Par5 is a member of the 14-3-3 family of 
proteins [172]. These proteins are critical for asymmetrical cell division of the early 
worm embryo, and regulate fundamental mechanisms regarding cell polarization 
(reviewed in [194]). Importantly, Par6, aPKC and Par3 form part of the polarity complex 
in diverse cell types, and this functional unit acts dynamically to regulate cell polarization 
processes in various contexts in diverse organisms. 
 
1.4.2 Par6 and the polarity complex 
Par6 was originally discovered as one of six Par (partitioning-defective) proteins 
required for the asymmetrical division of the C. elegans embryo [195-197].  Since then, 
Par6 has been found in metazoans ranging from worms to mammals (reviewed in ref. 
[194]) and has been established as a mediator in many cellular processes including 
apical-basal cell polarity, directional cell polarization, cell migration, cell proliferation 
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and axonal specification.  Par6 is an adaptor molecule for the polarity complex, a highly 
conserved group of interacting protein partners including aPKC, Par3 and several small 
GTPases that work in a spatiotemporally co-ordinated effort to generate asymmetry 
within a cell [161, 170, 171, 198-200]. This scaffolding ability is made possible by 
various important domains on Par6 including a PB1 domain which binds aPKC, a 
GTPase binding domain which has a semi-CRIB motif that binds Cdc42 and Rac1, and a 
PDZ domain which binds Par3 (reviewed in [201, 202]).  Many studies have documented 
the role for the polarity complex as fundamental players in normal cell functions, tissue 
maintenance and development. For example, the polarity complex controls the formation 
of tight junctions between epithelial cells, and contributes to apical-basal polarity [170, 
203-205]. The plasma membrane of epithelial cells is divided into an apical (facing the 
extracellular space), and a basolateral domain (the portion of the membrane that forms 
the base and side surfaces), and these membranes contain different lipid and protein 
compositions. The membrane domains of epithelial cells are separated by junctional 
complexes, such as tight junctions, adherens junctions, and desmosomes, which act to 
physically attach cells to each other and also provide a diffusion barrier to prevent the 
free movement of solutes through the extracellular space [206]. aPKC and Par6 bind 
through a PB1-PB1 domain heterodimerization, and this complex becomes activated 
through the binding of activated Cdc42 or Rac1 to the CRIB domain of Par6 [170, 203, 
205]. The active aPKC-Par6 complex then binds Par3 by directly interacting with aPKC 
kinase domain, and also through a PDZ domain interaction with Par6 [207, 208]. This 
tertiary complex is linked to junctional complex proteins such as JAM1 (junction 
adhesion molecule 1) through Par3 and promotes the formation of sub-apical junction 
formation (reviewed in [209]). Furthermore, active aPKC-Par6 complexes lead to the 
phosphorylation of LGL (lethal giant larvae), and this aPKC induced phosphorylation 
cause translocation of LGL to basolateral regions of the cell, and constricts them from 
being at the apical membrane [204, 210, 211]. This physical restriction of LGL to the 
basolateral region further potentiates cell polarity by interacting with the basolateral 
membrane bound proteins discs large 1 (DLG1) and Scribble [212, 213]. Thus, aPKC and 
Par6 are part of intricate signalling networks that regulate cell polarity through the basis 
of mutual exclusion and spatial restriction.           
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Similarly, Par6 and aPKC have been shown to be essential regulators of the 
polarized migration through the localized activation of Par6-aPKC at the leading edge 
through binding of the small GTPase Cdc42 [214]. In this model, scratching a monolayer 
of primary astrocytes leads to a reorganization of the microtubule network and 
repositioning of the Golgi apparatus, mediated by the integrin stimulated activation of 
Cdc42 at the leading edge of the migrating cells. Furthermore, the activation of aPKC-
Par6 at the leading edge of migrating cells, inhibits the activity of GSK-3, which 
promotes the localized association of adenomatous polyposis coli (APC) with the plus 
ends of microtubules and the formation of DLG1 positive puncta in the plasma 
membrane [199, 215]. DLG1 interacts with APC directly, and this interaction is required 
for the microtubule dynamics that regulate cytoskeleton polarization [199]. Thus, the 
activation of the aPKC-Par6 complex at the leading edge by Cdc42, drives the 
microtubule dynamics associated with elongation at the leading edge, which is crucial for 
cell polarization and directional migration [198, 199, 214, 216, 217].    
Interestingly, some of these polarity proteins may also play a role in membrane 
trafficking and endocytosis. Recently, a genome wide screen deciphered that several 
polarity proteins are critical in regulating membrane trafficking [218, 219]. These include 
aPKC, Par6, Par3, and the small GTPase, cdc42 [218, 219]. Knockdown of these proteins 
using small interfering RNA (siRNA) effected changes in clathrin dependent endocytosis, 
and endosomal recycling [218, 219]. Interestingly, these polarity proteins, once thought 
to be strictly involved in controlling cell polarity and migration, may also be important 
players in regulating endocytic traffic. 
Although polarity proteins regulate normal cell and tissue polarity, they are often 
deregulated in tumour cells (reviewed in ref. [220]) indicating that loss in tissue 
architecture and oncogenesis may go hand in hand. The loss in organization associated 
with oncogenic transformation is likely to involve changes in the expression, localization 
and activation patterns of key polarity proteins such as Par6 and aPKC [221].  Indeed 
Par6 has recently been reported to be overexpressed in breast cancer and enhances the 
progression of breast cancer through disruption of cellular organization and enhancing 
proliferation [222, 223] and roles for aPKC in oncogenesis are emerging as described 
above.  
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1.4.3 The TGF-Par6 axis 
 The alterations in the normal function of polarity proteins such as Par6 and aPKC 
may contribute to tumour progression. It is likely that the switch from controlling normal 
cell polarity to the disruption of tissue architecture may also depend on extrinsic cues in a 
context dependent manner. One such cue was discovered when a novel screen identified 
Par6 as a binding partner of the type I receptor of the TGF pathway [224].  This 
interaction proved to be important, as TGF activation induced the phosphorylation of 
Par6 by TRII on a conserved serine residue (S345) resulting in altered cytoskeletal 
plasticity and EMT (Figure 1.7) [155]. This phosphorylation stimulated the recruitment 
of the ubiquitin ligase Smurf1 to target RhoA for degradation at tight junctions. The 
localized degradation of RhoA was shown to be required for the dissolution of junctional 
complexes, rearrangement of the actin cytoskeleton, and EMT (Figure 1.7) [155]. 
Importantly, this pathway is parallel but independent of the classical TGF-Smad 
pathway known to regulate the genetic programme associated with EMT. Furthermore, 
phosphorylation of Par6 was found to be important in the invasion and metastatic 
progression of breast cancer cells and consequently has also been correlated with reduced 
survival in breast cancer patients [223].  Thus, the phosphorylation of Par6 is important in 
EMT, tumour cell invasion, tissue disruption, and ultimately tumour progression – and 
until recently, this phosphorylation has only been documented to occur through the TGF 
receptors. Uncovering the details around the TGF-Par6 axis with respect to normal cell 
polarization, and tissue disrupting processes such as EMT is an ongoing area of study. 
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Figure 1.7.  TGF receptors phosphorylate Par6 to trigger EMT 
TGF receptors participate in accessory non-Smad pathways to regulate responses. One 
such non-Smad pathway is the TGF-Par6 axis. The polarity proteins Par6 and PKC 
form a complex with the TGF type I receptor at junctional complexes of polarized 
epithelial cells. Upon TGF stimulation, the TGF type II receptor is recruited to the 
complex and phosphorylates Par6 on S345. This induces the recruitment of Smurf1 
which ubuiqitinates RhoA, a small GTPase critically involved in regulating the actin 
cytoskeleton, and targets it for degradation. This results in actin cytoskeleton remodeling, 
dissolution of tight junctions, and the onset of epithelial to mesenchymal transition 
(EMT) and tumour progression [155, 223]. 
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1.5 The Epithelial to Mesenchymal Transition (EMT) 
Normal epithelial cells have several defining characteristics. Firstly, they form 
organized layers of cells that are closely adjoined and held together by special junctional 
complexes such as tight junctions, adherens junctions, and desmosomes [225, 226]. Also, 
epithelial cells have apical-basolateral polarity, are attached to a basement membrane, 
and maintain complete cell-cell adhesion with their neighbours. Under normal conditions 
these cells do not detach and move away from the epithelial layer [225, 226]. 
Mesenchymal cells on the other hand, do not have apical-basal organization, have 
fibroblast morphology and are highly motile and migratory [225, 226]. Epithelial cells 
under certain environmental pressures can undergo a shift into a mesenchymal 
phenotype: a process known as epithelial to mesenchymal transition (EMT) and involves 
dissolution of junctional complexes, reorganization of the actin cytoskeleton, loss in 
polarity, and independent motile behavior (Figure 1.8) [155, 225]. EMT is characterized 
by a shift in cells from an epithelial phenotype expressing epithelial markers such as E-
cadherin, Occludins, and Desmosplakin to cells that are more motile expressing 
fibroblastic markers such as N-cadherin and Fibronectin [225, 226]. EMT, although a 
critically important process in development [159, 225, 227], marks a major pathological 
event in cancer biology whereby tumour cells attain an invasive and migratory phenotype 
and is a prelude to advanced metastatic disease [228, 229]. TGF signalling emerged as 
an important regulator of EMT through its promotion of invasion and metastasis [9, 12, 
57] and understanding the mechanisms by which TGF causes highly polarized and 
adjoined epithelial cells to transform into randomly migrating cells is critical to our 
understanding of tumour development.  
 
1.5.1 Types of EMT 
EMT is an evolutionarily conserved mechanism by which polarized epithelial 
cells, which are normally attached to a basement membrane, acquire a mesenchymal 
phenotype. This occurs through various biochemical changes leading to a cell phenotype 
that is characterized by enhanced invasive potential, increased resistance to apoptosis, 
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and increased deposition of extracellular matrix. The resulting transition yields cells that 
can degrade the basement membrane and escape the original epithelial layer from which 
they originated.  
Interestingly, EMT has been observed in three distinct biological settings. More 
specifically, EMT is observed during development, during wound healing, and during 
tumour progression. Although the exact interplay of cellular signals that dictate the EMTs 
in these various functional scenarios is not yet clear, it has been proposed that EMTs 
should be subcategorized into these three distinct types (reviewed in [230]).  
Type 1 EMT is the differentiation processes observed during development. For 
example, EMT is critical for the generation of the embryonic three layered body plan 
consisting of the endoderm, mesoderm, and ectoderm, which arise through gastrulation 
[225].  Thus, type 1 EMT is associated with implantation and embryonic gastrulation to 
generate the mesoderm, endoderm, and mobile neural crest cells. Furthermore, the 
primitive epithelium during development, and more specifically the epiblast, undergoes 
an EMT to become the primitive mesenchyme [230]. Importantly, type 1 EMTs neither 
cause systemic spread via the circulation, nor do they cause fibrosis. Principally, the 
purpose of type 1 EMT is to generate mesenchymal cells important during development. 
While EMT is critical for body patterning and organogenesis during development, 
the process can also be recapitulated in the adult. A second type of EMT is involved in 
tissue regeneration, wound healing, and organ fibrosis; this type has been termed type 2 
EMT. Type 2 EMTs are part of a repair-associated event that would normally create 
fibroblasts in order to reconstruct a damaged tissue after trauma or inflammatory injury 
[230]. Under normal conditions, this EMT is associated with inflammation and should 
desist once the inflammation has attenuated, as is the case for wound healing. However, 
persistent inflammation without attentuation can lead to a persistent EMT response 
leading to tissue fibrosis and eventual organ destruction through excessive ECM 
deposition and scarring [230]. Essentially, fibrosis can be considered the result of 
aberrant EMT and wound healing due to persistent inflammation, and this process is 
known to be involved in the fibrotic disorders of the kidney, liver, and lung [230].  
The third type, type 3 EMT, centers on the transition of neoplastic cells. In order 
for tumour cells to metastasize, they must detach from the primary tumour, invade into 
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the surrounding tissue or basement membrane, intravasate into the lymphatic or blood 
system, and extravasate at a distant site [231, 232]. During tumour progression, the 
ability of stationary epithelial cells to gain mesenchymal phenotype is essential to the 
metastatic process. Thus, the EMT program involved in the acquisition of invasiveness 
and metastatic potential of a growing primary tumour constitute type 3 EMTs. 
Interestingly, type 3 EMTs can occur in cancer cells to a different extent, with some cells 
retaining certain epithelial traits, while shedding others, whereas some cells can become 
fully mesenchymal [230]. This gradient in EMT potential is likely related to the 
biochemical and epigenetic heterogeneity of tumour cells, and although shares some 
common features with developmental EMT programmes, type 3 EMTs are different than 
the rigid execution of EMT seen during development.   
 
1.5.2 TGF in EMT 
Importantly, EMT is stimulated by extracellular activators that lead to complex 
genetic and intracellular signalling programmes that regulate this process. TGF 
signalling is a well-known activator of EMT and metastasis [233]. TGF was first shown 
to induce EMT in 1994, where the authors show that the stimulation of mammary 
epithelial cells with TGF induced a mesenchymal phenotype through a signal 
transmitted by the type I TGF receptor [234]. Since then, the process of EMT has been 
studied extensively in vitro, and TGF can stimulate the progressive loss of epithelial 
markers such as E-cadherin, ZO-1, Occludins, and cytokeratin, and the subsequent gain 
of mesenchymal markers such as N-cadherin, fibronectin, vimentin, and rearrangement of 
the cell cytoskeleton through various pathways [3, 4, 225, 230, 232, 233, 235]. Although 
multiple TGF pathways can regulate EMT, the downregulation the major adhesion 
molecule of epithelial cells, E-cadherin, is central to the EMT process. E-cadherin is a 
transmembrane cellular adhesion receptor, and constitutes the main type of adhesion 
system in epithelial cells [232]. E-cadherin based junctional complexes stabilize the 
multicellular architecture of the epithelium, providing a physical link between adjacent 
cells to maintain the structural integrity and polarized phenotype of epithelia [225, 232]. 
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TGF signalling can potently induce the downregulation of E-cadherin through 
transcriptional repression, but also by destabilizing cellular polarity. More specifically, 
the TGF Smad depedendent transcriptional programme induces the expression of the 
transcription factors SNAI1 (snail) and SNAI2 (slug), which transcriptionally repress the 
expression of E-cadherin [236-238].  Importantly, TGF stimulation can also lead to the 
destruction of E-cadherin based junctions through the phosphorylation of Par6 (the 
TGF-par6 pathway) as described above [155]. Thus, both Smad dependent, and Smad 
independent pathways are involved in the stimulation of EMT. 
TGF is a critical player in EMT during development, and TGF isoforms 
regulate EMTs in the atrioventricular canal of the heart, and are important for the fusion 
of the palate [225, 233]. Furthermore, upon pathological examination of human cancers, 
stromal TGF is often found at the invasion front, whose cells are characteristic of those 
that have undergone EMT [233]. Interestingly, TGF has also been discovered to 
promote cancer cells to acquire a stem cell-like phenotype, through the expression of 
stem cell markers and the acquisition of self-renewal [233, 239-241]. Importantly, TGF 
induced EMT can stimulate metastasis, but also may be important in generating cancer 
cells with the ability to self-renew (also referred to as cancer stem cells), thereby creating 
a tumour promoting phenotype [233]. Thus, characterizing the intricate mechanisms and 
interplay with other pathways by which TGF regulates EMT is an important area of 
research. 
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Figure 1.8.  Features of EMT 
Epithelial to mesenchymal transition (EMT) is an important process during development, 
but marks an important event during tumour progression where cells are becoming more 
invasive and metastatic. The essential components of EMT include the disruption of cell-
cell junctional complexes, (e.g. tight junctions [TJs], adherens junctions [AJs], and 
desmosomes), the loss of apical basal polarity, and a restructuring of the actin 
cytoskeleton.  Importantly, EMT also involves a shift in epithelial cell expression 
markers such as E-cadherin, Occludins, and cytokeratins to cells that express 
mesenchymal markers such as N-cadherin and Fibronectin. Cells that have undergone 
EMT show an enhanced migratory capacity, increased invasive potential, and an 
increased resistance to apoptosis. A reverse process, the mesenchymal to epithelial 
transition (MET), can also occur, allowing for environmentally regulated cell plasticity.  
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1.6 Non-canonical TGF signalling to MAPK 
The activation of the Smad signalling cascade by TGF is considered the 
canonical pathway, however, TGF receptors can also activate multiple other 
intracellular signalling cascades. Other pathways and effectors downstream of the TGF 
receptors have been shown to act independently, synergize, or even antagonize classical 
Smad signalling.  TGF is known to activate a variety of signalling networks including, 
the PI3 kinase-Akt pathway, Wnt pathways, Notch pathways, and MAPK pathways 
(reviewed in [32, 235, 242]. For this thesis, I will focus on MAPK pathways.  
 Mitogen-activated protein kinases (MAPKs) are signalling components that 
transduce extracellular stimuli into a range of intracellular responses. There are 3 
principle MAPK pathways: ERK, JNK, and p38 - each of which has a complex but 
apparent role in the development and progression of cancer [243].  In response to various 
stimuli (including TGF) MAPK members become activated through phosphorylation. 
This phosphorylation occurs through upstream MAP kinase kinases (MAP2Ks), which 
are activated by MAP kinase kinase kinases (MAP3Ks) [244]. ERKs are classically 
involved in mitogenic signalling, and often exhibit high expression and activation 
patterns in various tumours. Furthermore, they are the downstream targets of oncogenic 
Ras signalling [244]. The JNK and p38 MAPKs are SAPKs (stress associated protein 
kinases) that have more complicated roles in cancer as they can both inhibit, and/or 
stimulate tumour progression, depending on cellular context [243, 244].  
MAPK pathways generally have various mechanisms by which they respond to 
TGF induction [242]. MAPK signalling may modify the Smads (e.g. by 
phosphorylation) thereby mediating the activity of Smads as transcription factors by 
either stimulating or reducing nuclear translocation [235]. TGF receptors can activate 
non-Smad proteins to initiate signalling cascades that run parallel to Smad signalling to 
regulate a complex gene response [242]. New lines of research are uncovering networks 
of complex signalling patterns and crosstalk between multiple pathways that converge to 
elicit a specific physiological TGF response. 
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1.6.1 TGF and MAPK activation 
 TGF can activate all three MAPK pathways (Figure 1.9). TGF stimulation can 
activate ERKs through the type I receptor. Briefly, upon TGF stimulation, TRI recruits 
and directly phosphorylates ShcA, which then associates with the adaptor protein Grb2 
and a nucleotide exchange factor Sos, and this complex activates Ras, which then 
initiates ERK signalling through Raf and Mek. [245]. This pathway is Smad independent, 
and it is important to mention that the activation occurs at a much lower level than does 
stimulation with classical ERK activators such as tyrosine kinase activity [245].    
 TGF also activates the other two MAPK pathways, but by reportedly different 
mechanisms. Both p38 and JNK activation rely on the type I TGF receptor and also a 
MAP3K, TAK1 (TGF associated kinase 1). Briefly, upon TGF activation TRI 
directly associates with an E3 ubiquitin ligase called TRAF6 [192, 193]. TRAF6 becomes 
lys-63 poly-ubiquitinated, which promotes the association and activation of TAK1 [192]. 
This process was shown to be important in p38 and JNK activation, as knockdown of 
TRAF6 using siRNA (small interfering RNA) abrogated this effect [192]. Interestingly, 
this activation occurred independent of the kinase activity of TRI, but the E3 ligase 
activity of TRAF6 and TGF stimulation were required for TRAF6 auto-ubiquitination 
and TAK1 activation [193]. Importantly, the TGF-p38 MAPK pathway described has 
been reported to be important for p38-stimulated apoptosis. Inhibition of the TGF-
Traf6- p38 axis using pharmacological inhibition or siRNA knockdown blocks the TGF 
induced apoptosis of various epithelial cells [192, 193, 235, 246, 247]. However, 
signalling through p38 is complex, as in some instances p38 can also stimulate cell 
growth and survival indicating possible complex interplay of multiple pathways [243].   
Interestingly, aPKCs have been shown to play a role in p38 induced apoptosis, as 
inhibition or knockdown of aPKC sensitizes glioblastoma cells to chemotherapeutic 
agents via a p38 dependent mechanism [183]. Interestingly, aPKC is a known direct 
binding partner of TRAF6 and links it to other signalling pathways (such as NFB) 
through binding the late endosome marker and PB1 adaptor protein p62 (Figure 1.6) 
[153, 248]. Whether atypical PKC plays a role in TGF induced p38 MAPK signalling is 
still not clear. 
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Figure 1.9. TGF can activate MAPK pathways independently of Smads.   
Activated TGF receptors have been reported to activate all three MAPK pathways in a 
cell-type and context specific manner. TGF receptors can activate ERK MAPK through 
cascade starting with the direct phosphorylation of Shc. ERK signalling is typically 
mitogenic in epithelial cells. TRI can also bind the ubiquitin ligase TRAF6 to stimulate 
its autoubiquitination, which ultimately triggers a cascade that culminates in the 
phosphorylation and activation of p38 MAPK and JNK. Both p38 MAPK and JNK are 
generally pro-apoptotic in epithelial cells.  
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1.7 Purpose of Study, Hypothesis, Aims 
1.7.1 Purpose of Study 
TGF signalling controls a diverse set of cellular processes including cell 
polarity, wound healing, differentiation, migration and proliferation [6, 7, 23, 24]. 
Aberrant TGF signalling is a hallmark of many epithelial derived cancers [3, 55], and 
understanding the mechanisms by which TGF signalling is impaired would aid our 
understanding of tumour progression. Normally, TGF acts as a tumour suppressor by 
controlling the growth of the epithelium, but in many tumours TGF undergoes a role 
switch and becomes a metastatic agent through its induction of the mesenchymal 
transition and the promotion of invasion [3, 4, 55-58]. This loss of TGF growth control, 
followed by TGF induced cancer progression is exhibited in lung cancer [56-58].  Non-
small cell lung cancer (NSCLC) is the major form of lung cancer, and accounts for the 
majority of lung cancer related mortalities [249].  
 Although, TGF should normally play an anti-proliferative role in lung tumours, 
in NSCLC, the growth inhibitory effects of TGF are lost, despite these cells producing 
functional ligands and receptors [250]. Moreover, TGF induces NSCLC cell migration 
and invasion, which are hallmarks of metastatic tumours [56-58].  Therefore, 
understanding the mechanisms for TGF dysfunction is critical to furthering our 
understanding of lung cancer progression, and ultimately to developing therapies to 
circumvent altered TGF signalling patterns.  
Because TGF signal propagation is linked to the membrane trafficking of TGF 
receptors [68, 83, 89, 251, 252], elucidating the factors that contribute to altered 
membrane trafficking is an important area of research. Furthermore, characterizing the 
mechanisms that drive TGF signalling responses in cancer will require the examination 
of both Smad and Non-Smad signalling pathways. 
1.7.2 Rationale 
TGF tumour suppression is lost in NSCLC, and TGF signalling regulates lung 
tumour metastasis. The mechanisms by which TGF signalling is deregulated to become 
a tumour promoter are unknown. We believe that the deregulated TGF signalling 
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pathway seen in many NSCLC tumours may be related to altered TGF receptor 
trafficking, as well as alterations to both Smad-dependent and Smad-independent 
pathways (including Par6 and p38 MAPK). Several lines of evidence suggest that 
polarity proteins such as aPKC and Par6 have aberrant actions in NSCLC, with aPKC 
being considered an oncogene [157, 158, 160, 185-187, 253]. Furthermore, polarity 
proteins have recently been described as important regulators of vesicular trafficking 
[218]. Finally, aPKC is known effector and binding partner of multiple proteins in TGF 
pathways, including Par6 and TRAF6, although its exact role has not been defined. Thus, 
aberrant aPKC activity and a crosstalk with TGF components may contribute to how 
cells respond to TGF signalling (Figure 1.10).  
 
1.7.3 Hypothesis and Aims 
My Hypothesis is that aPKC regulates TGF receptor signalling pathways 
by: 
1) Altering TGF receptor internalization to alter Smad-dependent and Smad- 
independent signalling 
2) Altering Par6 phosphorylation leading to increased migration and EMT of 
lung cancer cells.  
This hypothesis was tested through the following 3 major aims: 
AIM 1:  Examine the role of PKC in TGF receptor trafficking and signalling.           
 
AIM 2: Elucidate the role of the aPKC in the TGF-Par6 pathway. 
AIM 3: Characterize TGF and aPKC knockdown dependent gene changes and 
examine other non-canonical TGF pathways such as p38 MAPK. 
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1.7.4 Overview of Cell Models 
This work primarily used A549s and H1299 lung adenocarcinoma cell lines as 
these are two readily used, and well established NSCLC cell models. These cell lines 
have been used for in vitro studies of cell migration [254-256], EMT [57, 257-260], as 
well as in in vivo metastasis mouse models [261, 262]. Furthermore, both of these cell 
lines have functional and intact TGF signalling pathways [263-265]. In addition to the 
above mentioned NSCLC cell lines, we also used HEK293T (human embryonic kidney) 
cells and Rat2 fibroblast cells, both of which are reliably used in our lab [266]. HEK293T 
cells were used for overexpression and interaction studies, as they are highly 
transfectable and are a key cell line in helping us dissect the molecular mechanisms 
surrounding the polarity proteins and TGF pathway. Rat2 cells are a highly migratory, 
mesenchymal, fibroblast cell type, and are used here as proof of concept, as they readily 
migrate, and respond to TGF. HEK293T and Rat2 cells are indispensable tools in 
helping us understand the molecular mechanisms surrounding TGF biology.  Finally, 
we also use Mink lung (Mv1Lu) cells which have been used extensively in the past to 
dissect the molecular mechanisms underlying the biology and signal transduction of the 
TGF receptors. These cells express TGFreceptors, their associated Smads, and are 
especially sensitive to TGFinduced gene induction and phenotypic response. However, 
the detection of the endogenous expression of TGFreceptors using immunofluorescence 
microscopy has been limited by a lack of good quality receptor antibodies.  Therefore, we 
use Mv1Lu cells stably expressing HA-tagged TGFtype II receptor (HAT cells).  These 
cells express near-endogenous levels of receptors but the HA tag on TRII allows us to 
readily study the trafficking of TGFreceptors from the cell surface into intracellular 
vesicles using HA antibodies [68, 267, 268]. 
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Figure 1.10.  Exploring a role for aPKC in Smad-dependent and Smad-independent 
pathways 
Activated TGF receptors can activate Smads, phosphorylate Par6, and trigger the 
phosphorylation of p38 MAPK. aPKCs have known roles in endocytic trafficking, and 
are known binding partners of Par6 and TRAF6 and thus have rational connections to the 
TGF pathway. Whether aPKC plays a role in TGF signalling processes is investigated 
in this thesis.  
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2 Chapter 2  
2.1 Chapter Summary 
TGFβ signalling is linked to the membrane trafficking of TGFβ receptors. The 
Protein Kinase C (PKC) family of ser/thr kinases have been implicated in modulating the 
endocytic processes of various receptors. The present study investigated whether PKC 
activity plays a role in the trafficking, and signalling of TGFβ receptors, and further 
explored which PKC isoforms may be responsible for altered TGFβ signalling patterns. 
Using immunofluorescence microscopy and 
125
I-TGFβ internalization assays, we show 
that the pharmacological inhibition of PKC activity alters TGFβ receptor trafficking and 
delays TGFβ receptor degradation. Consistent with these findings, I demonstrate that 
PKC inhibition extends TGFβ-dependent Smad2 phosphorylation. Previous studies have 
shown that PKC associates with TGFβ receptors to modulate cell plasticity.  I therefore 
used siRNA directed at the atypical PKC isoforms to investigate if reducing PKC and 
PKC protein levels would delay TGFβ receptor degradation and extend TGFβ 
signalling. Our findings suggest that atypical PKC isoforms regulate TGFβ signalling by 
altering cell surface TGFβ receptor trafficking and degradation. 
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2.2 Introduction 
The TGFβ signalling pathway is an essential regulator of many cellular processes 
including epithelial growth control, apoptosis, and the establishment of developmental 
fate. Alterations in the TGFβ pathway, such as changes in expression, mutations, or 
altered signalling patterns, have all been linked to pathological disorders of cell growth, 
such as fibrosis and cancer [1-5]  
 Although TGFβ signalling is cell type and context dependent, in most normal 
epithelium, TGFβ typically controls cell growth and division [1, 6-8]. However, in many 
pathologies, TGFβ signalling is deregulated and can induce gene changes that are 
associated with an invasive or fibrotic phenotype. Elucidating the factors that contribute 
to the alteration of the TGFβ signal can shed light on how TGFβ signalling is deregulated 
in various disease states. One major factor in the progression of the TGFβ signal involves 
receptor trafficking and endocytosis [9-13]. 
 The classical TGFβ signalling cascade involves the formation of a cell surface 
receptor complex that is composed of the TGFβ type I and type II receptors (TβRI and 
TβRII). TβRII is a constitutively active serine/threonine kinase, and phosphorylates TβRI 
upon ligand binding.  Once activated, TβRI further transduces the signal by 
phosphorylating Smad2 [14, 15]. 
 Ligand binding to cell surface TGFβ receptors induces their internalization from 
the cell membrane. The activated receptor complex internalizes one of two ways; 
Receptor endocytosis via a clathrin-dependent mechanism into the early endosome 
promotes TGFβ-dependent signal transduction, whereas partitioning into membrane rafts 
facilitates receptor degradation and signal termination [9].  
 Trafficking of TGFβ receptors into the early endosome, results in phosphorylation 
and activation of a TGFβ effector, Smad2.  Phosphorylated Smad2 complexes with 
Smad4, and this unit translocates to the nucleus to mediate TGFβ gene response. 
Alternatively, trafficking of receptors into caveolin positive membrane rafts leads to the 
recruitment of the inhibitory Smad7 and the binding of the E3 ubiquitin ligase Smurf2, 
which target the receptors for proteasomal degradation [9]. Thus, the membrane 
trafficking of TGFβ receptors plays an important role in the regulation of the TGFβ 
pathway and altered receptor trafficking may be linked to aberrant TGFβ signal 
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propagation. One family of proteins that is becoming increasingly important in endocytic 
trafficking is Protein Kinase C (PKC).  
 The PKC family consists of at least 10 members divided into three subgroups 
based on their structure and their requirements for activation. Conventional PKCs (cPKC) 
require calcium and diacylglycerol (DAG) for activation, novel PKCs (nPKC) depend 
only on DAG, and atypical PKCs (aPKC) are independent of DAG or calcium. The PKC 
serine/threonine kinases are involved in diverse cellular processes and signal transduction 
pathways that control cell proliferation, migration, differentiation and apoptosis [16-20]. 
 Several lines of evidence suggest that PKC carries important roles in controlling 
the vesicular pathways of various plasma membrane proteins, transporters and receptors 
([16, 21-24] reviewed in [25]). Furthermore changes in PKC expression, localization, or 
activity can lead to changes in receptor phosphorylation, endocytosis, desensitization, and 
receptor degradation.  For example, PKC has been shown to regulate the endocytosis and 
desensitization of various G protein coupled receptors (GPCRs) through direct 
phosphorylation [26]. PKC can also alter other membrane proteins, for example, PKC 
phosphorylation of the epidermal growth factor receptor (EGFR) regulates its 
intracellular trafficking, shifting it into recycling endosomes instead of a degradative 
pathway [27].  Similarly, the trafficking of the Dopamine transporter (DAT) has also 
been shown to be dependent on PKC activation [28], as DAT seems to be targeted for 
degradation through a PKC-dependent ubiquitination [29, 30]. Given the increasing 
evidence emerging that PKC is an important regulator of receptor trafficking, we have 
explored the role of PKC in regulating TGFβ signalling. 
 It is unknown whether one or more PKC isoforms plays a role in the regulation of 
TGFβ receptor trafficking. Interestingly, the atypical PKCs (aPKC) PKCι and PKCζ have 
recently been given considerable interest with respect to cancer, and others have 
classified PKCι to be an oncogene [31-35].  Notably, PKCζ has already been shown to be 
a factor in TGFβ induced epithelial to mesenchymal transitions through its involvement 
in the recruitment of ubiquitin ligases that drive degradation of the small GTPase RhoA, 
and ultimately epithelial cell plasticity [36, 37]. Thus, the aPKCs are likely candidates for 
regulating the endocytic trafficking of TGFβ receptors. 
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 In the present study, we show that PKC kinase activity alters TGFβ receptor 
trafficking, degradation, and ultimately TGFβ signalling. More specifically, we have 
shown that the inhibition of aPKC isoforms delays receptor degradation and extends 
TGFβ induced Smad2 phosphorylation. 
 
2.3 Materials and Methods 
2.3.1 Antibodies and Reagents 
 Commercially available antibodies were purchased from the following vendors: 
primary monoclonal anti-GFP (Living Colors-JL8), anti-Flag (Sigma F3165), anti-HA 
(Santa Cruz-Y11-SC-805), anti-β-Actin (Sigma-A2668), anti-PKCι (Santa Cruz-
SC11399), anti-PKCζ (Cell Signalling Tech-9372), anti-Phospho-Smad2 (Chemicon-
AB3849), anti-Smad2/3 (BD Trans-610842), anti-Smad7 (Santa Cruz SC-7004), anti-
Myc (Santa Cruz SC-40), anti-EEA1 (BD Trans Labs-610457) and anti-caveolin-1 (BD 
Trans Labs-610060) were used as per the manufacturers' suggestions.  HRP conjugated 
secondary goat anti-rabbit (Thermo Scientific-31460), goat anti-mouse (Thermo 
Scientific-31430) and donkey anti-goat (Santa Cruz SC-2020) were used for western blot 
analysis.  Fluorescently conjugated goat anti-mouse (Jackson ImmunoResearch-
715225150) and goat anti-rabbit (Jackson ImmunoResearch-711175152) were used for 
immunofluorescence studies. Protein G-Sepharose was purchased from GE Healthcare. 
Gö6976 and GF109203X were purchased from Calbiochem. siRNA to human PKCζ 
(10620319) and PKCι (10620319) were purchased from Invitrogen.  The constructs 
encoding Flag or HA-tagged TGFβ receptors, Myc-Smurf2, Smad7-HA and PKCζ-HA 
were used as previously described [36, 38].The GFP-tagged PKCι was a kind gift from 
Drs. A. Babwah (The Children's Health Research Institute, London ON, Canada) and S. 
Ferguson (Robarts Research institute, London ON, Canada) [39].  The HA-tagged 
Ubiquitin construct was a kind gift from Dr. L. Dagnino (University of Western Ontario, 
London, ON, Canada) [40]. 
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2.3.2 Cell Culture 
A549 non-small cell lung cancer (NSCLC), Rat2 fibroblast and HEK293T cell 
lines were maintained in Dulbecco’s Modified Eagle Medium supplemented with 10% 
fetal bovine serum. Mink Lung cells stably transfected with HA-tagged TβRII (HAT) 
cells were maintained in Minimal Essential Medium supplemented with 1% Non-
essential amino acids and 10% fetal bovine serum, and 0.3% hygromycin. Cells were 
kept in a humidified tissue culture incubator at 37ºC in 5% CO2. Calcium phosphate 
transfections were carried on cells at approximately 40% confluency, followed by a 
change in media approximately 24 hours from time of transfection. Cells were serum 
starved overnight in 0.2% FBS media prior to treatment with 250 pM TGFβ. siRNA 
transfections were conducted using Lipofectamine RNAi max according to the 
manufacturer’s protocol. For ubiquitination studies, transfected cells were pretreated with 
vehicle or GFX for 1 hour followed by the addition of the proteasome inhibitor MG132 
(2.5 M) for 6 hours prior to lysis. 
 
2.3.3 Protein Concentration 
Protein concentrations were determined using the Lowry method (Fisher). 
 
2.3.4 Immunoblotting and Immunoprecipitation 
Prior to cell lysis, cells were rinsed with phosphate buffered saline (PBS).  Cells 
were lysed in TNTE (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% 
Triton X-100, 1mM phenylmethylsulfonyl fluoride, and mixture of protease inhibitors 
[pepstatin, PMSF, NaF and NaPPi]) and centrifuged at 14,000 rpm at 4 °C for 10 min. 
Aliquots of supernatants were collected for analysis of total protein concentration. For 
immunoprecipitation, cell lysates were incubated with the indicated primary antibody, 
followed by incubation with protein-G-sepharose. The precipitates were washed three 
times with lysis buffer, eluted with Laemmli sample buffer. Proteins were resolved using 
SDS-PAGE. Proteins were transferred to nitrocellulose followed by blocking in 5% skim 
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milk, and incubation with primary antibody overnight at 4ºC. Following incubation with 
HRP conjugated secondary antibody, proteins were visualized using West Dura Super 
Signal ECL (Fisher) and imaged on a VersaDoc Imaging system (BioRad). 
 
2.3.5 Immunofluorescence Microscopy 
Receptor internalization experiments were carried out using Mv1Lu cells stably 
expressing extracellularly HA-tagged TβRII (HAT cells). HAT cells were incubated with 
anti-HA Fab fragments followed by anti-rabbit-cy3 Fab fragments in the presence of 
DMSO, Gö6976, or GF 109203X at 4°C. The cells were then incubated at 37°C for 1 hr 
to allow receptor internalization, fixed with 4% paraformaldehyde, permeabilized with 
0.25% Triton X-100, and incubated with rabbit anti-EEA1 and mouse anti-Cav1 
antibodies at 4°C overnight. Following incubation with the appropriate Cy-conjugated 
secondary antibodies, the early endosome and membrane rafts were visualized by 
immunofluorescence microscopy using an inverted IX81 Microscope (Olympus, 
Canada). Co-localization of receptors with EEA1 or Cav-1 were quantitated over 3 
experiments using computer software designed and programmed at the Samuel Lunenfeld 
Research Institute (SLRI) (Toronto, Ontario) and represented as the mean ±SD. At least 
30 cells per experiment per treatment were quantified.  
 
2.3.6 Affinity Labeling 
Cells were pre-incubated in control media (containing DMSO) or media 
containing 10 mM Gö6976, or GF 109203X for 1 hour at 37ºC, placed on ice and treated 
with 250 pM 
125I TGFβ in KRH plus 0.5% bovine serum albumin at 4ºC for 2h. 
Following cross-linking with disuccinimidyl suberate, cells were lysed (time 0) or 
incubated at 37ºC for 2, 4, or 8 hours prior to lysis. Receptors were visualized by SDS-
PAGE and quantified using phospho-imager analysis (Amersham Biosciences). 
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2.3.7 Phospho-Smad Signalling Assays and TGF Treatment 
Cells were pre-incubated in serum deprived media (0.2% FBS) containing 
DMSO, Gö6976, or GF 109203X for 1 hr. They were then treated with 250 pM TGFβ for 
30 minutes, washed and further incubated in the presence or absence of the PKC 
inhibitors in serum  deprived media for an additional 1 or 4 hours prior to lysis. Lysates 
were then processed for SDS-PAGE, and immunoblotted for Phospho-Smad2 and total 
Smad2 levels. 
 For the 24 hr TGFβ chase experiment, siRNA treated A549 cells were pre-
treated with DMSO (control) or SB431542 (10 mM) for 0.5 hours prior to TGFβ 
treatment for 1 hour. Cells were then washed with PBS 3 times, followed by incubation 
in low serum media containing DMSO or SB431542 for an additional 24 hours before 
lysis. Lysates were processed for SDS-PAGE and immunoblotted as described above. 
 
2.3.8 Statistical Analyses 
One-way or Two-way ANOVA analyses followed by post-hoc Tukey’s Test were 
used to evaluate the significance of the results. Statistical analyses were performed using 
GraphPad Prism® Software and p values of <0.05 were considered statistically 
significant. 
 
2.4 Results 
2.4.1 Inhibition of PKC alters TGF receptor trafficking 
TGFβ signal transduction is highly regulated through receptor endocytosis and 
membrane trafficking.  To determine whether PKC had an effect on the internalization of 
the TGFβ receptors, we pharmacologically inhibited PKC activity and assessed TGFβ 
receptor endocytosis using Mv1Lu cells stably expressing extracellularly HA-tagged 
TβRII receptors (HAT cells). Stable expression of HA tagged TRII in this cell line 
allows for sensitive detection of the movement of TGF receptors into intracellular 
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vesicles using immunofluorescence microscopy [9, 41]. The cells were cultured in 
control media, or media containing a classical PKC inhibitor (Gö6976), or a pan PKC 
kinase inhibitor, GF109203X (Figure 2.1).  Cell surface TGFβ receptors were labelled at 
4˚C and after incubation at 37°C for 1 hour, the cells were fixed, permeabilized and 
counterstained with markers for the early endosome (using anti-EEA1) or membrane rafts 
(anti-Cav-1) (Figure 2.1). 
 In untreated cells we observed that after 1 hr of internalization, TGFβ receptors 
gained access to the interior of the cell.  Approximately half of the receptors co-localized 
with either the EEA1-positive or Cav-1-positive compartments in equal proportion 
(Figure 2.1A, quantified in 2.1D).  The cPKC inhibitor, Gö6976, did not alter the ratio of 
receptors in the EEA1-positive or Cav-1-positive compartments (Figure 2.1B). We did 
however notice a general accumulation of receptors and Cav-1 positive vesicles at the 
peri-plasma region of the cell (Figure 2.1B). Interestingly, the pan PKC inhibitor, GF 
109203X, did not perturb the position of the Cav-1 compartment but increased TGFβ 
receptor co-localization with the EEA1 compartment (Figure 2.1C and 2.1D).  
 These results suggest that the inhibition of different PKC isoforms will alter 
receptor trafficking.  Indeed, pan PKC inhibition shifted the ratio of receptors into the 
EEA1-positive signalling endosomes whereas targeting classical PKC isoforms did not 
(Figure 2.1D). From these results we predicted that the rate of receptor degradation, and 
possibly signal transduction, would be affected.  We first assessed whether the alteration 
in receptor internalization would lead to changes in the rate of TGFβ receptor 
degradation.  
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Figure 2.1 
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Figure 2.1.  PKC inhibition alters TGF receptor trafficking 
Mv1Lu cells stably expressing extracellularly HA-tagged TRII were incubated with 
anti-HA Fab fragments followed by anti-rabbit-cy3 Fab fragments in the presence of 
DMSO (Control; A), 10 M Gö6976 (B), or 10 M GF109203X (C). The cells were then 
incubated at 37°C for 1 hr (to allow receptor internalization), fixed, permeabilized and 
incubated with mouse anti-EEA1 and rabbit anti-Cav1 antibodies. Following incubation 
with the appropriate secondary antibodies, the receptors (red), the early endosomal 
compartment (EEA1; blue) and membrane rafts (Cav-1; green) were visualized by 
immunofluorescence microscopy. Co-localization of receptors with EEA1 or Cav-1 is 
indicated with arrowheads or arrows, respectively. Note that Gö6976 induces an 
accumulation of receptors and Cav-1-positive structures at the peri-plasma membrane 
(grey arrowheads; B).  Bar = 10 m. 
(D) Receptors co-localizing with EEA1 or Cav-1 positive vesicles were quantitated from 
three separate experiments and represented as the mean +/-SD. (n=3). 
 
 
 
 
 
 
 
 
 
82 
 
 
2.4.2 Inhibition of PKC activity extends TGF receptor half-life 
To determine whether PKC kinase activity had an effect on TGFβ receptor 
degradation, we used 
125
I-radiolabelled TGFβ to conduct receptor half-life studies. 
Briefly, serum starved Mv1Lu cells were treated with 
125
I-TGFβ at 4°C; a temperature 
where TGFβ receptors halted at the cell surface. After cross-linking the 125I-TGFβ to cell 
surface receptors, the cells were incubated in control media or media containing PKC 
inhibitors (Gö6976 or GF109203X) at 37°C. Cells lysates were then processed for SDS-
PAGE, and receptor levels are analyzed using phospho-imaging (Figure 2.2).  We 
observed that the inhibition of PKC kinase activity with either inhibitor decreased the rate 
of TGFβ receptor degradation (Figure 2.2A). The receptor half-life in untreated cells was 
2.4 ± 0.3 hours and extended to 4.4 ± 0.8 in Gö6976-treated and 6.6 ± 1.7 in GFX-treated 
cells (Figure 2.2B). Interestingly, receptor degradation was reduced in the presence of 
either classical or pan PKC inhibitors. 
 After observing that PKC inhibition could alter receptor degradation and receptor 
trafficking, we next addressed if PKC inhibition would affect TGFβ dependent Smad2 
phosphorylation. 
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Figure 2.2 
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Figure 2.2.  PKC inhibition extends TGF receptor half-life 
(A) Mv1Lu cells incubated in the presence of DMSO (control), 10 M Gö6976 or 10 M 
GF109203X were affinity labelled with 
125
I-TGF, cross-linked and incubated at 37°C 
for 0, 2, 4, or 8 hours. Cells were then lysed, and subjected to SDS-PAGE followed by 
phospho-imaging.  The relative mobilities of 
125
I-TGF-bound TRII (~90 kDa) and 125I-
TGF-bound TRI (~65 kDa) are indicated. 
(B) Three separate experiments as described in Panel A were carried out and the amount 
of the receptors was quantitated using QuantityOne software and plotted as a percentage 
of receptors at time 0.  The mean +/- SD is shown. (n=3). 
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2.4.3 TGF dependent Smad phosphorylation is extended with PKC 
inhibition 
Smad2 phosphorylation is a key component in TGFβ signalling and is the central 
mediator of TGFβ-dependent transcription. To assess whether PKC could alter TGFβ 
dependent Smad signalling, we assessed Smad2 phosphorylation levels over a 4-hour 
time course (Figure 2.3).  Briefly, HAT, Rat2 fibroblast or A549 human lung 
adenocarcinoma cells were treated for 1 hr with DMSO (control), Gö6976 or 
GF109203X, prior to TGFβ stimulation for 0.5 hr. After washing out the TGFβ, cells 
were incubated in the respective serum-deprived media in the presence or absence of 
inhibitors for an additional 1 or 4 hr before they were lysed (Figure 2.3A). Activated 
TGF receptors will continuously signal until degraded once internalized, thus washout 
of TGF allows for analysis of the duration of TGF signalling of internalized receptors. 
Quantitation showed that HAT cells that were incubated in media containing PKC 
inhibitors had prolonged levels of Smad2 phosphorylation compared to vehicle-treated 
cells (Fig 2.3B). These results were not cell line or cell type specific as Rat2 fibroblasts 
and A549 human NSCLC cells also showed increased and prolonged Smad2 
phosphorylation in the presence of PKC inhibitors (Figure 2.3C and 2.3D). We next 
sought to further determine which class of PKCs was responsible for this extension. 
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Figure 2.3 
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Figure 2.3.  PKC inhibition extends TGF induced Smad2 phosphorylation 
(A) Schematic of the experimental procedure to assess phosphorylated Smad2 levels in 
PKC inhibited cells.  HAT (B) Rat2 (C) or A549 (D) cells were pre-incubated in media 
containing 10 M Gö6976, 10 M GF109203X, or DMSO (vehicle). They were then 
treated with 250 pM TGF for 0 or 30 minutes, washed and further incubated in the 
presence or absence of the PKC inhibitors for an additional 1 or 4 hours prior to lysis. 
Lysates were then processed for SDS-PAGE and immunoblotted with anti ()-phospho-
specific Smad2 or Smad2/3 antibodies as indicated. Accompanying densitometrical 
analyses of average P-Smad2 levels from at least 3 independent replicate experiments is 
presented graphically for each representative immunoblot. The mean +/- SEM is shown, 
Two-way ANOVA, *p <0.05.  
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2.4.4 Targeting aPKC kinases extends Smad2 phosphorylation 
Although we observed that both types of PKC inhibitors could extend Smad2 
phosphorylation, the signalling pattern was much more prominent in cells inhibited with 
the broad PKC inhibitor GF109203X compared to the classical PKC inhibitor. This 
suggested that classical PKC isoforms may play a more subtle role in TGFβ signalling 
compared to either the novel or aPKC isoforms. To test whether aPKC isoforms were the 
likely candidates in dampening TGFβ signalling, we carried out similar signalling assays 
as described above in A549 cells (Figure 2.4). For this assay we incubated cells with two 
different concentrations of GF109203X: 1 M, which only effectively inhibits the 
classical and novel PKC isoforms, and 10 M, which inhibits all classes of PKCs. Our 
results demonstrated that signalling was more prominently extended in cells inhibited 
with 10 M GF109203X, suggesting that aPKC kinase activity was important in 
regulating TGFβ signalling. 
 To confirm our pharmacological observations, we next assessed the effects of 
PKC isoforms on TGFβ-dependent receptor signalling and degradation via 
overexpression and siRNA studies. 
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Figure 2.4 
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Figure 2.4.  aPKC inhibition extends TGF induced Smad2 phosphorylation 
A549 cells were incubated with 1 M (inhibits classical and novel PKCs) or 10 M 
(inhibits all PKCs) GF109203X for 1 hour. They were then treated with 250 pM TGF 
for 0 or 30 minutes, washed and further incubated in the presence or absence of the PKC 
inhibitor for an additional 1 or 4 hours prior to lysis. Lysates were then processed for 
SDS-PAGE and immunoblotted with anti phospho-specific Smad2 or Smad2/3 antibodies 
as indicated.  Accompanying densitometrical analysis of average P-Smad2 levels from 3 
independent replicate experiments is presented graphically for each representative 
immunoblot. The mean +/- SEM is shown, n=3, Two-way ANOVA, *p <0.05.  The 
asterisk (*) beside immunoblots indicates a second band underneath Smad2 in A549 cells 
that may represent Smad3 in this cell line.  
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2.4.5 aPKC over-expression reduces TGF receptor steady state 
levels 
TGFβ receptor degradation may be a key determinant in the extension of Smad2 
signalling. Our data suggested that aPKCs may be primarily responsible for the negative 
regulation of TGFβ receptors. To test this, we expressed TGFβ receptors and increasing 
amounts of a representative member of the classical PKC family, PKC, or increasing 
amounts of an aPKC, PKCι into HEK 293T cells (Figure 2.5A). Western blot analysis 
indicated that PKCι decreased the levels of steady state TGFβ receptors. Of note, the 
multiple bands that represent the core and glycosylated forms of TRII receptors as well 
as TRI were reduced in the presence of increasing levels of PKCι. In contrast, no 
apparent changes in receptor levels were noted with increasing expression of the classical 
PKC, PKC. Quantitation confirmed that aPKC, but not the cPKC, reduced receptor 
levels (Figure 2.5B). 
 To test if aPKC kinase activity was necessary for altering receptor levels, we 
conducted similar experiments with increasing expression levels of wild-type (WT) or 
kinase-deficient (KR) versions of PKCζ. Our results showed that increasing amounts of 
PKCζ lead to decreased steady-state levels of TGFβ receptors.  In contrast, increasing 
amounts of the kinase-deficient PKCζ did not alter TRI or TRII expression (Figure 
2.5C and 2.5D). We next assessed TGF receptor ubiquitination levels. 
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Figure 2.5 
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Figure 2.5.  aPKC overexpression reduces steady state TGF receptor levels 
(A) HEK 293T cells were transiently transfected with cDNA encoding the indicated 
proteins. Equal amounts of TRI-FLAG and TRII-HA were co-transfected with 
increasing amounts of either GFP tagged PKC, or PKC. 48 hours post-transfection, 
cells were lysed and processed for SDS-PAGE and immunoblotting to assess receptor 
levels. A representative immunoblot from three separate independent trials is shown. 
(B) Average densitometrical quantitation of TGF receptors was carried out from 3 
separate experiments using QuantityOne software and graphed (n=3).  
(C) HEK 293T cells were transiently transfected with cDNA encoding the indicated 
proteins. Equal amounts of TRI-FLAG and TRII-HA were co-transfected with 
increasing amounts of either HA tagged PKC-WT or a kinase deficient version, PKC-
KR. 48 hours post-transfection, cells were lysed and processed for SDS-PAGE and 
immunoblotting to assess receptor levels. A representative immunoblot from three 
separate independent trials is shown. 
(D) Average densitometrical quantitation of TGF receptors was carried out from 3 
separate experiments using QuantityOne software and graphed (n=3). 
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2.4.6 PKC inhibition alters TGF receptor ubiquitination levels 
TGF receptors can be degraded through the conjugation of ubiquitin to activated 
receptor complexes by the E3 ubiquitin ligase Smurf2 [38]. Therefeore, we next 
addressed whether PKC inhibition could affect receptor ubiquitination levels (Figure 2.6).  
HEK293T cells expressing receptors, ubiquitin, Smad7 and Smurf2 were incubated in the 
presence or absence of GF109203X. Following co-expression of receptors with ubiquitin 
and wild type Smurf2 and Smad7, the steady state levels of the TGF receptors, as well 
as Smurf2 and Smad7 in the total cell lysates was reduced (Figure 2.6, lower panel lane 
3).  This was paralleled with an increase in high molecular weight ubiquitinated 
complexes in the receptor immunoprecipitations (Figure 2.6, top panel lane 3). In 
contrast, receptors that were co-expressed with a catalytically inactive mutant of Smurf2 
(Smurf2-CA) were protected.  Interestingly, the levels of the higher molecular weight 
ubiquitinated complexes increased in cells treated with PKC inhibitor (Figure 2.6, top 
panel lane 5).  Taken together these findings suggested that aPKC kinase activity might 
be altering TGFβ receptor trafficking to enhance degradation, and inhibiting aPKC results 
in an increase of ubiquitinated receptors. To test this hypothesis, we next used small 
interfering RNA directed at the aPKCs and examined cell surface TGFβ receptor 
degradation.  
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Figure 2.6 
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Figure 2.6.  PKC inhibition reduces clearance of ubiquitinated TGF receptor 
complexes 
HEK 293T cells expressing combinations of TRII, TRI-Flag, Ubiquitin-HA, Smad7-
HA, and the wild-type (WT) or catalytically inactive (CA) E3 ubiquitin ligase, Myc-
Smurf2, were lysed, immunoprecipitated using anti-Flag monoclonal antibodies to isolate 
TGF receptors.  The immunoprecipitates were then subjected to SDS-PAGE, followed 
by immunoblotting with the indicated antibodies. Anti-HA immunoblotting was used to 
detect ubiquitinated receptors and/or associated proteins (denoted by the asterisk). Total 
lysates are shown in the bottom panel. Cells were pre-treated with vehicle or GF109203X 
for 1 hour followed by addition of the proteasome inhibitor MG132 for 6 hours prior to 
lysis. A representative immunoblot from 3 independent replicate experiments is presented 
(n=3). 
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2.4.7 siRNA targeting aPKC reduces TGF receptor degradation 
We next addressed whether endogenous aPKC, and which isoform, regulates the 
degradation of endogenous TGFβ receptors.  To ensure that we were able to detect each 
aPKC specifically, we first tested our antibody specificity in HEK293T cells to test for 
possible cross-reaction of isoforms (Figure 2.7A). By western blotting, we observed that 
both the PKCι and PKCζ antibodies were specific.  We next we next assessed our siRNA 
targeting of the two aPKC isoforms was specific and effective.  Our results showed that 
the siRNA constructs are specific for their targets, however, we also noted that there is a 
compensation effect for PKCζ, when we silence PKCι: In siPKCι knock down cells, there 
was a small, yet consistent, increase in expression of PKCζ (Figure 2.7B).  Having 
ascertained that the siRNA to the different aPKC isoforms was specific and effective, we 
assessed their influence on TGFβ receptor degradation (Figure 2.7C).  Consistent with 
our observations using pharmacological inhibitors, we observed that silencing aPKC 
isoforms with siRNA resulted in a significant reduction in the degradation of cell surface 
TGFβ receptors after 8 hours (Figure 2.7C and 2.7D).  
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Figure 2.7 
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Figure 2.7.  aPKC knockdown reduces TGF receptor degradation 
(A) Lysates from HEK 293T cells expressing GFP tagged PKC or PKC were subjected 
to SDS-PAGE followed by immunoblotting with antibodies directed at GFP, PKC, 
PKC and Actin as a loading control. 
(B) A549 cells were transfected with siRNA directed at PKC, PKC, both PKC and 
PKC   (PKC/) or control siRNA. Cells were lysed and subjected to SDS-PAGE and 
immunoblotting to assay for PKC or PKC protein expression. Note: Both PKC and 
PKC siRNAs are effective in all 3 conditions. 
(C) A549 cells transfected with the indicated siRNA were affinity labelled with 
125
I-
TGF, cross-linked and incubated at 37°C for 0, 2, 4 or 8 hours. Cells were then lysed, 
and subjected to SDS-PAGE followed by phospho-imaging analysis.  The relative 
mobilities of 
125
I-TGF-bound TRII (~90 kDa) and 125I-TGF-bound TRI (~65 kDa) 
are indicated. 
(D) Three separate experiments as described in Panel C were carried out and the amount 
of the receptors was quantitated using QuantityOne software and plotted as a percentage 
of receptors at time 0.  The mean +/- SD is shown, n=3, Two-way ANOVA, *p<0.05.  
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2.4.8 Knockdown of aPKC extends Smad2 phosphorylation 
Using PKC kinase inhibitors and PKC overexpression, we observed that aPKC 
expression increases receptor degradation and aPKC activity also negatively regulates 
TGFβ induced Smad2 signalling. Furthermore, knockdown of aPKC using siRNA results 
in reduced TGFβ receptor degradation.  Next we used siRNA to test whether knockdown 
of specific aPKCs could extend TGFβ induced signalling. After transfecting A549 cells 
with combinations of siRNA directed towards aPKC isoforms, we conducted Smad2 
phosphorylation time courses (Figure 2.8).  Our results indicate that in cells where both 
aPKCs were knocked down (siPKCι/), there was an extension of phospho-Smad2 levels 
compared to cells transfected with control siRNA. This extension was also seen in 
siPKCζ cells, but less pronounced in siPKCι cells, indicating that silencing both aPKCs 
had the greatest effect on phospho-Smad2 levels (Figure 2.8). We next tested to see 
whether aPKC knockdown could cause longer phospho-Smad2 levels.  
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Figure 2.8.  aPKC knockdown extends Smad2 phosphorylation 
A549 cells transfected with the indicated siRNA were serum starved and treated with 250 
pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours prior to lysis. 
Lysates were then processed for SDS-PAGE and immunoblotted with anti phospho-
specific Smad2 or Smad2/3 antibodies. Accompanying densitometrical analysis of P-
Smad2 levels from 3 independent replicate experiments is presented graphically for each 
representative immunoblot. The mean +/- SEM is shown, n=3, Two-way ANOVA, *p 
<0.05. 
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2.4.9 Smad2 phosphorylation persists 24 hours in aPKC silenced 
cells 
 To test if phospho-Smad2 levels could persist for an extended period of time, we 
stimulated siRNA treated cells with TGFβ for 1 hour, followed by washout and further 
incubation of cells for 24 hours (Figure 2.9). Interestingly, we found that in knock down 
cells, phospho-Smad2 was maintained even after cells were washed of exogenously 
added ligand. Finally, to test whether any extended Phospho-Smad2 levels were 
specifically due to the activation of TGFβ receptors, we incubated cells with the TβRI 
kinase inhibitor, SB431542. This inhibitor blocks TβRI from phosphorylating Smad2, 
and thus should reduce TGFβ induced phospho-Smad2 signalling. As expected, the 
extension in phospho-Smad2 levels was abrogated when cells were co-treated with 
SB431542, indicating that any changes we observed in signalling were TGFβ receptor 
dependent (Figure 2.9). 
 Taken together, our data suggest that aPKC isoforms regulate TGFβ signal 
transduction by regulating receptor trafficking and degradation, summarized in Figure 
2.10. 
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Figure 2.9.  aPKC knockdown extends TGF induced Smad2 phosphorylation even 
after 24 hours 
siRNA transfected A549 cells were serum starved and pre-treated with vehicle (DMSO) 
or 1 M of the TRI kinase inhibitor, SB431542. Cells were then treated with 250 pM 
TGF for 1 hour, washed and further incubated for 24 hours in control or SB431542 
media prior to lysis. Lysates were then processed for SDS-PAGE and immunoblotted 
with anti phospho-specific Smad2 or Smad2/3 antibodies. Accompanying densitometrical 
analysis of P-Smad2 levels from 3 independent replicate experiments is presented 
graphically for each representative immunoblot. The mean +/- SEM is shown, n=3, Two-
Way ANOVA, *p <0.05. 
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Figure 2.10.  Regulation of TGF receptor trafficking and signalling by atypical 
protein kinase C 
Pharmacological inhibition of all PKC isoforms alters TGF receptor trafficking by 
shifting receptors into the early endosome, reducing receptor degradation, and extending 
TGF-induced Smad2 phosphorylation. siRNA knockdown of atypical PKC isoforms 
also reduces TGF receptor degradation and extends TGF induced Smad2 
phosphorylation. 
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2.5 Discussion 
The TGFβ signalling pathway controls many biological responses orchestrated 
through the regulation of various genes and downstream effectors. Altered TGFβ 
signalling patterns are often a hallmark in epithelial derived cancers. In certain tumours 
the proteins involved in TGFβ signalling are still intact and functional, but the pathway is 
deregulated by some other means. This seems to be the case in non-small cell lung cancer 
(NSCLC) as many of these tumours are unresponsive to the tumour suppressive 
properties of TGFβ, despite producing functional ligands and receptors [42, 43]. One 
proposed mechanism is a change in TGFβ receptor signalling patterns due to altered 
membrane trafficking of the TGFβ receptors upon internalization. PKCs, which are major 
regulators of intracellular trafficking, may therefore regulate TGFβ signalling.  In the 
present study we propose that atypical PKC isoforms are involved in altering the 
vesicular fate of TGFβ receptors to ultimately change TGFβ signalling patterns.  
 We have shown that PKC kinase activity plays a role in the membrane trafficking 
and degradation of TGFβ receptors, as broad PKC inhibition with GF109203X caused a 
shift of receptors into the early endosome and a reduction in TGFβ receptor degradation. 
Interestingly, the classical PKC inhibitor, Gö6976, did not shift receptors into the early 
endosome, but did however alter the trafficking of Cav-1 positive vesicles and reduced 
TGFβ receptor degradation. This brings up the possibility that classical PKC isoforms 
alter general membrane trafficking and we suspect that this would have an effect not only 
on TGF receptor trafficking but other cell membrane proteins as well. 
 We observed that the overexpression of aPKC isoforms negatively regulate the 
steady state levels of both the type I and type II TGFβ receptors. This is in contrast to 
steady receptor levels when a classical PKC (PKC) or a kinase deficient aPKC are 
overexpressed.  
 Furthermore, using siRNA targeted to aPKC isoforms, we observed that 
knockdown of aPKC expression results in a reduction in TGFβ receptor degradation from 
the cell surface. These data suggest that aPKC promotes TGFβ receptor degradation upon 
endocytosis. Interestingly, the PKCζ knockdown and the double PKCι/ knockdown 
seem to produce the greatest effect. However, it is important to note that in siRNA treated 
cells where PKCι has been silenced, we observed a consistent increase in PKCζ 
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expression, which may be responsible for the less prominent effects on Smad2 
phosphorylation. We reason that both aPKC isoforms are capable of increasing TGFβ 
receptor degradation as double knockdown of PKC produces the greatest effect on 
temporal extension of TGF induced P-Smad2 levels. 
Interestingly, although we observe reductions in TGF receptor cell surface 
degradation with PKC inhibition, Smurf2 mediated ubiquitination of TGF receptors was 
increased. This may be the result of an accumulation of ubiquitinated complexes due to 
an increased residence time of receptors in intracellular compartment(s) and is consistent 
with our observations that PKC inhibition can delay receptor degradation and extend the 
duration of phosphorylated Smad2 levels. 
 This study addresses the idea that aPKC can alter TGFβ receptor trafficking and 
also alter local TGFβ signalling patterns in A549 lung cancer cells after an initial short 
TGFβ stimulus. It will be interesting to see whether aPKC knockdown can alter 
phenotypic changes in cells that receive constant TGFβ stimulation; similar to tumour 
cells growing in a microenvironment where autocrine and paracrine TGFβ 
overproduction leads to higher and constant levels of TGFβ stimulation. 
 Aberrant aPKC expression and activity are becoming more apparent in various 
cancers [32, 34, 44-46]. More specifically, in NSCLC where an increased expression of 
aPKC is reported, it is plausible that the TGF receptor signalling pathway may be 
altered by an interplay with aPKC. More specifically, our data suggest that enhanced 
aPKC expression and activity may contribute to increases in TGF receptor degradation, 
alterations in the TGF signal, and consequently a loss in some of the characteristic 
TGF tumour suppressive properties.  This is supported by the fact that aPKC localize 
and can be anchored to late endosomes that are targeted for degradation [24]. 
Furthermore, since we have observed that aPKC kinase activity is important for changes 
in TGF receptor trafficking, degradation, and signalling, there exists the possibility that 
aPKC directs TGF receptor trafficking into specific compartments through the 
phosphorylation of one or more of the TGF receptors, as is the case for the EGFR [27]. 
This is supported by the finding that PKCζ is a TGF receptor interacting partner in a 
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complex which regulates cytoskeletal changes involved in epithelial to mesenchymal 
transition [36, 37]. 
 
2.6 Footnotes 
The work carried out in this study was supported by the Canadian Institutes of Health 
Research (GMDG, grant: MOP-93625). 
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3 Chapter 3 
3.1 Chapter Summary 
EMT is controlled by cellular signalling pathways that trigger the loss of cell-cell 
adhesion and lead to the restructuring of the cell cytoskeleton. TGF has been shown to 
regulate cell plasticity through the phosphorylation of Par6 on a conserved serine residue 
(S345) by the type II TGF receptor. Here we show that aPKC isoforms are an essential 
component to this signalling pathway in non-small cell lung cancer (NSCLC) cells.  We 
show that the aPKC, PKC interacts with TGF receptors through Par6, and that these 
proteins localize to the leading edge of migrating cells. Furthermore, Par6 
phosphorylation on Ser 345 by TGF receptors is enhanced in the presence of aPKC. 
aPKC kinase activity as well as association with Par6 were found to be important for 
Par6 phosphorylation. In effect, siRNA-targeting aPKC reduces TGFinduced RhoA 
and E-cadherin loss, cell morphology changes, stress fibre production and the migration 
of NSCLC cells. Interestingly, re-introduction of a phospho-mimetic Par6 (Par6-S345E) 
into aPKC-silenced cells rescues both RhoA and E-cadherin loss with TGF stimulation. 
In conclusion, our results suggest that aPKCs co-operate with TGF receptors to regulate 
phospho-Par6-dependent EMT and cell migration. 
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3.2 Introduction 
During tumour progression, EMT characterizes an event where the cohesive, 
apico-basolaterally polarized cells of the epithelium detach from the basement membrane 
and acquire the ability for independent movement as mesenchymal like cells [1-3]. EMT 
is characterized by the loss of E-cadherin based adherens junctions allowing for 
stationary carcinoma cells to escape the physical constraints of cell-cell adhesion leading 
to invasion of the stromal compartment [3]. The process of EMT involves altering cell 
genetic programs and inducing morphological changes that foster an invasive and 
migratory phenotype [1, 2, 4-6]. TGF signalling is an important regulator of EMT 
through its promotion of invasion and metastasis [7-9].  In conjunction to the canonical 
TGF-Smad pathway that has been shown to alter transcriptional responses leading to 
EMT, a second TGF pathway was defined, in which the conserved polarity protein Par6 
was shown to be a binding partner and substrate of the TGF receptors [10, 11].  Indeed, 
TGF-dependent phosphorylation of Par6 on Serine 345 leads to Smurf1 mediated 
degradation of RhoA. This in turn leads to significant remodelling of the actin 
cytoskeleton, and the dissolution of tight and adherens junctions leading to EMT and 
metastasis [10, 12, 13]. 
Par6 is an adaptor molecule for the polarity complex [14-18]; a highly conserved 
group of interacting protein partners, including aPKC, Par3, and several small GTPases 
that work in concert to control apical-basal cell polarity, directional cell polarization, 
migration, and cell proliferation [14, 17, 19-24].  Notably, aPKC was shown to be part of 
the complex that regulates protrusion formation through the TGF receptors [10, 25, 26] 
although its exact role has not been defined. 
The aPKCs, which consist of PKC and PKC are a unique subset of PKCs that 
do not require diacylglycerol (DAG), phosphatidylserine, or calcium for their activation 
[27]. PKChas been implicated in carcinogenesis [28-34] and is considered to be the first 
member of the PKC family to be a human oncogene [29]. Our recent work has shown 
that PKC activity can regulate the trafficking and degradation of TGF receptors as well 
as the duration of Phoshpho-Smad2 signalling [35]. 
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Here, we report that in addition to TGF receptors, aPKCs phosphorylate Par6 on 
Ser 345, and aPKC expression increases Par6 steady state levels.  Furthermore, reduction 
in aPKC expression or the association of aPKC with Par6 reduces EMT and migration of 
NSCLC cells.  
 
3.3 Materials and Methods 
3.3.1 Antibodies and Reagents 
Primary monoclonal anti-GFP (Living Colors-JL8), anti-Flag (Sigma F3165), 
anti-HA (Santa Cruz-Y11-SC-805), anti--Actin (Sigma-A2668), anti-PKC (Santa Cruz-
SC11399)/ (BD Transduction-610175), anti-PKCand anti-PPKC (Cell Signalling 
Tech-9372 and -9378), anti-Rac1 (BD Transduction-610650), and anti-E-cadherin (BD 
Transduction-610182 and Cell Signalling Tech-3195) were used as per the 
manufacturers' suggestions.  Anti-P-Par6 (S345) was a gift from Dr. Jeff Wrana.  HRP 
conjugated secondary goat-anti-rabbit (Thermo Scientific -31460) and goat-anti-mouse 
(Thermo Scientific -31430) were used for immunoblot analysis.  Fluorescently 
conjugated goat -mouse (Jackson ImmunoResearch-715225150), goat -rabbit (Jackson 
ImmunoResearch-711175152) and Cy3 conjugated Streptavidin (Jackson 
ImmunoResearch-016160084) were used for immunofluorescence studies. A555 
conjugated Phalloidin (Invitrogen-A34055) was used for F-actin staining.. Human siRNA 
constructs were purchased from Invitrogen (Stealth)  (siPKC, siPKC and siControl 
catalogue numbers: (10620319-HSS183348, 10620319-HSS183318, 12935112) 
respectively. The constructs encoding Flag or HA-tagged TGFβ receptors, Flag-Smurf1, 
Flag-Par6 (WT and S345), PKCζ-HA were used as previously described [10, 36].The 
GFP-tagged PKCι was a kind gift from Drs. A. Babwah (The Children's Health Research 
Institute, London ON, Canada) and S. Ferguson (Robarts Research institute, London ON, 
Canada) [37]. Transwell migration assays were conducted using Costar transwell 
permeable support inserts with a pore size of 8 m (Costar-3422).  
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3.3.2 Cell Culture and Transfections 
Rat2 fibroblast, and HEK293T cell lines were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum. A549 and H1299 
NSCLC cell lines were maintained in F12K and RPMI-1640 Medium (respectively) 
supplemented with 10% fetal bovine serum.  Cells were kept in a humidified tissue 
culture incubator at 37ºC in 5% CO2. Calcium phosphate transfections were carried on 
cells at approximately 40% confluency, followed by a change in media approximately 24 
hours from time of transfection. siRNA transfections were conducted using 
Lipofectamine RNAi max (Invitrogen) according to the manufacturer’s protocol. DNA 
transfection of H1299 and A549 cells was conducted with Lipofectamine 2000 
(Invitrogen) or Lipofectamine LTX (Invitrogen) respectively, according to the 
manufacturer’s protocol. 
 
3.3.3 Protein Concentrations 
Protein concentrations were determined using the Lowry method (Fisher). 
 
3.3.4 Immunoblotting and Immunoprecipitation 
Cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and a mixture of protease inhibitors) 
and centrifuged at 14,000 rpm at 4 °C for 10 min. Aliquots of supernatants were collected 
for analysis of total protein concentration. For immunoprecipitation, equal amounts of 
remaining cell lysates were incubated with primary antibody, followed by incubation 
with protein G-Sepharose beads. The precipitates were washed three times with lysis 
buffer, eluted with sample buffer, and subjected to SDS-PAGE. Proteins were transferred 
to nitrocellulose followed by blocking in 5% skim milk, and incubation with primary 
antibody in TBST overnight at 4ºC. Following incubation with HRP conjugated 
secondary antibody, proteins were visualized using West Dura Super Signal ECL (Fisher) 
and imaged on a VersaDoc Imaging system (BioRad). 
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3.3.5 Scratch Assays and Polarization Assay 
To assess cell migration, a confluent monolayer of cells was scratched with a 
sterile pipette tip to create an opening, or “wound”. Following wounding, cells were 
incubated in serum containing medium for 4 hours to allow for cell polarization and 
leading edge formation. Cells were then fixed and processed for Immunofluorescence 
microscopy. For the polarization assay, A549 cells were transfected with control or aPKC 
directed siRNA. 24 hours post transfection, cells were seeded subconfluently onto 
coverslips to allow cells to establish front-rear polarization. 24 hours following seeding, 
cells were fixed and processed for immunofluorescence microscopy. For quantification of 
polarization, immunofluorescence images were acquired and scored for polarization 
phenotype. At least 100 cells were assessed per condition, per experiment. Graphs 
represent the average of 3 independent experiments ±SD.  
 
3.3.6 Immunofluorescence Microscopy 
For immunofluorescence microscopy studies, cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.25% Triton X-100 and incubated for 1 hour in 
blocking solution (10% FBS/PBS) then incubated with the indicated primary antibodies 
in blocking solution. Following incubation with the appropriate Cy-conjugated secondary 
antibodies (or streptavidin), and A555 Phalloidin, cells were visualized by 
immunofluorescence microscopy using an inverted IX81 Microscope (Olympus, 
Canada).  
 
3.3.7 Transwell Migration Assays 
H1299 cells were transfected with equal amounts of either empty vector (pIRES) 
or one of the Par6 constructs in the pIRES vector. Cells were serum starved for 3 hours 
prior to being seeded onto the top of a transwell chamber (Costar). 30 000 cells per 
condition were seeded and were allowed to migrate towards medium containing 10% 
serum. In parallel, 30 000 cells from each condition was seeded onto coverslips in 
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medium containing 10% serum. After 18 hours, cells on the topside of the transwell 
membrane were removed with a cotton swab, and the migrated cells (on the underside of 
the transwell) were fixed with 4% paraformaldehyde. Cells on both transwell and the 
coverslips were stained with DAPI and mounted onto glass slides. Images were acquired 
using an IX81 inverted microscope (Olympus). Ten representative fields were acquired at 
200x magnification and quantified. Graphs represent the average of 3 independent 
experiments.  Cells expressing GFP were counted for each transwell. Cells that were 
plated simultaneously on coverslips were also quantified and were compared to DAPI 
stained cells (total cells) to determine transfection efficiencies. 
 
3.3.8 EMT and Migration 
A549 cells were transfected with either control or aPKC directed siRNA. 24 hours 
post transfection, cells were serum starved for 3 hours prior to treatment. Cells were then 
incubated in serum free medium containing none, or 250 pM TGF for 0, 48, or 72 hours 
to induce EMT. At each time point, cells were brightfield imaged using a IX71 inverted 
microscope (Olympus), processed for immunofluorescence microscopy, or processed for 
immunoblotting. For quantification of stress fibre formation, immunofluorescence images 
(multiple fields) were acquired and assessed for F-Actin morphology over 3 independent 
experiments.  At least 100 cells were assessed per condition, per experiment (> 600 cells 
total per experiment were assessed). “Cortical” was defined as cells showing F-actin 
staining to the outer regions (membrane) with no F-Actin fibres through the middle of the 
cell; “Intermediate” was defined as cells that still showed some cortical staining, but had 
several F-actin fibres spanning through the middle of the cell (1-5); “Elongated” was 
defined as cells that showed little cortical staining, and >5 stress fibres spanning through 
the middle of the cell.  Graphs represent the average of 3 independent experiments.
 For cell migration analysis, transfected A549 cells were serum starved and treated 
with TGF for 48 hours. After 48 hours, 30 000 cells were seeded into transwell 
chambers. Cells were allowed to migrate towards serum free medium, or medium 
containing 10% FBS. After 18 hours, transwell chambers were processed as described 
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above. Cell nuclei on the underside of the membrane were visualized and counted using 
DAPI staining. Ten representative fields were acquired at 200x magnification and 
quantified. Graphs represent the average of 4 independent experiments normalized to the 
serum free control. Cells that were plated simultaneously into a 6 well culture dish were 
lysed after 18 hours and processed for SDS-PAGE to assess E-cadherin loss, and 
subsequently whether EMT had occurred. 
 
3.3.9 Reverse Transcription, Real time PCR and Statistical Analyses 
Total RNA was isolated from A549 cells using the RNAeasy Mini kit (Qiagen) 
according to the manufacturer’s protocol.  For complementary DNA (cDNA) synthesis, 
1000 ng of total RNA was reverse transcribed using the Superscript® VILO cDNA 
synthesis kit according to manufacturer’s protocol. (Applied Biosystems). A cDNA 
equivalent to 10 ng of total RNA was used for all PCR reactions in a total volume of 20 
l. Each reaction was carried out in triplicate. Quantitative PCR (qPCR) reactions were 
conducted using SsoFast

 EvaGreen® supermix (BioRad) using a Chromo4 Real-time 
Thermal Cycler (Bio-Rad) according to the recommended protocol of the manufacturer. 
Primer sequences (5'-3') are as follows: PKC (TACGGCCAGGAGATACAACC and 
TCGGAGCTCCCAACAATATC), PKCATCATTCATGTTTTCCCGAGCA and 
GTTGGCACGGTACAGCTTCSNAI-1 (AATCGGAAGCCTAACTACAGCG 
andGTCCCAGATGAGCATTGGCA),SNAI-2 (ATACCACAACCAGAGATCCTCA 
andGACTCACTCGCCCCAAAGATG), Beta-Actin 
(GGGAAATCGTGCGTGACATTAAG andTGTGTTGGCGTACAGGTCTTTG), and 
POLR2A (GGATGACCTGACTCACAAACTG and CGCCCAGACTTCTGCATGG).  
Primers were selected using Primer3 [38] as well as PrimerBank [39-41]. Baseline and 
threshold for Ct calculation were set manually using the Opticon Monitor 3.1 Software 
(Bio-Rad). PCR efficiencies (E) were calculated using cDNA dilution curves and were > 
90% for all genes assessed. Calculated PCR efficiencies were used for gene expression 
quantification using the Pfaffl formula[42], ratio = (Etarget)
Ct target(control-treated)
/ (Ereference)
Ct 
ref(control-treated)
, where control = siControl, no TGF. Final ratios were calculated using 
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geometric averaging [43] from two reference genes: POLR2A, a gene which was found 
to be a suitable reference gene in NSCLC models [44], and -Actin. Gene expression of 
each treatment is expressed in relation to the control (siControl, no TGF) and is an 
average of 3 independent experimental trials. One- way ANOVA analysis followed by 
post-hoc Tukey’s Tests was used to evaluate the significance of the results. Statistical 
analyses were performed using GraphPad Prism® Software 5.0 and p values of <0.05 
were considered statistically significant. 
 
3.3.10 Site Directed Mutagenesis 
Lysine (K) 19 and Serine (S) 345 were mutated to alanine (A) and glutamic acid 
(E) respectively using the Quikchange mutagenesis kit (Agilent Technologies) onto the 
Par6-Flag-pCMV5b template according to manufacturer guidelines. Both mutants were 
transformed into a XL1 Blue strain of Escherichia coli, amplified, purified by the Qiagen 
Miniprep Kit (Qiagen), and sequenced at the London Regional Genomics Centre 
(London, ON, Canada). 
3.3.11 Statistical Analysis 
One-way or Two-way ANOVA analysis followed by post-hoc Bonferroni’s Tests 
were used to evaluate the significance of the results. Statistical analyses were performed 
using GraphPad Prism® Software 5.0 and p values of < 0.05 were considered statistically 
significant.  
 
3.4 Results 
3.4.1 TGF receptors and aPKC localize to the leading edge of 
migrating cells 
Migrating fibroblasts are polarized and show a clear leading edge as they migrate 
towards a wound.  The TGF receptors as well as the atypical PKC have been shown to 
localize to the leading edge of migrating cells [45]. Furthermore, PKC, TGF and Par6 
120 
 
have been shown to be involved in membrane protrusion dynamics through Smurf1 [12, 
25].  Here we investigated whether PKC, the other member of the aPKC family, co-
localizes with TGF receptors at the leading edge and membrane protrusions of 
migrating cells. To do this we carried out scratch assays followed by 
immunofluorescence microscopy (Figure 3.1). Polarized Rat2 fibroblasts were 
immunostained for PKC and Rac1, a leading edge marker, and TGF receptors, using 
biotin-labelled TGF ligand. We observed that the TGF receptors and PKC co-
localized with Rac1 at the leading edge of migrating fibroblasts (Figure 3.1A), whereas 
GM130, a marker for the Golgi apparatus, was not detected at the leading edge with 
PKC and the TGF receptors (Figure 3.1B).  This co-localization was also observed in 
polarized A549 adenocarcinoma cells (Figure 3.9B, please see below).  Having 
ascertained that aPKC and TGFreceptors co-localized in migrating cells, we next 
sought to determine whether there was an interaction between PKC and the TGF 
receptors. 
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Figure 3.1 
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Figure 3.1.  Atypical PKC co-localizes with TGF receptors at the leading edge of 
migrating cells 
Rat2 fibroblasts were scratched and incubated for 4 hours to establish cell polarity and 
then fixed, permeabilized and immunostained with anti-PKC (PKC, blue), biotin-
labelled TGF (biotin-TGF; red), anti-Rac1 (Rac1, green; A) or anti-GM130 (Golgi 
apparatus marker, green; B). The direction of cell migration is indicated with the white 
arrows and PKC, Rac1 and TGF receptors at the leading edge of migrating cells are 
indicated by blue, green and red arrowheads, respectively.  The white arrowheads 
indicate the co-localization of all three proteins. Shown are representative images from at 
least 3 independent replicate experiments. Bar = 10 m. 
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3.4.2 TGF receptors and PKC interact via Par6 
Previous work has shown that PKC interacts with TGF receptors through an 
association with Par6 [10]. Par6 and aPKC each contain a distinct PB1 (Phox-BEM1) 
domain through which they interact [46]. Par6 is also known to be an adaptor protein 
linking several kinases and small GTPases to facilitate cellular processes such as cell 
polarization and migration [16, 17, 24, 26, 47]. To determine if PKC interacted with 
TGFreceptors, we expressed TGF receptors in the presence of wild-type Par6 or a 
mutant of Par6 that lacks the PB1 domain (Par6-PB1) and PKC in HEK293T cells.  
Following immunoprecipitation of TRII and immunoblot analyses, we observed that 
PKC interacted with TGF receptors.  Furthermore, this association occurred in the 
presence of wild-type Par6 but not in the presence of the mutant of Par6 that lacks the 
PB1 domain (Figure 3.2, lanes 9 and 10). This result suggests that there is a complex 
formation between the TGF receptors and aPKC via Par6. 
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Figure 3.2.  Atypical PKC associates with TGF receptors through Par6 
HEK293T cells expressing the indicated combinations of GFP-tagged PKC, HA-tagged 
TGF type II receptors (TRII), Flag-tagged TGF type I receptors (TRI), wild type 
Par6 (Par6 WT) or a mutant of Par6 that does not associate with TGF receptor (Par6-
PB1) were lysed and immunoprecipitated (IP) with anti-HA antibodies.  The 
immunoprecipitates were then subjected to SDS-PAGE, and immunoblotted with anti 
()-GFP, -HA or -Flag antibodies as primary antibodies to visualize proteins that co-
precipitated with TRII (top panel). The non-specific immunoglobulin heavy chain is 
indicated (IgG) and cell lysates are shown in the bottom panel. Shown are representative 
immunoblots from at least 3 independent replicate experiments. 
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3.4.3 aPKC phosphorylates Par6 
Phosphorylation of Par6 by TRII on S345 is an important step in TGF-
dependent epithelial to mesenchymal transition (EMT) [10, 12]. Given the oncogenic role 
of aPKC in various cancers, and after seeing that aPKC and TGF receptors co-localized 
and interacted through Par6, we assessed whether aPKC had an effect on phospho-Par6 
levels (P-Par6). We used immunoblotting to determine the levels of S345 phosphorylated 
Par6 in the presence of receptors and aPKC isoforms (Figure 3.3). 
We first expressed TGF receptors and Par6 in HEK293T cells and assessed P-
Par6 levels in the presence of TGF receptors (Figure 3.3A). As expected, co-expression 
of TGF receptors and Par6 resulted in Par6 phosphorylation. We next determined 
whether co-expression of aPKC would alter P-Par6 levels by co-expressing TGF 
receptors, wild type Par6, a Par6 mutant that does not bind aPKC (Par6 K19A), and/or 
aPKC isoforms (Figure 3.3B). Expression of Par6 with TGF receptors resulted in an 
increase in P-Par6 levels and this was greatly increased in the presence of either PKC or 
PKC (Figure 3.3B, lanes 2, 4 and 7). Interestingly, when we co-expressed the receptors, 
aPKC and a mutant of Par6 that does not interact with aPKC Par6 (K19A), we observed 
Par6 phosphorylation levels seen with TGF receptors alone (Figure 3.3B, lanes 5 and 8). 
This indicated that aPKC enhanced Par6 phosphorylation when co-expressed with 
receptors, however, the possibility existed that aPKC could phosphorylate Par6 
independent from the TGF receptor (diagrammed in Figure 3.3C). We explored this idea 
next. 
3.4.4 aPKC phosphorylates Par6 independent of TGF receptors 
To further assess if aPKC could induce the phosphorylation of Par6 in the absence 
of TGF receptors, we expressed Par6 in the presence or absence of wild-type or kinase 
deficient aPKC, in the absence of exogenous TGF receptor expression (Figure 3.4A). 
We observed that active aPKC phosphorylated Par6 but the kinase deficient aPKC did 
not (Figure 3.4A).  To assess if the physical interaction of aPKC and Par6 is necessary for 
the phosphorylation of Par6, we conducted an immunoprecipitation experiment in cells 
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expressing the indicated WT or mutant constructs (Figure 3.4B). We observed that both 
the wild type and kinase deficient PKC associated with Par6, but only active PKC 
increased P-Par6 levels (Figure 3.4B). In addition, we utilized a mutant of Par6 (Par6-
K19A) that does not interact with aPKC due to the mutation of a lysine residue in the 
PB1 domain of Par6 [22, 48, 49]. Accordingly, we observed that both active and kinase 
deficient PKC do not associate with Par6-K19A, and correspondingly, we observed very 
little Par6 phosphorylation. Finally, when we co-expressed Flag-Par6 and each aPKC in 
A549 NSCLC cells we also observed that both aPKCs increased phosphorylated Par6 
levels indicating that the above results were not cell type specific (Figure 3.4C). These 
results show that in addition to TGF receptors, Par6 can be phosphorylated by aPKC.  
Furthermore, this phosphorylation is dependent on both aPKC-Par6 association and 
aPKC kinase activity. These results are summarized in a diagram in Figure 3.4D.  
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Figure 3.3 
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Figure 3.3.  aPKCs associate and phosphorylate Par6 on S345 
 (A) TGF Receptors phosphorylate Par6 on S345.  HEK 293T cells expressing the 
indicated combinations of HA-tagged TGF type II receptors (TRII), Flag-tagged TGF 
type I receptors (TRI) or Par6 (Par6) were lysed and immunoblotted with anti ()-HA, 
-Flag or -Phospho-specific S345 Par6 (-P-Par6) antibodies.  The relative mobility of 
each protein is indicated on the left. Shown are representative immunoblots from at least 
3 independent replicate experiments. 
(B) aPKC isoforms enhance TGF receptor phosphorylation of Par6.  HEK293T cells 
expressing the indicated combinations of GFP-tagged PKC, HA-tagged PKC or TGF 
type II receptors (TRII), Flag-tagged TGF type I receptors (TRI), wild type Par6 
(Par6 WT) or a mutant of Par6 that does not associate with aPKC (K19A) were lysed, 
subjected to SDS-PAGE, and immunoblotted with anti () -GFP, -PKC, -Flag, -
Par6 or -P-Par6 antibodies. Shown are representative immunoblots from at least 3 
independent replicate experiments. 
(C) A summary of the data are diagrammed in C. (1): aPKC can increase Par6 
phosphorylation alongside TGF receptors, but also, potentially independent of the TGF 
receptors (2). 
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Figure 3.4 
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Figure 3.4.  aPKC can phosphorylate Par6 independent of TGF receptors 
(A) Par6 phosphorylation is dependent on aPKC activity.  HEK293T cells expressing the 
indicated combinations of HA-tagged wild type (WT) or kinase deficient (KR) PKC and 
Flag-tagged Par6 (Par6) were lysed, subjected to SDS-PAGE and immunoblotted with 
anti ()-PKC, -Par6 or -P-Par6 antibodies. Shown are representative immunoblots 
from at least 3 independent replicate experiments. 
(B) Par6 phosphorylation is dependent on aPKC association.  HEK293T cells expressing 
HA-tagged wild type (WT) or kinase deficient (KR) PKC and Flag-tagged Par6 (Par6) 
or a mutant of Par6 that does not associate with aPKC (K19) were lysed and 
immunoprecipitated (IP) with anti-Flag antibodies.  The immunoprecipitates were then 
subjected to SDS-PAGE and immunoblotted with anti ()-PKC, or -Par6 antibodies 
(top panel).   Cell lysates were immunoblotted with the antibodies indicated to assess 
protein expression and Par6 phosphorylation (bottom panel). Shown are representative 
immunoblots from at least 3 independent replicate experiments. 
(C) Par6 phosphorylation occurs in A549 cells. A549 cells transfected with the indicated 
combinations of Flag-Par6, GFP-PKC, and HA-PKC were lysed, processed for SDS-
PAGE, and immunoblotted for anti()-GFP, -HA, -Flag, -Actin and -P-Par6 as 
indicated.  A non-specific band in the P-Par6 blot is indicated by an asterisk. Shown are 
representative immunoblots from at least 3 independent replicate experiments. 
(D) A summary of the data are diagrammed in D.  aPKC can phosphorylate Par6 in the 
absence of TGF receptors. The kinase activity of aPKC and aPKC binding ability to 
Par6 are important for this phosphorylation. 
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3.4.5 Par6 acts as a scaffold between aPKC and TGF receptors 
We next set out to determine whether increased expression of aPKC would affect 
the association of Par6 with type I TGF receptors (TRI; Figure 3.5A). TRI and Par6 
constructs (WT or K19A) were expressed in the presence of increasing levels of aPKC. 
Par6 protein was then immunoprecipitated and immunoblotted for aPKC and TRI to 
assess association with these binding partners. We found that increasing aPKC expression 
reduced the amount of TRI bound to Par6, accompanied by an increased association of 
aPKC with Par6 (Figure 3.5A). However, the Par6 mutant that cannot associate with 
aPKC (K19A) continued to associate with TRI despite increasing aPKC levels (Figure 
3.5B, right panel). Interestingly, we also observed that the steady state levels of Par6 
increased when it was displaced from the TRI (Figure 3.5A; cell lysates, lanes 4-6).   
However, this was not observed in cells expressing Par6 K19A (Figure 3.5A; cell lysates, 
lanes 8-10). 
The ubiquitin ligase Smurf1 is known to regulate the levels of Par6 as well as the 
TGF receptors [50-52]. Interestingly, we observed that expression of Par6 with TGF 
receptors and Smurf1 decreased the steady state levels of receptors, Par6 and Smurf1 
(Figure 3.5B). This effect was reduced when the K19A or S345A mutants were expressed 
in place of WT Par6, suggesting that both endogenous aPKC association with Par6 and 
phosphorylation on S345 may be involved in Smurf1 mediated degradation of the TGF 
receptor-Par6 complex. 
These data further substantiate the scaffolding of TRI and aPKC via Par6 and 
implicates aPKC in the degradation of receptor associated Par6. Taken together, our 
results suggest that aPKC association and S345 phosphorylation of Par6 can regulate 
TGF receptor and Par6 levels. 
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Figure 3.5 
 
133 
 
Figure 3.5.  aPKC reduces TRI associated Par6 
 (A) aPKC displaces Par6 from TGF Receptors.  HEK293T cells were transfected with 
Flag-TRI, Flag-Par6 (WT or K19A) and increasing amounts of GFP-tagged PKC. 
Lysates were immunoprecipitated (IP) with anti-Par6 antibodies. The immunoprecipiates 
(IP) were subjected to SDS-PAGE, and immunoblotted anti ()-GFP, or -Flag 
antibodies as primary antibodies to visualize proteins that co-precipitated with Par6. Total 
lysates are shown in the bottom panel. Par6-associated TRI levels were quantitated and 
are shown graphically. Shown are representative immunoblots from 3 independent 
replicate experiments. (n=3 ± SEM, Two-way ANOVA, *p<0.05).  
(B) Par6 mutants attenuate aPKC-dependent reduction of TGF Receptor steady state 
levels.  HEK 293T cells expressing HA-tagged TGF type II receptors (TRII), Flag-
tagged TGF type I receptors (TRI), Flag-tagged Smurf1, and Flag-tagged Par6 (WT, 
K19A, or S345A) were lysed, subjected to SDS-PAGE and immunoblotted with anti -
HA, -Flag, -Actin, or -Phospho-specific S345 Par6 (-P-Par6) antibodies. Shown are 
representative immunoblots from at least 3 independent replicate experiments. 
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3.4.6 aPKC expression and association increases Par6 levels 
After observing that the expression of aPKC displaced Par6 from TRI and 
increased steady state Par6 levels, we assessed the protein stability of Par6 when co-
expressed with PKC (Figure 3.6A). Using the translation inhibitor, cycloheximide, cells 
expressing Par6 were assessed for Par6 levels over a 6 hour time course.  We observed 
that Par6 levels dropped to approximately 16.2% ± 8.3% within 6 hours (Figure 3.6A, 
right panel). When Par6 was co-expressed with aPKC, we observed stabilization of Par6 
protein levels. Indeed, when Par6 was expressed with aPKC, Par6 protein levels 
remained 88.8% ± 3.9% of the Time 0 control (Figure 3.6A, right panel).    
We next assessed the effect of Smurf1 on Par6 levels.  We observed that the co-
expression of Par6 with Smurf1 led to reduced steady state levels of Par6 (Figure 3.6B). 
However, co-expression of aPKC with Par6 blocked this degradation, as observed by an 
increase in steady state levels of Par6 (Figure 3.6B). We further wanted to explore 
whether S345 phosphorylation of Par6 would alter its steady state levels. We analyzed 
this by expressing aPKC in cells expressing Par6 or the K19A and S345A mutants 
(Figure 3.6C). Notably, we observed an increase in steady state Par6 levels when aPKC 
was introduced to cells expressing WT or S345A Par6 mutant (Figure 3.6C, lanes 2 to 3 
and lanes 6 to 7). This effect was not observed in cells expressing Par6-K19A, a mutant 
that cannot associate with aPKC (Figure 3.6B, lane 4 vs. 5). These results suggest that 
aPKC association and not the phosphorylation of Par6 inhibited Smurf1-mediated 
reduction of steady state levels of Par6 (Figure 3.6C).  
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Figure 3.6.  aPKC expression stabilizes Par6 protein levels 
(A) HEK 293T cells were transfected with Flag-Par6 and empty vector or with Flag-Par6 
and GFP tagged PKC. These cells were then subjected to a time course with the 
translation inhibitor cycloheximide (100 g/mL) and lysed after the indicated time points. 
Lysates were subjected to SDS-PAGE, followed by immunoblotting with -GFP, -Flag, 
or -GAPDH  (loading control). Average Par6 levels over time were quantitated and are 
shown graphically in the right panel. Shown are representative immunoblots from 3 
independent replicate experiments. (n=3 ± SEM, Two-way ANOVA, **p<0.01). 
(B) HEK 293T cells expressing combinations of Flag-Smurf1, GFP-PKC, and Flag-
Par6, were subjected to SDS-PAGE, followed by immunoblotting with -GFP, -Flag, 
or -P-Par6 to assess protein or phosphoprotein levels. Shown are representative 
immunoblots from at least 3 independent replicate experiments.  
(C) HEK 293T cells expressing combinations of Flag-Smurf1, GFP-PKC, and Flag-
Par6, Flag-Par6-K19A, or Flag-Par6S345A (phosphorylation site mutated) were lysed 
and subjected to SDS-PAGE, followed by immunoblotting with the primary antibodies 
indicated on the right of the panels. Par6 protein levels were quantitated and shown 
graphically. Shown are representative immunoblots from 6 independent replicate 
experiments.  (n=6, ± SEM). 
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3.4.7 Par6 phosphorylation and aPKC association are important for 
Par6 induced migration 
Expression and phosphorylation of Par6 have been shown to increase the 
migration and metastatic processes of breast cancer cells [12]. We therefore tested 
whether Par6 phosphorylation and aPKC association could affect cell migration of a 
metastatic NSCLC cell line (H1299) using transwell migration assays (Figure 3.7). 
Briefly, H1299 cells were transiently transfected with empty pIRES vector, wild type 
Par6 or the two mutant Par6 constructs (K19A, S345A). Relative expression levels are 
shown in Figure 3.7A. Our results indicated that overexpression of wild type Par6 
increased cell migration (5.3 ± 0.1 fold) towards serum compared to control cells.  Cells 
expressing the aPKC binding mutant of Par6 (Par6-K19A) also stimulated H1299 cell 
migration by 2.4 ± 0.4 fold.  This muted, yet significant stimulation of cell migration was 
expected, as Par6-K19A can still associate with TGF receptors and be phosphorylated 
by TRII on S345.  Finally, cells expressing the S345 mutant of Par6 that cannot be 
phosphorylated by either TRII or aPKC did not significantly stimulate cell migration 
(Figure 3.7B). 
 Taken together, these results suggest that aPKC isoforms play a role in NSCLC 
cell migration both through Par6 association and S345 phosphorylation. We next 
explored if siRNA directed towards aPKC would affect TGF-dependent EMT.  
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Figure 3.7.   Par6 induces cell migration 
(A) H1299 cells were transiently transfected with empty vector (pIRES), wild-type Par6 
(Par6-WT), Par6-K19A or Par6-S345A constructs. Immunoblots of lysates show relative 
expression levels of transfected cells. 
(B) Cells transfected as described in Panel A were plated into the top chamber of a 
transwell chamber and allowed to migrate towards serum for 18 hours. Representative 
images from the migration assay are shown above graphical analysis. Data are presented 
as a percentage of control (pIRES) and represent the average of 3 independent 
experiments (n=3 ± SEM, One-way ANOVA, **p<0.01). Bar = 100 m. 
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3.4.8 aPKC siRNA alters RhoA levels 
The TGF-Par6 pathway has been shown to regulate EMT by stimulating 
cytoskeletal remodelling and cell plasticity. A critical step in this process is TGF 
induced degradation of RhoA by Smurf1 [10]. Interestingly, this was shown to be 
Smurf1-dependent, as reduction of Smurf1 expression blocked RhoA degradation and 
EMT [10, 25]. Furthermore, both the phosphorylation of Par6 as well as PKC activity, 
were shown to be important for the recruitment of Smurf1 and targeting of RhoA for 
degradation [10, 25]. Since we observed that aPKC co-operate with TGF receptors to 
phosphorylate Par6, we next determined whether aPKC played a role in TGF induced 
RhoA degradation.  Using siRNA targeting both aPKC isoforms, we monitored RhoA 
levels in response to TGF in A549 NSCLC cells (Figure 3.8). 
 Previous work has shown, that upon TGF stimulation, RhoA levels are reduced 
by ~20%, followed by the cell cytoskeletal and morphological changes associated with 
EMT [10]. Similarly, we detected a consistent reduction in RhoA levels following TGF 
treatment in cells transfected with control siRNA (Figure 3.8). However, siRNA targeting 
aPKC resulted in a TGF-dependent increase in RhoA steady state levels (Figure 3.8).   
Intriguingly, this result was similar to previous findings that RhoA accumulates with 
Smurf1 knockdown [25]. We next monitored activated aPKC levels in response to TGF 
treatment. 
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Figure 3.8.  aPKC silencing attenuates TGF-dependent decreases in RhoA levels 
A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota and 
zeta (siPKC /) were treated with TGF followed by lysing and processing for SDS-
PAGE and immunoblotting with anti -RhoA, -PKC, -PKC or -actin antibodies. 
Average RhoA levels were quantitated and graphed in the bottom panel. Shown are 
representative immunoblots from 5 independent replicate experiments. (n=5 ± SEM, 
Two-way ANOVA, *p<0.05). 
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3.4.9 TGF treatment activates aPKC 
We next examined aPKC activity in response to TGF using a phospho-specific 
antibody that detects T410 phosphorylated PKC (or T403 in PKC). Phosphorylation of 
aPKC on this site is known to regulate its enzymatic activity [53]. Consistent with studies 
carried out using prostate cancer cells and mouse embryonic fibroblasts [24], we 
observed that TGF treatment increased the levels of endogenous phospho-PKC/in 
A549 cells (Figure 3.9, Cell lysates).  Interestingly, expression of Par6 also increased P-
PKC/ levels to equivalent levels seen with TGF addition, indicating that Par6 may 
also scaffold aPKC to endogenous activators.  Following immunoprecipitation of Par6 
and immunoblotting for activated aPKC, we found that Par6-associated P-PKC/ levels 
increased by 22 ± 7% upon TGF treatment compared to control (Figure 3.9, IP and 
Graph). These results prompted us to assess whether aPKC played a role in TGF 
induced cell morphology and EMT.       
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Figure 3.9.  TGF increases total and Par6 associated aPKC activity 
A549 cells transfected with empty vector or Flag-tagged Par6 were treated with (or 
without) TGF for 1 hour. Cell lysates were immunoprecipitated (IP) with anti-Flag 
antibodies. The immunoprecipitates (IP) were subjected to SDS-PAGE, and 
immunoblotted with anti (-phospho-specific PKC (P-PKC), total PKC, and -Flag 
as indicated. The asterisk (*) denotes a non-specific band. Average Par6 associated P-
PKC levels were quantitated and are shown graphically below immunoblots. Shown are 
representative immunoblots from 3 independent replicate experiments.  (n=3 ± SEM). 
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3.4.10 aPKC siRNA induces changes in cell morphology 
TGF-treated A549 cells acquire a spindle–shaped appearance and reduce cell-
cell contacts [7].  We observed that siRNA-medated aPKC silencing reduced TGF 
induced morphological changes of A549 cells, as assessed by DIC microscopy (Figure 
3.10A).  In cells expressing aPKC isoforms, the cobblestone appearance of A549 cells 
became elongated in the presence of TGFafter 48 and 72 hours.  In contrast, aPKC 
silenced cells retained their cobblestone morphology with TGF treatment at both time 
points. We also examined the front-rear polarization of sub-confluent control and aPKC 
silenced A549 cells (Figure 3.10B). Interestingly, we found that the proportion of cells 
that polarize and form a leading edge is reduced in aPKC silenced cells. Furthermore, we 
detected a greater number of cells with a rounded phenotype in aPKC-silenced cells than 
in control (Figure  3.10C). This is in agreement with previous work that aPKC plays an 
important role in cell polarization [21] and similar to work that cells are less protrusive 
with Smurf1 knockdown [25].  
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Figure 3.10 
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Figure 3.10.  aPKC silencing reduces TGF induced changes in cell morphology 
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) were treated with TGF for 0, 48, or 72 hours and imaged by 
brightfield microscopy. Shown are representative images from at least 3 independent 
replicate experiments.  Bar = 100 m. 
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) were plated sub-confluently, fixed, permeabilized and 
immunostained with anti-PKC (PKC, blue) anti-Rac1 (Rac1, green), and biotin-labelled 
TGF (biotin-TGF; red). Shown are representative images from 3 independent replicate 
experiments. 
(C) The average number of total elongated verses rounded cells was quantitated over 3 
experiments and is presented graphically (n=3 ± SEM, Two-way ANOVA, **p<0.01). 
Bar = 100 m. 
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3.4.11 aPKC siRNA reduces TGF induced EMT 
Since we observed that both aPKCs and TGF receptors could phosphorylate 
Par6, that TGF increases activated aPKC levels, and that aPKC modulates TGF 
induced RhoA degradation, we next determined to what extent aPKC was involved in 
TGF induced EMT. TGFβ-dependent EMT involves the loss, in the expression and 
organization, of the adhesion protein E-cadherin [1, 2, 7] and leads to decreased cell 
adhesion and increased cell motility. 
Using siRNA directed at both aPKC isoforms, we assessed changes in TGF 
induced E-cadherin protein levels in A549 NSCLC cells (Figure 3.11A). Control, or 
aPKC-silenced cells were treated with TGF for 0-72 hours and cell lysates were 
immunoblotted for E-cadherin, P-Smad2, PKC, PKC, Smad2 and Actin. We observed 
that E-cadherin protein levels were significantly reduced in control cells incubated with 
TGF after 48 or 72 hours (Figure 3.11A, lanes 1-3).  In addition, we observed Smad2 
phosphorylation after 48 and 72 hours of TGFtreatment.  In contrast, basal E-cadherin 
levels were significantly higher in aPKC-silenced cells and were only moderately 
decreased in response to TGF (Figure 3.11A, lanes 4-6). This suggested that aPKC was 
important for TGF induced E-cadherin loss despite efficient phosphorylation of Smad2. 
Interestingly, the levels of mRNA for the transcriptional repressors of E-cadherin, SNAI1 
and SNAI2, both increased to a similar extent in control and aPKC silenced cells (Figure 
3.11B). This is consistent with the idea that Smad2 signalling was still occurring in both 
control and aPKC silenced cells.      
We next assessed E-cadherin expression and stress fibre formation in A549 cells 
by immunofluorescence microscopy. We observed that in the absence of TGF 
treatment, 88 ± 5% of control cells and 82 ± 4% of siPKC/ cells contained few 
spanning stress fibres and maintain a cortical F-actin distribution (Figure 3.11C). In 
contrast, upon TGF treatment, the majority of cells transfected with control siRNA (76 
± 4%) display elongated, cell spanning stress fibres after 48 and 72 hours. This effect was 
significantly reduced in aPKC-silenced cells in which only 15 ± 5% of cells show 
elongated stress fibres (Figure 3.11C). Furthermore, TGF induced E-cadherin loss was 
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reduced in aPKC silenced cells (Figure 3.11C), consistent with immunoblot analyses 
(Figure 3.11A).  Taken together, these data suggest that aPKC is necessary for efficient 
TGF induced EMT of NSCLC cells.  
After observing that aPKC knockdown attenuated TGF induced EMT, we next 
assessed cell motility. Our results showed that after 48 hours of TGFstimulation, 
siControl cells migrated towards serum to a greater extent than aPKC-silenced cells, as 
assessed by transwell migration assays (Figure 3.11D). This indicated that aPKC silenced 
cells that did not undergo EMT were also less motile.  
 
3.4.12 aPKC knockdown reduces claudin loss and individual aPKC 
siRNA reduces TGF induced EMT 
We also examined levels of a second epithelial marker, Claudin 1, in cells 
transfected with control siRNA or siRNA targeting both aPKC isoforms. Similar to E-
cadherin levels, TGF induced a loss in Claudin1 levels in control cells, but this effect 
was abrogated in aPKC knockdown cells (Figure 3.12A). Furthermore, we wanted to 
examine whether individual aPKCs were involved in reducing TGF induced E-cadherin 
loss. Using siRNA directed at each aPKC isoform individually as well as both aPKC 
isoforms together, we assessed changes in TGF induced E-cadherin protein levels in 
A549 NSCLC cells. Interestingly, knockdown of individual aPKCs (siPKC, or 
siPKC,) could also reduce TGF induced E-cadherin loss, although only cells 
transfected with siPKC showed statistically significant results through average 
densitometrical analysis (Figure 3.12B). Importantly, the double knockdown (siPKC /) 
also significantly reduced TGF induced E-cadherin loss as observed before (Figure 
3.12B). Taken together, these results indicated that aPKC knockdown cells were indeed 
exhibiting a greater degree of epithelial phenotype when stimulated with TGF. We next 
assessed whether re-introduction of exogenous P-Par6 into aPKC silenced cells could 
restore TGF induced EMT. 
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Figure 3.11.  aPKC silencing reduces TGF induced EMT and motility 
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) were treated with TGF for 0, 48, or 72 hours.  Cells were then 
lysed and processed for SDS-PAGE and immunoblotting with anti ()-E-cadherin, -
phospho-specific Smad 2 (-P-Smad2), -Smad2, -PKC, -PKC or -actin 
antibodies. The asterisk (*) denotes a non-specific band.  Shown are representative 
immunoblots from at 5 independent replicate experiments. Average E-cadherin levels 
were quantitated and graphed (bottom panel, n=5 ± SEM, Two-way ANOVA, **p<0.01). 
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) were treated with or without TGF. After 24 hours, total RNA was 
extracted; reverse transcribed, and subjected to quantitative real time PCR analysis 
(qPCR) of PRKCI (PKC, PRKCZ (PKC, SNAI1 (Snail) and SNAI2 (Slug). Average 
relative gene expression from 3 independent experiments is shown graphically (n=3 ± 
SEM, Two-way ANOVA, p<0.05). 
(C) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) were treated with or without TGF 48 hours followed by processing 
for immunofluorescence microscopy and stained for filamentous actin with Phalloidin 
(red), E-cadherin (green) and DAPI to image nuclei (blue). Cell morphology changes 
over 3 independent experiments were quantified and are displayed graphically below 
representative images. "a" indicates a statistically significant change with TGF 
treatment. "b" indicates a statistically significant difference between siControl and 
siPKC/ cells at the indicated time point. (n=3 ± SEM, Two-way ANOVA, *p<0.05). 
Bar = 100 m. 
 (D) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) were untreated, or treated with TGF for 48 hours and assessed for 
migration towards serum for 18 hours. Representative images from the migration assay 
are shown below the graphical analysis (n=4 ± SEM, Two-way ANOVA, **p<0.01). Bar 
= 100 m. 
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Figure 3.12.  aPKC silencing reduces TGF induced Claudin-1 loss and individual 
aPKC knockdown also reduces TGF induced E-cadherin loss  
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC/) were treated with or without TGF 48 hours.  Cells were then lysed 
and processed for SDS-PAGE and immunoblotting with  ()-Claudin1, or -Actin 
antibodies. Shown are representative immunoblots from 3 independent replicate 
experiments (n=3). 
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
(siPKC), zeta (siPKC), or both (siPKC/) were treated with or without TGF for 48 
hours.  Cells were then lysed and processed for SDS-PAGE and immunoblotting with -
E-cadherin or -actin antibodies. Three experiments were carried out as described in 
Panel A, quantitated and are shown graphically below immunoblot (n=3 ± SEM, Two-
way ANOVA, *p<0.05) 
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3.4.13 Phospho-mimetic Par6 induces TGF-dependent EMT and 
RhoA degradation in aPKC silenced cells 
We next sought to test whether a reduction in phospho-Par6 was indeed 
responsible for the reduced EMT response we were seeing in aPKC-silenced cells. To 
carry this out, we generated a serine 345 phospho-mimetic version of Par6 (Par6 S345E). 
We first ascertained that the Par6 S345E mutant was phospho-mimetic by immunoblot 
analysis using the phospho-Par6 antibody (Figure 3.13A). Indeed, the phospho-S345 Par6 
antibody recognized the Par6 S345E mutant. 
Next, we introduced Par6 S345E into aPKC-silenced cells, and assessed E-
cadherin protein levels following TGF-treatment (Figure 3.13B).  Consistent with 
observations in Figure 3.11A, aPKC silencing reduced TGF-dependent loss of E-
cadherin levels (Figure 3.13B, lanes 1-4).  However, the Par6 S345E mutant restored the 
TGF effect (lanes 9 and 10).  Furthermore, Par6 S345E reduced the induction of basal 
E-cadherin levels observed in aPKC-silenced cells (Figure 3.13B, lane 3 vs. 9). 
As observed with the E-cadherin analysis, expression of the phospho-mimetic 
Par6 S345E mutant significantly reversed the effect of aPKC silencing on TGF-
dependent RhoA levels (Figure 3.13C).  aPKC silenced cells contained a significant 
increase of RhoA protein levels in response to TGF. However, not only did Par6 S345E 
reduce this effect, cells expressing this Par6 mutant had lower RhoA levels than cells 
transfected with only control siRNA (Figure 3.13C, bottom panel). 
Taken together, the data suggest that the phosphorylation of Par6 by both TGF 
receptors and aPKC is necessary for efficient EMT of A549 NSCLC cells (summarized 
in Figure 3.14). 
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Figure 3.13 
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Figure 3.13.  A S345E phospho-mimetic Par6 mutant restores TGF-dependent E-
cadherin and RhoA loss in aPKC silenced cells 
(A) HEK293T cells transfected with Flag-Par6 (WT, K19A, S345A, or S345E) were 
lysed, processed for SDS-PAGE and immunoblotted with anti ()-Flag, or -Phospho-
Par6 antibodies to determine the relative levels of P-Par6. A representative immunoblot 
from three independent replicate experiments is shown. 
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota 
and zeta (siPKC /) and Par6-S345E or empty vector, were incubated in the presence or 
absence of TGF for 48 hours.  Cells were then lysed and processed for SDS-PAGE and 
immunoblotting with anti ()-E-cadherin, -PKC, -PKC or -Actin antibodies. 
Average E-cadherin levels from 4 independent replicate experiments were quantitated by 
densitometrical analysis and graphed below a representative immunoblot (n=4 ± SEM, 
Two-way ANOVA, *p<0.05). 
(C) A549 cells were treated as described in panel B. Cells were then lysed and processed 
for SDS-PAGE and immunoblotting with anti ()-RhoA, and -Actin antibodies. 
Average RhoA levels from 4 independent replicate experiments were quantitated by 
densitometrical analysis and graphed below a representative immunoblot (n=4 ± SEM, 
Two-Way ANOVA *p<0.05). 
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Figure 3.14 Atypical PKC phosphorylates Par6 and facilitates TGF induced EMT 
TGF stimulation leads to the activation of aPKC. Both aPKC and TGF receptors can 
phosphorylate Par6 on S345 to initiate RhoA degradation, E-cadherin loss and 
subsequently EMT.   
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3.5 Discussion 
Epithelial to mesenchymal transition is a critical event in tumour progression 
leading to the disorganization of tissue architecture. The aPKC-Par6 axis is an emerging 
pathway shown to be important in the stimulation of EMT and progression of metastatic 
tumours. Phosphorylation of Par6 is associated with tumours that are more invasive and 
have been correlated with reduced survival in breast cancer patients [12]. Until now, Par6 
phosphorylation on Serine 345 has only been reported to occur through TGF receptor 
activation. 
In this report, we have observed that both atypical PKC isoforms ( and ) also 
phosphorylate Par6 on S345 and suggests a role for aPKC in promoting epithelial derived 
tumour cells into EMT through the Par6 pathway. Coupled with the observations that 
aPKC shows malignant activity in various cancers [32, 33, 54] and oncogenic potential in 
lung cancer [28-30, 34], our results suggest that aberrant phosphorylation of Par6 by 
aPKC may be a major tumour promoting process.   
 Interestingly, we discovered that aPKC increases steady state Par6 protein levels, 
which we attribute to a decrease in Smurf1 mediated degradation. A recent report has 
indicated that protein kinase A (PKA)-dependent phosphorylation of Smurf1 leads to the 
protection of Par6 and the simultaneous Smurf1 mediated degradation of RhoA [52]. 
Given our observations, it would be interesting to explore whether aPKC can also 
phosphorylate Smurf1, thus leading to protection of Par6 from Smurf1 mediated 
degradation. Furthermore, Smurf1 may target TGF receptors and Par6 for degradation 
via aPKC association and Par6 S345 phosphorylation. Since we have previously 
described a role for aPKC in TGF receptor trafficking and degradation [35], we believe 
the current results suggest a role for aPKC regulation of TGF receptor-Par6 complexes. 
Ozdamar et al. have previously shown that Par6 phosphorylation on S345 is 
important for TGF mediated RhoA degradation and adherens junction dissolution [10]. 
Here, we show that basal E-cadherin levels are significantly higher in aPKC-silenced 
cells, and furthermore, TGF -induced reductions of both RhoA and E-cadherin are 
severely impaired when aPKC is silenced. This effect was seen despite similar Phospho-
Smad2 signalling levels between control and aPKC silenced cells, highlighting the 
importance of aPKC in the EMT process via the Par6 pathway.    
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A similar effect has been reported with respect to the ability of the ErbB2 receptor 
to disrupt tissue architecture of polarized epithelia [22]. Inhibiting the interaction of 
aPKC and Par6 (with K19A) blocked the ability of ErbB2 to disrupt the acinar 
organization of breast epithelial cells [22]. Interestingly, activation of the TGF-Par6 
pathway has also been shown to disrupt acini-like structure formation in normal murine 
mammary gland (NMuMG) cells [12]. This effect is reduced through expression of the 
S345A Par6 mutant indicating that phosphorylation of Par6 on S345 is important for this 
disruption. Given the observations that both aPKC association with Par6 and S345 
phosphorylation are important for tissue organization, we believe that aPKC 
phosphorylation of Par6 may be critical in the disorganization of normal tissue 
architecture. Interestingly, introduction of the Phospho-mimetic Par6 (S345E) into aPKC 
silenced cells restored full TGF induced E-cadherin loss and RhoA degradation - 
highlighting an important role for aPKC induced P-Par6 in these processes.  
Taken together, we propose that multiple tumour promoting pathways (including 
TGF and ErbB2) may require aPKC to disrupt cell polarity, and that aPKC may be a 
target for blocking oncogenic signalling pathways that induce tissue disruption during 
tumour progression. Indeed, we observed that the silencing of aPKC reduces TGF 
induced EMT and migration of A549 adenocarcinoma cells. Furthermore, others have 
shown that loss of function experiments of PKC in A549 cells showed reduced invasive 
activity as well as significantly reduced tumour growth and expansion in vivo in nude 
mice [30, 34].  aPKC has recently been implicated in various disease states, and several 
studies have highlighted the oncogenic characteristics of PKC in NSCLC [28, 30, 31, 
54-56], with an elevated level of PKC expression reported to be correlated with poor 
outcome in NSCLC patients. Patients with early stage lung cancer and high 
PKCexpression are more than 10 times likely to perish from the disease than those with 
low levels of PKC. A similar trend is evident in patients with increased PKC DNA 
copy number and ovarian cancer [33].  Increased PKCexpression is also correlated with 
increased cyclin E expression in ovarian cancers, and is implicated with increased 
proliferation, defects in cell polarity, and decreased survival rates [33]. Furthermore, 
aPKC has been shown to be important in the Par6 induced cell proliferation in breast 
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epithelial cells, as the K19A Par6 mutant reduces the mitogenic effects of Par6 signalling 
[23].  
We believe that aPKC is an important component of TGF activated 
phosphorylation of Par6, and that silencing of aPKC gene expression blocks TGF 
induced EMT and migration of NSCLC cells. It will be interesting to explore whether the 
aPKC-Par6 axis is an important pathway in the metastatic progression of NSCLC 
tumours in vivo.    
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4 Chapter 4 
4.1 Chapter Summary 
TGFβ signalling regulates many cellular responses including proliferation, EMT, 
and apoptosis. This wide array of responses occurs through the intricate control of Smad 
activity as well as other non-Smad pathways including Par6 and MAPK. My previous 
work demonstrated that aPKCs are important for TGF receptor trafficking, degradation, 
and signalling pathways. Here I analyzed gene changes and responses in A549 lung 
cancer cells in which aPKC has been silenced using siRNA. 
When analyzing the gene responses in aPKC-silenced cells, we observed a 
dampening of TGF response, as assessed by microarray and qPCR, which correlated 
with a reduction in Smad2 nuclear accumulation in response to TGF. Interestingly, we 
also detected an increase in p38 MAPK phosphorylation in aPKC-silenced cells. 
Although the enhanced p38 MAPK levels parallelled an increase in apoptotic response, 
p38 inhibition did not rescue Smad2 nuclear accumulation. p38 MAPK activation in 
aPKC silenced cells was found to occur downstream of TRAF6, as TRAF6 knockdown 
abrogated the increased p38 MAPK phosphorylation we observed in aPKC silenced cells. 
Interestingly, knockdown of aPKC stabilized TRAF6-TGF receptor complexes, 
providing a mechanism for the enhanced p38 activation observed. Finally, in aPKC 
silenced cells we observed an increase in the expression of the Smad2 cytoplasmic 
retention factor, SARA, and concomitantly a reduction in Smad2 release upon TGF 
stimulation. Furthermore, this followed a reduction in Smad2-Smad4 complex formation 
in aPKC-silenced cells. We reason this deregulated SARA-Smad2-Smad4 exchange leads 
to a reduced nuclear accumulation of R-Smads and reduced transcriptional response.  
We conclude that aPKC influences the stability of receptor binding partners (such 
as TRAF6 and SARA) which can subsequently affect TGF signalling and cellular 
response. 
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4.2 Introduction 
 TGF signalling controls many cellular processes including proliferation, 
apoptosis, and EMT. Aberrant TGF signalling is a hallmark of several pathological 
conditions including cancer and fibrosis [1-5]. The canonical TGF pathway involves the 
cell surface binding of TGF ligand to TRII, which then binds and phosphorylates TRI 
[6]. Phosphorylation of TRI leads to its activation, and its ability to transduce 
intracellular signalling through the phosphorylation of substrate proteins such as the R-
Smads, Smad2 and Smad3 [2, 6]. Once phosphorylated, R-Smads accumulate in the 
nucleus where they act as transcription factors to regulate subsequent TGF gene 
response [2, 6-9]. Entry into the nucleus of R-Smads is facilitated by directly binding the 
nucleopore complex, binding to Importins (for Smad3), or facilitated by the binding of 
the common Smad, Smad 4 [8, 10] 
Proteins that control the membrane trafficking and endocytosis of TGF receptors 
play a role in regulating the intensity and duration of TGF signals. For example, the 
efficient regulation of Smad signalling can be facilitated by the adaptor protein SARA 
(Smad anchor for receptor activation). SARA contains a Smad binding domain, as well as 
a TGF receptor complex interacting region, and acts as a bridge, facilitating R-Smad 
presentation to the activated receptor complex [11, 12]. SARA also contains a 
phosphatidylinositol 3-phosphate (PI3P) binding FYVE domain, which induces its 
association with the early endosome, and links receptor endocytosis and trafficking to 
Smad signal transduction [12, 13]. Once SARA-bound R-Smads are phosphorylated, they 
dissociate from the SARA-receptor complex, bind to Smad4, and subsequently 
translocate to and accumulate in the nucleus to regulate transcription [14]. Interestingly, 
although receptor endocytosis has been reported to be dispensable for the 
phosphorylation of R-Smads, it has been reported that endocytosis is required for the 
efficient dissociation of R-Smads from SARA, nuclear accumulation, and subsequent 
transcriptional response [15]. The precise regulation of transcriptional activity of Smads 
in the nucleus is important for the proper execution of embryonic development by 
controlling tissue patterning, normal organ development, and also for controlling cellular 
growth and apoptotic response in adult tissues [4, 7, 8, 16, 17]. 
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Although it is established that Smads are central regulators of gene response to 
TGF, multiple Smad independent pathways are also initiated upon TGF receptor 
activation [10, 16-19]. TGF can activate the mitogen associated protein kinase family 
(MAPK). There are three principle MAPK proteins: ERK, JNK, and p38 - each of which 
has a role in the development and progression of cancer [20]. The p38 MAPK pathway 
downstream of TGF has gained considerable interest as a pathway that regulates 
apoptosis. Briefly, TGF receptor activation leads to the recruitment and Lys-63 linked 
auto-ubiquitination and activation of TRAF6, an E3 ubiquitin ligase. This stimulates a 
cascade that culminates in the activation of p38 MAPK and ultimately apoptosis in 
various cell types [21-23]. Interestingly, aPKC isoforms interact with TRAF6 to mediate 
cytokine signalling [24], but less is known about whether aPKC mediates the TGF-p38 
MAPK pathway. 
We have previously shown that aPKC isoforms can alter TGF signalling patterns 
in NSCLC cells by altering receptor trafficking, degrading specific receptor complexes 
and by enhancing Par6 dependent phosphorylation [25, 26]. However, we had not 
examined gene changes on a large scale. Furthemore, we have not examined whether 
aPKCs alter TGF-induced MAPK pathways. The aPKC isoforms, which consist of 
PKC and PKC, are a subset of the Protein Kinase C family that are calcium and 
diacylglycerol (DAG) independent [27]. Importantly, the aPKCs show altered expression 
and activities in various cancers [28], and PKC has been described as an oncogene [29, 
30]. Interestingly, aPKC isoforms have been known to play a role in p38 MAPK induced 
apoptosis, as inhibition or knockdown of aPKC sensitizes glioblastoma cells to 
chemotherapeutic agents via a p38 dependent mechanism [31].  
 In this report we examined TGFβ-dependent transcriptional response in aPKC 
silenced cells by microarray analyses, and also examined how knockdown of aPKC alters 
Smad dynamics and MAPK pathways to alter cellular apoptosis.  
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4.3 Materials and Methods 
4.3.1 Antibodies and Reagents 
Primary antibodies were purchased from the following vendors: Anti--Actin 
(Sigma-A2668), anti-PKC (BD Transduction-610175), anti-PKC (Cell Signalling 
Tech-9372), anti-Phospho-Smad2 (Cell Signalling Tech-3101), anti-Smad2/3 (BD Trans-
610842), anti-Tubulin (Sigma-T4026),  anti H3-Histone (Millipore-05-499), anti- 
phospho-p38 (Cell Signalling-9211), anti p38 (Cell Signalling- 9212), anti phospho-ERK 
(Cell Signalling – 4370), anti-phospho-JNK (Cell Signalling Tech-9255s),  anti-Smad4 
(Abcam-AB40759), anti-SARA (Santa Cruz, sc-9135), anti-Flag (Sigma Aldrich – 
F3165), anti-Traf6 (Cell Signalling Tech- 8028s), anti-EEA1 (BD Transduction-610457). 
HRP conjugated secondary goat-anti-rabbit (Thermo Scientific -31460) and goat-anti-
mouse (Thermo Scientific -31430) were used for immunoblot analysis.  Fluorescently 
conjugated donkey -mouse (Life Technologies A21206), donkey -rabbit (Life 
Technologies-A31572) were used for immunofluorescence studies. Human siRNA 
constructs were purchased from Life Technologies (siPKC, siPKC and siControl 
catalogue numbers: (10620319-HSS183348, 10620319-HSS183318, 12935112) 
respectively. TRAF6 siRNA was purchased from Life Technologies, product number 
s14389- 4390824). p38 MAPK inhibitor was purchased from Calbiochem (506126).   
 
4.3.2 Cell Culture and Transfections 
A549 and H1299 NSCLC cell lines were maintained in F12K and RPMI-1640 
Medium (respectively) supplemented with 10% fetal bovine serum.  Cells were kept in a 
humidified tissue culture incubator at 37ºC in 5% CO2. siRNA transfections were 
conducted using Lipofectamine RNAi max (Life Technologies) according to the 
manufacturer’s protocol. TGF treatments (250 pM) were conducted in serum deprived 
media (0.2% FBS) for the indicated times after cells were serum deprived overnight.  
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4.3.3 Protein Concentrations 
Protein concentrations were determined using the Lowry method (Fisher). 
 
4.3.4 Immunoblotting and Immunoprecipitation 
Cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and a mixture of protease inhibitors) 
and centrifuged at 14,000 rpm at 4 °C for 10 min. Aliquots of supernatants were collected 
for analysis of total protein concentration. For immunoprecipitation, equal amounts of 
remaining cell lysates were incubated with primary antibody, followed by incubation 
with protein G-Sepharose beads. The precipitates were washed three times with lysis 
buffer, eluted with sample buffer, and subjected to SDS-PAGE. Proteins were transferred 
to nitrocellulose followed by blocking in 5% skim milk, and incubation with primary 
antibody in TBST overnight at 4ºC. Following incubation with HRP conjugated 
secondary antibody, proteins were visualized using West Dura Super Signal ECL (Fisher) 
and imaged on a VersaDoc Imaging system (BioRad). 
 
4.3.5 Cellular Fractionation 
Cytoplasmic and Nuclear cellular fractions were isolated using the Thermo 
Scientific Kit NE-PER
®
 kit (78833) according to the manufacturer’s protocols. 
 
4.3.6 Immunofluorescence Microscopy 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-
100, and incubated with primary antibodies at 4°C overnight. Following incubation with 
the appropriate  fluorescent probe conjugated secondary antibodies, the probes were 
visualized by immunofluorescence microscopy using an inverted IX81 Microscope 
(Olympus, Canada). 
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4.3.7 RNA Quality Assessment, Probe Preparation and GeneChip 
Hybridization 
All GeneChips were processed at the London Regional Genomics Centre (Robarts 
Research Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) 
and the RNA 6000 Nano kit (Caliper Life Sciences, Mountain View, CA). Single 
stranded complimentary DNA (sscDNA) was prepared from 200 ng of total RNA as per 
the Ambion WT Expression Kit for Affymetrix GeneChip Whole Transcript WT 
Expression Arrays (Applied Biosystems, Carlsbad, CA) and the Affymetrix GeneChip 
WT Terminal Labeling kit and Hybridization User Manual (Affymetrix, Santa Clara, 
CA). Total RNA was first converted to cDNA, followed by in vitro transcription to make 
cRNA. 5.5 ug of single stranded cDNA was synthesized, end labeled and hybridized, for 
16 hours at 45°C, to Human Gene 1.0 ST arrays. All liquid handling steps were 
performed by a GeneChip Fluidics Station 450 and GeneChips were scanned with the 
GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA) using Command Console 
v1.1. Probe level (.CEL file) data was generated using Affymetrix Command Console 
v1.1. Probes were summarized to gene level data in Partek Genomics Suite v6.5 using the 
RMA algorithm adjusted for GC content[32]. Using Partek, any batch affect due to scan 
date was removed and an ANOVA (Yijk = μ + Condition * Timeij+ eijk) using Method 
of Moments [33] was run to determine gene level p-values. Fold change comparisons are 
expressed relative to untreated siControl cells, and represent the average of three separate 
experiments (3 separate gene chips per condition). A fold change of ±1.6 was considered 
as the cutoff for induction.  
 
4.3.8 Reverse Transcription, Real time PCR and Statistical Analyses 
Total RNA was isolated from A549 cells using the RNAeasy Mini kit (Qiagen) 
according to the manufacturer’s protocol.  For complementary DNA (cDNA) synthesis, 
1000 ng of total RNA was reverse transcribed using the Superscript® VILO cDNA 
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synthesis kit according to manufacturer’s protocol (Applied Biosystems). A cDNA 
equivalent to 10 ng of total RNA was used for all PCR reactions in a total volume of 20 
l. Each reaction was carried out in triplicate. Quantitative PCR (qPCR) reactions were 
conducted using SsoFast

 EvaGreen® supermix (BioRad) using a Chromo4 Real-time 
Thermal Cycler (Bio-Rad) according to the recommended protocol of the manufacturer. 
Primer sequences (5'-3') are as follows: PKC (TACGGCCAGGAGATACAACC and 
TCGGAGCTCCCAACAATATC), PKCATCATTCATGTTTTCCCGAGCA and 
GTTGGCACGGTACAGCTTCPKCACAACCTTCCAACAACCTTGAC and 
CCTTCCTGTCGGCAAGCAT) SNAI-1 (AATCGGAAGCCTAACTACAGCG 
andGTCCCAGATGAGCATTGGCA),SNAI-2 (ATACCACAACCAGAGATCCTCA 
andGACTCACTCGCCCCAAAGATG), E-cadherin (CCCACCACGTACAAGGGTC 
and CTGGGGTATTGGGGGCATC), MMP9 (CATTTCGACGATGACGAGTTGT and 
CGGGTGTAGAGTCTCTCGC),  PAI-1 (CTCTCTCTGCCCTCACCAAC and 
GTGGAGAGGCTCTTGGTCTG), SMURF2 (GTCCAGAGACCGAATAGGCAC and 
CCAGAGGCGGTTCTCCTTTC), TIEG1 (TTCCGGGAACACCTGATTTTC and 
GCAATGTGAGGTTTGGCAGTA), DAPK1 (AGCTTCGGCTCAAATCCCAAT and 
TCTCCTTCTCGGTTCTTGATGT), Beta-Actin 
(GGGAAATCGTGCGTGACATTAAG andTGTGTTGGCGTACAGGTCTTTG), and 
POLR2A (GGATGACCTGACTCACAAACTG and CGCCCAGACTTCTGCATGG).  
Primers were selected using Primer3 [34] as well as PrimerBank [35-37]. Baseline and 
threshold for Ct calculation were set manually using the Opticon Monitor 3.1 Software 
(Bio-Rad). PCR efficiencies (E) were calculated using cDNA dilution curves and were > 
90% for all genes assessed. Calculated PCR efficiencies were used for gene expression 
quantification using the Pfaffl formula[38], ratio = (Etarget)
Ct target(control-treated)
/ (Ereference)
Ct 
ref(control-treated)
, where control = siControl, no TGF. Final ratios were calculated using 
geometric averaging [39] from two reference genes: POLR2A, a gene which was found 
to be a suitable reference gene in NSCLC models [40], and -Actin. Gene expression of 
each treatment is expressed in relation to the control (siControl, no TGF) and is an 
average of 3-6 independent experimental trials. Two-way ANOVA analysis followed by 
post-hoc Bonferonnis’s Tests were used to evaluate the significance of the results. 
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Statistical analyses were performed using GraphPad Prism® Software 5.0 and p values of 
<0.05 were considered statistically significant. 
 
4.3.9 Cell Death Assays 
A549 and H1299 cells transfected with the appropriate siRNA constructs were 
serum deprived (0.2% FBS), and then incubated with or without TGF in serum deprived 
media in the presence or absence of a p38 MAPK inhibitor for 48 hours. After 48 hours, 
apoptosis of A549 and H1299 cells was analyzed by examining nuclear morphology after 
Hoechst 33342 staining. Hoescht stain (1 ug/mL) was added directly to the medium and 
incubated for 30 minutes at 37°C. The cells were then visualized using a fluorescent 
microscope (Olympus IX71), and ten random images were acquired per condition. 
Normal, and apoptotic nuclei were counted and the apoptotic nuclei (characterized by 
condensed chromatin) were scored as a proportion of normal/healthy cells.       
 
4.3.10 Statistical Analysis  
One-way or Two-way ANOVA analyses followed by post-hoc Bonferonnis’s Test 
were used to evaluate the significance of the results. Statistical analyses were performed 
using GraphPad Prism® Software 5.0 and p values of <0.05 were considered statistically 
significant. 
 
4.4 Results 
4.4.1 Knockdown of Atypical PKC isoforms alters TGF induced gene 
expression 
We have previously reported that aPKC gene silencing using small interfering 
RNA (siRNA) leads to a temporal extension of TGF induced Smad2 phosphorylation 
[25], and that aPKC facilitates Par6 signalling [26]. Here we assessed global 
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transcriptional changes in aPKC-silenced cells using gene array (microarray) analysis. 
Using small interfering RNA (siRNA) targeted to aPKC iota (siPKC) and zeta (siPKC), 
we were able to successfully reduce protein levels of both aPKC  and  individually, as 
well as together (siPKC/) in A549 lung adenocarcinoma cells (Figure 4.1A). As we 
have previously reported in these cells, knockdown of PKC alone results in a 
compensatory expression of PKC (Figure 4.1A). Furthermore, as reported previously, 
knockdown of aPKC temporally extends P-Smad2 levels 4.5 hours after TGF treatment 
(Figure 4.1B) as well as 24 hours following a pulse of TGF stimulation (Figure 4.1C) 
[25].  
To conduct the microarray analyses, we stimulated siRNA treated cells (siControl 
vs. siPKC/ double knockdown) with TGF for 1 hour, followed by washout and further 
incubation of cells for 24 hours in serum-deprived media. Total RNA was extracted and 
submitted to the London Regional Genomics Centre for microarray analyses. The raw 
data were processed and normalized as outlined in the Methods section and a summary 
table of selected TGF gene changes is presented in Table 4.1. 
We summarized fold change differences between siControl and siPKC/ cells 
after TGF induction (Table 4.1). This list was selected from a set of commonly known 
genes to be regulated by TGF, modified from [7]. The full microarray data set can be 
accessed online at the NCBI Gene Expression Omnibus website (GEO; GSE26241). 
Interestingly, there are several classical TGF genes that show similar expression 
patterns between control and aPKC silenced cells including BMP4, SNAI1, and SNAI2.  
However, there were several genes that had muted TGF-dependent gene changes in 
aPKC-silenced cells compared to control cells, including IL1A, SMURF2, MMP2, and 
MMP9. We next followed up on these gene changes using real-time PCR. 
 
 
 
 
174 
 
 
Figure 4.1 
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Figure 4.1.  aPKC knockdown prolongs TGF induced Smad2 phosphorylation 
 (A) A549 cells transfected with the indicated siRNA were grown for 24 hours and then 
lysed.  Cell lysates were processed for SDS-PAGE and immunoblotted with anti ()-
PKC, anti-PKC, or anti-Actin antibodies as indicated to observe protein knockdown 
levels. 
(B) A549 cells transfected with the indicated siRNA were serum starved and treated with 
250 pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours prior to 
lysis. Lysates were then processed for SDS-PAGE and immunoblotted with anti ()-
phospho-specific Smad2 or Smad2/3 antibodies. A representative immunoblot from 3 
independent replicate experiments is shown. 
(C) A549 cells transfected with the indicated siRNA were serum starved and treated with 
250 pM TGF for 1 hour, washed and further incubated for 24 hours in serum deprived 
media prior to lysis. Lysates were then processed for SDS-PAGE and immunoblotted 
with ()-phospho-specific Smad2 or Smad2/3 antibodies. A representative immunoblot 
from 3 independent replicate experiments is shown. 
 
 
 
 
 
 
 
 
 
176 
 
 
Table 4.1 
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Table 4.1.  aPKC knockdown alters TGF gene response by microarray analysis 
A549 cells transfected with control (siControl) or siRNA directed at aPKC isoforms 
(siPKC/) were serum starved and treated with 250 pM TGF for 1 hour, washed and 
further incubated for 24 hours in serum deprived media. Total RNA was then extracted 
and subjected to microarray analysis. Shown is a selected list of genes that differed 
between control and aPKC silenced cells after 24h for several genes regulated by TGF  
(list adapted from Table 1 in [7]) Fold change comparisons are expressed relative to 
untreated siControl cells (siControl, -TGF), and represent the average of three separate 
experiments (n=3). In bold are some genes that show a muted response in aPKC 
knockdown cells. 
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4.4.2 Knockdown of Atypical PKC alters TGF induced gene 
expression in qPCR analyses 
We next re-examined some of the changes we observed in microarray analysis by 
qPCR. Control and aPKC-silenced cells were treated as described above in the 
microarray analyses. However, in this case, total RNA was extracted, reverse transcribed, 
and subjected to qPCR analysis for various TGF induced genes. SNAI-1, SNAI-2, E-
cadherin, MMP9, PAI-1, Smurf2, DAPK1, and TIEG 1 were tested for relative gene 
expression in TGF induced control or aPKC knockdown cells. We also tested 
expression of PKC, PKC, and PKCto confirm aPKC knockdown efficiency. Relative 
gene expression was normalized using 2 reference genes (Beta-Actin and POLR2A) as 
described in the Methods section. The graphs represent the average gene expression from 
at least 3 independent experimental trials. 
 Figure 4.2A indicates that siRNA targetting aPKC iota and zeta was successful at 
reducing gene expression of the atypical PKCs (aPKC and ), but not the classical 
isoform PKC. Figure 4.2B shows the gene expression of the various TGF-induced 
genes in aPKC knockdown and control cells.  SNAI-1 (Snail), SNAI-2 (Slug) and E-
cadherin are TGF dependent genes involved in the maintenance of epithelial cell 
junctions. In invasive cancers, TGF is known to trigger breakdown of epithelial cell 
junctions to promote an invasive phenotype by reducing E-cadherin levels through the 
transcriptional repressors SNAI-1 and SNAI-2 [17]. Our results indicate the transcription 
factors SNAI-1 and SNAI-2 increase with TGF treatment. Furthermore, E-cadherin 
gene expression is reduced with TGF treatment. These results were similar in both 
control and aPKC silenced cells indicating that aPKC may not be important for 
transcriptional regulation of these genes. However, several other genes were dampened 
with aPKC knockdown. 
Smurf2 (SMAD ubiquitination regulatory factor 2), is a regulatory factor for the 
TGF receptors, typically involved in targeting Smads and receptors for ubiquitin 
mediated degradation [8, 13]. Our results indicate that upon TGF stimulation, there is an 
increase in SMURF2 gene expression, however, this effect is abrogated in aPKC-silenced 
cells.       
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 TGF signalling is often involved in inducing expression of genes that are 
involved in the remodelling of the extracellular matrix and degradation of the basement 
membrane. These types of TGF induced gene changes are implicated in the progression 
of fibrotic disorders as well as metastatic phenotypes in cancer. Two such genes regulated 
by TGF are PAI-1 (plasminogen activator 1) and MMP9 (matrix metalloproteinase 9)[7, 
41]. In observing the gene expression of PAI-1, we saw that TGF stimulation induced a 
significant increase in PAI-1 expression in siControl cells. However, PAI-1 induction 
was significantly reduced in aPKC silenced cells. Similarly, MMP9 gene expression 
increases with TGF induction and this effect is also significantly reduced in aPKC- 
silenced cells. 
 TGF Smad signalling can also stimulate pro-apoptotic effects in the epithelium 
through the positive regulation of genes such as DAPK1 (death-associated protein kinase 
1) and TIEG1 (TGF-inducible early response gene 1) [19]. Interestingly, we found that 
in A549 cells, TGF actually stimulates a modest decrease in DAPK1 and no change in 
TIEG 1 expression. No significant differences were observed in aPKC-silenced cells 
compared to control.   
Notably, as we observed in the microarray data, the significant differences we 
observed in TGF-induced expression in aPKC knockdown cells were actually decreased 
gene response. This is despite having temporally extended P-Smad2 levels. We next 
sought to determine what might be causing this muted TGF response.   
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Figure 4.2 
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Figure 4.2.  aPKC silencing alters TGF dependent gene induction  
Real time PCR analysis of TGF  induced  mRNA levels in A549 control siRNA cells as 
compared to aPKC double silenced cells (siPKC/). RNA extracts were isolated from 
cells treated for one hour with TGF followed by 24 hours of incubation in the absence 
of ligand. Two-way ANOVA analysis followed by post-hoc Bonferonni‘s tests were used 
to determine statistical significance of gene changes (PKC, PKC, PKC, CDH1, 
SNAI1, SNAI2, n=3; all other genes n=6, ±SEM, Two-Way Anova *=p<0.05) a= 
significant change with TGF; b= significant change with aPKC knockdown (A) aPKC 
siRNA is specific. aPKC knockdown was effective in silencing aPKC gene expression, 
but not classical PKC  expression. (B) TGF effected similar changes in SNAI-1, 
SNAI-2, E-cadherin, and DAPK1 in control and aPKC silenced cells. However, aPKC 
knockdown results in reduced TGF induced MMP9, PAI-1 and Smurf2 expression. 
TIEG1 was unaffected by TGF treatment or aPKC knockdown. 
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4.4.3 aPKC knockdown reduces TGF induced Smad2 nuclear 
accumulation 
Activated TGF receptors phosphorylate receptor regulated Smads (Smad2 and 
Smad3) on a C-terminal SSXS motif which facilitates their accumulation in the nucleus 
[8]. Since the reduced transcriptional response we were observing in aPKC silenced cells 
may be due to a reduced nuclear translocation of Smad2, we examined the cytosolic-
nuclear translocation of Smad2 in control and aPKC silenced cells using 
immunofluorescence microscopy (Fig 4.3A). As expected, in cells tranfected with control 
siRNA, TGF induced an increase in Smad2 nuclear staining, indicating a robust nuclear 
accumulation of Smad2 (Fig 4.3A). However, aPKC silenced cells showed a reduced 
nuclear accumulation of Smad2 in response to TGF. To verify this observation, we also 
conducted subcellular fractionation studies and immunoblotting of cellular cytosolic and 
nuclear fractions when cells were treated in the presence or absence of TGF. Consistent 
with our immunofluorescence microscopy analysis, TGF treatment stimulates an 
increase in nuclear Smad2 levels in cells transfected with control siRNA (Figure 4.3B) 
This is in contrast to aPKC knockdown cells, which show significantly reduced nuclear 
Smad2 levels upon TGF addition. We next assessed whether knockdown of aPKC was 
mediating effects specific to the TGF pathway or whether it was affecting general 
nuclear import. 
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Figure 4.3 
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Figure 4.3.  aPKC knockdown reduces TGF induced Smad2 nuclear accumulation 
(A) A549 cells were transfected with the indicated siRNA, serum starved and treated with 
250 pM TGF for 1 hour.  The cells were processed for immunofluorescence microscopy 
with antibodies against Smad2. DAPI was used to visualize DNA. Representative images 
from at least 3 independent replicate experiments are shown. Bar = 10 µm 
(B) A549 cells were transfected and treated with TGF as described in panel A.  The 
cells were then subjected to subcellular fractionation to isolate cytoplasmic and nuclear 
fractions.  The fractions were subjected to SDS-PAGE and immunoblotted using anti ()-
Smad2, anti-tubulin, and anti-Histone H3 antibodies to determine the subcellular 
distribution of Smad2. Histone H3 and Tubulin antibodies were used as loading controls 
for the nuclear and cytoplasmic fractions, respectively Average nuclear Smad2 levels 
from 3 independent replicate experiments were quantitated by densitometrical analysis 
and graphed below the representative immunoblots. (n=3 ± SEM, Two-way ANOVA, 
*p<0.05.)   
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4.4.4 siRNA targeting aPKC does not alter TNF induced NF-B 
nuclear translocation 
After finding that the cytosolic retention of Smad2 was increased in aPKC 
silenced cells, we next sought to determine whether aPKC knockdown might be altering 
general nuclear import. To test this, we examined the classical NF-B pathway, wherein 
subsequent to TNF stimulation, NF-B translocates to the nucleus via a classical 
importin dependent mechanism [42]. Using immunofluorescence microscopy we 
examined the subcellular localization of NF-kB in cells treated with or without TNF 
(Figure 4.4). In cells transfected with either control siRNA or siRNA targeting aPKC, 
NF-B showed a robust accumulation in the nucleus following TNF stimulation (Figure 
4.4). This suggested that the reduction in Smad2 nuclear localization in aPKC silenced 
cells was not likely due to an inhibition of general nuclear import machinery and 
therefore was possibly specific to the Smad pathway. We next sought to determine the 
cause of cytosolic retention of Smad2 in aPKC silenced cells.  
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Figure 4.4.  aPKC knockdown does not alter TNF induced NF-B nuclear 
accumulation 
A549 cells transfected with the indicated siRNA were serum deprived, treated with 
10ng/mL TNF for 30 minutes, and then fixed and processed for immunofluorescence 
microscopy with antibodies against NF-B to observe NF-B subcellular localization. 
DAPI was used to visualize DNA. Representative images from 3 independent replicate 
experiments are shown. Bar = 10 µm.  
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4.4.5 Knockdown of aPKC enhances P-p38 MAPK levels 
R-Smads shuttle to and from the nucleus and their subcellular localization is 
primarily controlled through their C-terminal phosphorylation. The protein structure of 
Smads has been largely conserved among species and consists of 2 Mad homology 
domains (MH1 and MH2) connected by an intermediate, proline rich linker region [8]. 
Interestingly, this linker region contains multiple phosphorylation sites that have been 
shown to alter Smad localization and function [10]. Originally, linker phosphorylation 
was discovered to occur through ERK MAPK (via Ras) to exclude Smad from the 
nucleus [43]. Given our observation of reduced nuclear accumulation of Smads in aPKC 
silenced cells, we next assessed whether MAPK pathways were altered in aPKC depleted 
cells. We analyzed the levels of activated MAPK pathways in response to a pulse of 
TGF in control and aPKC silenced cells (Figure 4.5).  We noted that at 1 and 24 h time 
points there did not appear to be a difference between siControl and siPKC/cells with 
regards to the levels of phosphorylated ERK 1/2. However, aPKC knockdown increased 
basal levels of phosphorylated p38 MAPK and extended the duration of p38 
phosphorylation to at least 24 hours (Figure 4.5A). Appreciable levels of P-JNK (the last 
MAPK) were not detected in this cell line (Figure 4.5A). We went on to test a shorter 
time course of p38 MAPK activation in control and aPKC knockdown cells and 
discovered that in aPKC-silenced cells (single, or double knockdown) TGF-induced p38 
MAPK phosphorylation was increased and extended in duration compared to control 
cells (Figure 4.5B). Because MAPK crosstalk is well known to alter Smad nuclear-
cytoplasmic shuttling dynamics [10, 44, 45], we hypothesized that increased p38 MAPK 
activity may be altering Smad2 nuclear import in aPKC-silenced cells. Thus, after 
determining that aPKC knockdown was enhancing p38 MAPK signalling, we next sought 
to test whether this enhanced p38 MAPK activity might play a role in Smad2 nuclear 
entry. 
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Figure 4.5 
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Figure 4.5.  aPKC knockdown increases and prolongs p38 MAPK phosphorylation 
in response to TGF 
(A) A549 cells transfected with control siRNA (siControl) or siRNA directed at the 
aPKC isoforms (PKC/) were treated with or without 250 pM TGF for 1 or 24 hours 
prior to lysis. Samples were then processed for SDS-PAGE and immunoblotted with anti 
()-phospho-specific antibodies directed at phosphorylated forms of ERK, p38, and JNK 
as indicated on the right of the panels. Shown are representative immunoblots from at 
least 3 independent replicate experiments.  Immunoblotting for Actin was used as a 
loading control. 
(B) A549 cells transfected with the indicated siRNA were serum starved and treated with 
250 pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours prior to 
lysis. Lysates were then processed for SDS-PAGE and immunoblotted with the anti ()-
phospho-specific p38 and total p38 MAPK antibodies as indicated on the right of the 
panels.  Average P-p38 MAPK levels from 3 independent replicate experiments were 
quantitated by densitometrical analysis and graphed below the representative 
immunoblots. (n=3 ± SEM, Two-way ANOVA, *p<0.05, **p<0.01). 
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4.4.6 Inhibition of p38 MAPK does not rescue Smad2 nuclear 
translocation 
Given that we observed increased levels of P-p38 MAPK, we next wanted to 
assess whether p38 MAPK was responsible for the altered Smad2 nuclear translocation 
observed in aPKC silenced cells. To carry this out, we phamacologically inhibitted p38 
activity in aPKC silenced cells and assayed for Smad2 nuclear translocation by 
immunofluorescence microscopy. As we previously observed, in cells transfected with 
control siRNA, TGF induced a robust nuclear accumulation of Smad2, whereas in 
aPKC knockdown cells Smad2 nuclear accumulation was impaired (Figure 4.6).  
Interestingly, we found that the p38 MAPK inhibitor did not rescue Smad2 nuclear 
translocation in aPKC silenced cells (Figure 4.6). This result suggested that p38 MAPK 
activity was likely not responsible for the reduced Smad2 nuclear accumulation observed 
in aPKC silenced cells. Although, we found that inhibiting p38 MAPK did not rescue 
Smad2 nuclear accumulation, we wanted to address whether the enhanced p38 MAPK 
levels we observed might be altering TGF induced apoptosis. 
 
191 
 
 
 
Figure 4.6 
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Figure 4.6.  p38 MAPK inhibition of aPKC knockdown cells does not rescue Smad2 
nuclear accumulation 
A549 cells transfected with the indicated siRNA, were serum deprived in the presence or 
absence of a p38 MAPK inhibitor, and then treated with 250 pM TGF for 1 hour. Cells 
were then fixed and processed for immunofluorescence microscopy with antibodies 
against Smad2 to observe Smad2 subcellular localization. DAPI was used to visualize 
DNA. Representative images from at least 3 independent replicate images are shown. Bar 
= 10 µm. 
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4.4.7 Knockdown of aPKC increases TGF induced apoptotic 
response via p38 MAPK 
TGF receptors can activate the p38 MAPK pathway to stimulate apoptosis [18, 
46]. We next examined whether the increased p38 MAPK signalling observed in aPKC 
silenced cells could sensitize cells to TGF induced apoptotic response. To measure 
apoptosis, control and aPKC silenced cells were treated with or without TGF for 48 
hours, and the percentage of apoptotic cells was measured through the assessment of 
nuclear morphology after Hoescht staining. Cells treated with control SiRNA showed a 
modest apoptotic response to TGF, which is in contrast to aPKC-silenced cells, which 
exhibited a significant increase in cell death when treated with TGF (Figure 4.7A). 
Importantly, treatment of aPKC silenced cells with a p38 MAPK inhibitor reduced the 
number of apoptotic nuclei, indicating the apoptotic response observed was downstream 
of p38 MAPK. Furthermore, cleaved-Parp levels (a marker of apoptosis) induced by 
TGF were significantly higher in aPKC silenced cells than in control cells (Figure 
4.7B). Similar to the above results, p38 MAPK inhibition reduced cleaved-Parp levels in 
aPKC silenced cells indicating that the apoptotic response observed in aPKC silenced 
cells likely involved the p38 MAPK pathway (Figure 4.7B). We next tested another 
NSCLC cell line, H1299 cells, for apoptotic response and Smad2 nuclear accumulation to 
assess whether the results we were observing were cell type specific.  
 
4.4.8 Knockdown of aPKC also mediates TGF effects in H1299 
NSCLC cells 
We next examined whether the results we observed in A549 cells could be 
recapitulated in H1229 cells, a second NSCLC cell line. We tested whether aPKC 
knockdown in H1299 cells altered Smad2 nuclear accumulation upon TGF stimulation. 
Using an immunofluorescence approach as we have done above (Figure 4.3A), we 
examined the localization of Smad2 after TGF treatment in control, and aPKC 
knockdown cells. Similar to our findings with A549 cells, TGF treatment increased the 
nuclear localization of Smad2 in H1299 cells transfected with control siRNA (Figure 
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4.8A). Furthermore, siRNA targeting aPKC reduced TGF induced nuclear accumulation 
of Smad2 (Figure 4.8A). We also tested whether aPKC knockdown cells showed 
enhanced p38 MAPK phosphorylation by treating cells with TGF in a timecourse as we 
have done before for A549 cells. As we had seen in A549 cells, aPKC-silenced H1299 
cells also showed an enhanced p38 MAPK response compared to control cells (Figure 
4.8B). Furthermore, we also observed that this increased p38 MAPK signalling correlated 
with an increased apoptotic response in aPKC knockdown cells (Figure 4.8C), and that 
this effect was abrogated with a p38 MAPK inhibitor. Importantly, these results are in 
agreement with our A549 cell data. After seeing that the results we had observed did not 
seem to be cell type specific, we next wanted to investigate the mechanisms for these 
altered responses in aPKC knockdown cells. The TGF signalling pathway to p38 
MAPK involves the recruitment and activation of the ubiquitin ligase TRAF6 [21, 22]. 
To gain mechanistic insight into why aPKC silenced cells showed enhanced p38 MAPK 
levels, we next examined the role of TRAF6 in this pathway.  
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Figure 4.7 
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Figure 4.7.  aPKC knockdown enhances TGF induced apoptotic response 
(A) A549 cells transfected with control siRNA (siControl) or siRNA directed at the 
aPKC isoforms (PKC/) were serum deprived and treated with or without 250pM TGF 
for 48 hours in the presence or absence of a p38 MAPK inhibitor. Hoescht 33342 was 
used to stain the nuclei of cells prior to image acquisition and cell counting. 
Quantification of apoptotic nuclei (yellow arrowheads) from four independent 
experiments are expressed graphically to the right of the representative images. 
(n=4±SEM, Two-way ANOVA, *=p<0.05)   
 (B) A549 cells were treated as in (A) and then lysed. Cell lysates were processed for 
SDS-PAGE and immunoblotted with anti ()-cleaved PARP and anti-Actin antibodies. 
Average densitometrical analysis from 4 independent replicate experiments is shown 
graphically below the representative immunoblot. (n=4±SEM, Two-way ANOVA, 
*=p<0.05.) 
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Figure 4.8 
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Figure 4.8. aPKC knockdown in H1299 cells also reduces Smad2 nuclear 
accumulation, increases p38 MAPK levels, and enhances apoptosis, similar to A549 
cells 
(A) H1299 NSCLC cells were transfected with the indicated siRNA, serum starved and 
treated with 250 pM TGF for 1 hour.  The cells were processed for immunofluorescence 
microscopy with antibodies against Smad2. DAPI was used to visualize DNA. 
Representative images from at least 3 independent replicate experiments are shown. Bar 
= 10 µm 
(B) H1299 NSCLC cells transfected with the indicated siRNA were serum starved and 
treated with 250 pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours 
prior to lysis. Lysates were then processed for SDS-PAGE and immunoblotted with anti 
()-phospho-specific p38 and total p38 MAPK antibodies as well as anti-PKC and anti-
PKC antibodies as indicated on the right of the panels.  Representative immunoblots 
from at least 3 independent replicate experiments is shown. 
(C) H1299 NSCLC cells transfected with control siRNA (siControl) or siRNA directed at 
the aPKC isoforms (PKC/) were serum deprived and treated with or without 250pM 
TGF for 48 hours in the presence or absence of a p38 MAPK inhibitor. Hoescht 33342 
was used to stain the nuclei of cells prior to image acquisition and cell counting. 
Quantification of apoptotic nuclei (yellow arrowheads) from four independent replicate 
experiments are expressed graphically to the right of the representative images. 
(n=4±SEM, Two-way ANOVA, **= p<0.01)   
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4.4.9 Knockdown of aPKC increases TRI-TRAF6 complexes 
TGF-stimulated apoptosis mediated via p38 MAPK has been previously 
reported to occur through the recruitment and activation of the E3 ubiquitin ligase 
TRAF6 [21, 22]. Briefly, upon TGF activation, TRAF6 is recruited to TRI of the 
TGF receptor complex. This causes TRAF6 to become auto-ubiquitinated, which 
activates TAK1 (a MAP3K), which in turn triggers the MAPK cascade to p38 activation 
[21, 22]. We have previously shown that aPKC expression can alter binding patterns of 
TRI substrates [26]. We hypothesized that the increased TGF-p38 MAPK signals we 
observed in aPKC silenced cells, may have beeen due to an increased association of 
TRAF6 with TGF receptors when aPKC was depleted. Indeed we have also previously 
shown that overexpressed aPKC can negatively regulate steady-state TGF receptor 
levels and that knockdown of aPKC reduces the rate of activated TGF receptor complex 
degradation [25]. We tested this idea by immunoprecipitating endogenous TRAF6 from 
control, and aPKC silenced cells, followed by immunoblotting for exogenously expressed 
TRI (Figure 4.9). Interestingly, TRI associated to a greater degree with TRAF6 in the 
absence of aPKC expression (Figure 4.9). This finding suggested that TRI-TRAF6 
complexes were more stable in aPKC knockdown cells.  We reasoned that this increase in 
TRI-TRAF6 complexes may have led to increased TGF-induced p38 MAPK signals in 
aPKC silenced cells.  To test this idea, we next examined whether TRAF6 knockdown 
could abrogate the p38 MAPK signalling seen in aPKC silenced cells. 
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Figure 4.9.  aPKC knockdown increases levels of TRI-TRAF6 complexes 
HEK 293T cells transfected with control siRNA (siControl) or siRNA targeting aPKC 
isoforms (PKC/) were co-transfected with cDNA encoding Flag-tagged TGF type 1 
receptor (FlagTRI) as indicated.  Cells were then lysed and endogenous TRAF6 was 
immunoprecipitated (IP) using anti-TRAF6 antibodies.  The immunoprecipitates were 
processed for SDS-PAGE and immunoblotted with anti ()-Flag and anti-TRAF6 
antibodies to visualize immunoprecipitated Flag-tagged TRI and TRAF6 (top panel).  
Cell lysates were immunoblotted with anti- PKC, anti-PKC, anti-Flag and anti-TRAF6 
antibodies to visualize endogenous aPKC and TRAF6 levels as well as expressed Flag-
tagged TRI (bottom panel). Representative immunoblots from at least from 3 
independent replicate experiments are shown.  
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4.4.10 Knockdown of TRAF6 in aPKC silenced cells reduces 
activated p38 MAPK and apoptosis  
Because aPKC knockdown was enhancing P-p38 MAPK levels in response to 
TGF, we inferred that knockdown of TRAF6 may reduce this effect. We used siRNA to 
knockdown the aPKCs alone, TRAF6 alone, or aPKC and TRAF6 together. As we had 
seen before, aPKC silencing increased P-p38 MAPK levels in response to TGF (Figure 
4.10A). Interestingly, in cells where we depleted protein levels of aPKC and TRAF6 
simultaneously by siRNA knockdown, TGF-induced p38 MAPK phosphorylation was 
abrogated (Figure 4.10 A). Furthermore, as we had observed before, aPKC knockdown 
cells exhibited an increased TGF-induced apoptotic response as measured by Hoescht 
staining and quantitation of pyknotic nucleic (Figure 4.10B). In contrast, simultaneous 
knockdown of TRAF6 and aPKC reduced the TGF-induced apoptotic effect (Figure 
4.10B), which corresponds to the reduced p38 MAPK phosphorylation seen in these cells 
(Figure 4.10A). These results suggested that the enhanced p38 MAPK signalling and 
apoptosis we had observed in aPKC silenced cells were TRAF6 dependent. Although, we 
found that p38 MAPK was enhancing apoptosis via a TRAF6 dependent mechanism in 
aPKC depleted cells, we still did not resolve why Smad2 nuclear translocation was 
reduced. We therefore next assessed Smad2-Smad4 complex formation in aPKC 
knockdown cells. 
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Figure 4.10.  Knockdown of TRAF6 abrogates TGF-p38 MAPK effects observed in 
aPKC depleted cells  
(A) A549 cells transfected with control siRNA, or siRNA directed at aPKC (siPKC/), 
TRAF6 (siTRAF6), or both aPKC and TRAF6 (siPKC/ + TRAF6) were serum starved 
and treated with 250 pM TGF for 1 hour prior to lysis. Lysates were then processed for 
SDS-PAGE and immunoblotted with the anti ()-phospho-specific p38 and total p38 
MAPK antibodies as indicated on the right of the panels. Immunoblotting using anti-
TRAF6, anti-PKC, and anti-PKC antibodies were used to determine knockdown levels.  
Average P-p38 MAPK levels from 3 independent replicate experiments were quantitated 
by densitometrical analysis and graphed below the representative immunoblots 
(n=3±SEM, Two-way ANOVA, **= p<0.01). 
(B) A549 cells transfected as in (A) were serum deprived and treated with or without 250 
pM TGF for 48 hours. Hoescht 33342 was then used to stain the nuclei of cells prior to 
image acquisition and cell counting. Quantification of apoptotic nuclei (yellow 
arrowheads) from three independent experiments are expressed graphically below the 
representative images. (n=3±SEM, Two-way ANOVA, *=p<0.05).    
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4.4.11 Knockdown of aPKC reduces Smad2-Smad4 complex 
formation 
In the basal state, Smad2 is predominantly localized to the cytoplasm, however, in 
response to phosphorylation, Smad2 associates with Smad4, and accumulates in the 
nucleus [2, 8]. Although phosphorylated R-Smads can activate transcription alone, a full 
TGF response requires complex formation of Smad2 and Smad4 [47].  We next 
examined whether aPKC silencing was altering TGF-induced Smad2-Smad4 interaction 
by immunoprecipitating Smad2 and immunoblotting for Smad4 in Control and aPKC 
silenced cells (Figure 4.11). As expected, in cells transfected with control siRNA, the 
addition of TGF increased the amount of Smad4 co-immunoprecipitating with Smad2 
indicating that TGF treatment induced Smad2-Smad4 complex formation (Figure 4.11). 
In contrast, aPKC silenced cells exhibited a signficantly reduced level of Smad2 
associated Smad4 with TGF addition (Figure 4.11). This indicated that the reduction in 
gene response we observed in aPKC silenced cells may be due to reduced Smad2-Smad4 
interaction. We next examined whether SARA could be playing a role in this process.        
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Figure 4.11 
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Figure 4.11. aPKC knockdown reduces TGF-induced Smad2-Smad4 complex 
formation 
A549 cells transfected with control siRNA (siControl) or siRNA directed at the aPKC 
isoforms (PKC/) were serum starved and treated with or without 250 pM TGF for 1 
hour prior to lysis. Cell lysates were then immunoprecipitated (IP) using anti ()-Smad2 
antibodies, followed by immunoblotting for Smad4 to determine the level of induction of 
Smad2-Smad4 complex formation. Cell lysates were included to show relative 
endogenous protein expression. Average densitometrical analysis from three independent 
replicate experiments is shown below the representative immunoblots. (n=3 ±SEM, Two-
way ANOVA, **=p<0.01).   
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4.4.12 Knockdown of aPKC increases SARA expression  
The subcellular localization of R-Smads can be controlled by a balance between 
binding factors that retain them in the cytoplasm vs. transcription factors that retain them 
in the nucleus. One such cytoplasmic retention factor is the Smad anchor for receptor 
activation (SARA), an early endosome anchored FYVE domain containing protein.  
Under normal conditions, Smad2 can be anchored to the early endosome by SARA [12, 
15, 48]. Originally the function of SARA was described to recruit non-phosphorylated 
Smad2 to the activated receptor complex [12, 15, 48].  However, a more complex role for 
SARA is emerging, as recent reports have indicated that SARA may be dispensable for 
TGF signalling [49], and also that SARA may be involved in more general endocytic 
trafficking mechanisms [50]. Because we have previously reported alterations in 
membrane trafficking of TGF receptors upon PKC inhibition ([25]; Chapter 2), we next 
examined whether SARA levels were altered in aPKC silenced cells. Interestingly, aPKC 
silenced cells showed an increased total protein expression of SARA compared to control 
cells (Figure 4.12A), although no appreciable alterations were observed in early 
endosome localization with aPKC knockdown by immunofluorescence microscopy 
(Figure 4.12B). We next analyzed whether the increased SARA levels could be retaining 
Smad2 in the cytoplasm.   
 
4.4.13 Knockdown of aPKC increases cytosolic rentention of 
Smad2 by SARA 
SARA preferentially binds unphosphorylated forms of Smad2, and it is thought 
that the activated receptor complex formed at the plasma membrane is captured by SARA 
in the early endosome, which then presents the bound R-Smad to the receptor for 
phosphorylation [2]. Smad2 then dissociates from SARA and associates with Smad4 
prior to nuclear translocation and the initiation of transcription [2]. We examined whether 
the increased SARA levels in aPKC silenced cells correlated with enhanced cytoplasmic 
retention. We immunoprecipitated Smad2 from control and aPKC silenced cells treated 
with TGF to examine whether SARA was dissociating from Smad2 upon TGF 
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addition. As expected, TGF addition causes a dissociation of SARA from Smad2 
(Figure 4.13). Smad2 dissociation from SARA is followed by a concomitant increase in 
the binding of Smad4, similar to what we observed in Figure 4.11. Interestingly, in aPKC 
silenced cells TGF addition reduced SARA-Smad2 dissociation, and also reduced the 
binding of Smad2 to Smad4 (Figure 4.13). This implied that SARA was retaining Smad2 
in the cytoplasm to a greater degree in aPKC silenced cells, and was likely responsible 
for the observed reduced nuclear translocation of Smad2 that we had observed. Thus, in 
summary, we found that aPKC silenced cells showed reduced Smad2 nuclear 
accumulation in response to TGF probably due to an increased cytoplasmic retention by 
SARA, and furthermore, aPKC silenced cells showed increased TRI-TRAF6 complex 
levels, and enhanced TGF-induced p38 MAPK phosphorylation and apoptotic response 
(summarized in Figure 4.14).  
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Figure 4.12.  Knockdown of aPKC increases steady state SARA protein levels 
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting aPKC 
isoforms (PKC/) were lysed and immunoblotted using antibodies for SARA and Actin 
as indicated on the right of the panels.  Average densitometrical analysis of steady state 
SARA levels from three independent experiments is shown graphically to the right of the 
representative immunoblots. (n=3±SEM, Two way ANOVA, *=p<0.05). 
(B)  aPKC knockdown does not inhibit the localization of SARA in the early endosome. 
A549 cells were transfected as described in Panel A and processed for 
immunofluorescence microscopy to visualize EEA1 (green) and SARA (red).  DAPI was 
used to visualize DNA (blue). Representative images from at least 3 independent 
experiments are shown.Bar = 10m.   
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Figure 4.13.  Knockdown of aPKC reduces TGF induced Smad2 release from 
SARA 
A549 cells transfected with control siRNA (siControl) or siRNA directed at the aPKC 
isoforms (PKC/) were serum starved and treated with or without 250 pM TGF for 1 
hour prior to lysis. Cell lysates were then immunoprecipitated (IP) using anti ()-Smad2 
antibodies, and subjected to SDS-PAGE and immunoblotting using -SARA, -Smad4 
and -Smad2 antibodies. IgG heavy chain is indicated. Cell lysates were included to 
show relative endogenous protein expression. Average densitometrical analysis of Smad2 
associated SARA levels from three independent replicate experiments is shown 
graphically below the representative immunoblots. (n=3 ±SEM, Two Way Anova, 
*=p<0.05).  
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Figure 4.14.  aPKC knockdown alters TGF induces Smad-dependent and Smad-
independent pathways 
Knockdown of aPKC increased steady state levels of SARA. aPKC knockdown cells also 
exhibit reduced Smad2 nuclear accumulation in response to TGF due to increased 
SARA mediated Smad2 cytosolic retention, and reduced Smad2-Smad4 complex 
formation. Knockdown of aPKC also increased levels of TRI-TRAF6 complexes, and 
enhanced TGF-induced, TRAF6-dependent p38 MAPK phosphorylation to stimulate 
apoptotic response.  
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4.5 Discussion 
The TGFβ pathway controls an array of developmental and homeostatic processes 
and alterations in the pathway are associated with various pathologies such as fibrosis 
and cancer. Given the varied responses associated with a TGF signal, it is clear that the 
context dependent execution of signalling may be regulated at multiple levels. We have 
recently demonstrated an important role for aPKC in regulating TGF signals. More 
specifically, we have previously reported that aPKC alters TGF receptor trafficking, as 
well as the execution of a full EMT response through Par6 signalling. Here we have 
found that aPKC knockdown alters both Smad-dependent and the Smad-independent p38 
MAPK signalling pathways. 
 In this report we examine the transcriptional changes associated with TGF 
signalling in an aPKC silenced background. In this context, we found that several TGF 
stimulated genes showed reduced transcriptional activity. We discovered that aPKC 
silencing played an important role in allowing a full Smad2 nuclear translocation. 
Interestingly, we found aPKC expression was also required for a full Smad2-Smad4 
interaction following TGF stimulation. How aPKC controls Smad2-Smad4 dynamics is 
an area that requires further examination.  
One possibility is an alteration in the access of Smad4 for Smad2. The correct 
subcellular localization of Smad2 is controlled by trafficking of Smads and their 
association with SARA. In this report we find that the knockdown of aPKC increased the 
basal protein levels of SARA. This finding is important, because increased SARA levels 
have been reported to reduce TGF receptor degradation, and also to correlate with the 
maintenance of epithelial phenotype [13, 51]. Given our previous finding that aPKC 
alters the membrane trafficking of the TGF receptors [25], it would be interesting to 
explore whether aPKC alters the function or localization of SARA to control the context 
under which Smads are signalling. Although we did not detect appreciable changes in 
early endosome localized SARA levels, it is possible that in aPKC-silenced cells, the 
normal trafficking of SARA (and its binding partners) to other subcellular compartments 
could be altered. Indeed, a very recent report has implicated SARA in general endocytic 
processes via classical ESCRT complex machinery [50]. More specifically, the correct 
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subcellular trafficking of the EGFR from the early endosome to late endosomes to 
regulate EGFR degradation was dependent on SARA, implicating SARA with a more 
general role in endocytic trafficking than was previously appreciated [50]. This may have 
important implications with respect to our findings that aPKC knockdown reduces TGF 
receptor degradation and stabilizes particular TGF receptor-protein complexes [25, 26]. 
One possibility is that aPKC controls the normal degradative trafficking of the TGF 
receptors, and depletion of aPKC leads to an accumulation of SARA and TGF receptor 
complexes. Indeed, aPKCs has previously been reported to be involved in the trafficking 
of membrane proteins, as well as being involved in the passage of EGFR to lysosome 
targeted endosomes through the anchoring protein p62 [52]. Whether the knockdown of 
aPKC in our model is causing a reduced passage of receptors to lysosomes is an 
important area for future study. Furthermore, if this is the case, it would be important to 
examine whether altered SARA trafficking changes the subcellular availability of Smad4 
for Smad2. Interestingly, although TGF receptors can phosphorylate Smad2 in the 
absence of SARA, it has been reported that SARA is required for proper Smad2 nuclear 
translocation [15]. Furthermore, although inhibiting TGF receptor internalization from 
the membrane only slightly altered phosphorylated Smad2 levels, it did significantly 
impact the ability of Smad2 to dissociate from SARA [15].    This suggests that the 
coordinated function and subcellular localization of SARA and associated Smads are 
important for mediating TGF dependent transcription properly.  
Interestingly, our transcriptional analyses revealed that in aPKC silenced cells, 
some genes showed a muted response to TGF  (e.g. PAI-1, Smurf2, MMP9) but others 
responded to the same degree (e.g. SNAI1, SNAI2, E-Cadherin). Surprisingly, this is 
consistent with a report that TGF can stimulate two classes of genes: genes which are 
Smad4 dependent and genes which are Smad4 independent [53]. Using genetic 
knockdown and microarray analyses, the authours identify PAI-1 and Smurf1 as Smad4 
dependent genes, and SNAI-2 as a Smad4 independent gene [53]. This suggests that 
possibly some of the reduced transcripts we observe in aPKC silenced cells are due to 
Smad4 not accessing the nucleus in response to TGF. This is consistent with our 
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findings that the SARA-Smad2-Smad4 exchange and Smad nuclear translocation is 
altered in aPKC silenced cells.  
Interestingly, a recent analysis of Smad mutations in colorectal cancer indicates 
that a great proportion of mutations in Smad4 map to the conserved R-Smad binding 
surface [54]. Furthermore, the authors report several other R-Smad mutations that reduce 
Smad4 binding [54] – indicating that loss of Smad complex formation is an important 
event during colorectal tumor formation. This opens the possibility that a post-
translational modification of Smad4 may inhibit Smad2 interaction in aPKC silenced 
cells. Certainly, this has been shown before, as Smad4 ubiquitination and 
deubiquitination play pivotal roles in Smad complex formation and disassembly [47, 55]. 
Interestingly, previous reports have described Smad4 dependent and Smad4 independent 
gene changes with respect to TGF. Whether ubiquitination status of Smad4 alters 
Smad2 binding in aPKC silenced cells remains to be elucidated.  
Here, we also made a novel finding that the knockdown of aPKC increased and 
prolonged TGF-induced p38 MAPK activation, and this sensitized NSCLC cells to 
apoptosis. We found that knockdown of aPKC stabilized TRI-TRAF6 complexes, and 
that knockdown of TRAF6 in aPKC silenced cells returned p38 MAPK activation levels 
back to control levels. This result is important, because it suggests that the variability 
seen in p38 MAPK activation by TGF in various cell models may be due to factors that 
destabilize TRAF6-receptor complexes, such as the expression of aPKC.  
 In line with our results, increases in p38 MAPK activity have been reported 
before upon aPKC silencing [31] indicating that aPKC may attenuate p38 MAPK 
signalling in multiple cancer cell types. Interestingly, when aPKC is knocked down, p38 
MAPK is able to signal an apoptotic response indicating that in some situations aPKC 
may be a viable therapeutic target. However, the role of p38 MAPK in cancer is also 
complex, and context dependent – and in addition to sensitizing cells to a death response, 
p38 activity is also associated with cancer cell survival and both the stimulation and 
suppression of EMT [20, 56, 57]. The role of Smad2 linker phosphorylation by MAPK 
members in TGF signalling has also yielded mixed results. The original reports show 
that linker phosphorylation by MAPK blocked Smad2 nuclear accumulation [43, 58], 
however, nuclear stabilization of Smad2 by linker phosphorylation has also been reported 
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[44, 59] suggesting that Smad linker phosphorylation is more complex than originally 
thought, and thus requires further examination. We report here that the enhanced p38 
MAPK activation in aPKC silenced cells was not responsible for the reduction in Smad2 
nuclear accumulation. It would be interesting to see whether linker phosphorylation alters 
Smad2-Smad4 complex formation. In any case, the role of Smad linker phosphorylation 
is complex and requires further detailed examination.  
 In conclusion, we have found aPKC plays multiple roles in TGF signalling and 
the localization and expression patterns of aPKC may dictate how a cell responds to 
TGF. This is especially important since aPKCs have recently been implicated cancer 
progression [28, 60] and aPKC has been classified as a human oncogene [29, 61]. 
Although many interesting questions still remain to be answered, our work suggests that 
aPKCs may alter the way cells respond to TGF signals. 
 
4.6 Footnotes 
The work carried out in this study was supported by the Canadian Institutes of Health 
Research (GMDG, grant: MOP-93625). 
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5 Chapter 5 
5.1 General Summary 
TGF regulates pleiotropic signalling pathways that execute key signalling 
programs, which have important roles in development, tissue homeostasis and disease. It 
is now clear that the complex and versatile responses to TGF signalling are substantially 
defined by regulatory mechanisms that control the intensity and duration of TGF 
signals, but also by interacting protein partners that can define which particular signal 
will be propagated. It is also clear that this complex regulation of TGF signals is 
inherently linked to trafficking, as the internalization and subcellular itinerary of the 
TGF receptors can control signalling outcome.  
 It has been shown that TGF signalling through the Smad family of proteins is 
propagated when the receptors internalize via clathrin-coated pits into the early 
endosome, whereas TGF receptors are more likely to be degraded when they internalize 
via membrane rafts. Thus, receptor trafficking is an important aspect of whether a Smad 
signal is propagated or degraded [1]. Furthermore, upon TGF stimulation, non-Smad 
pathways are also initiated. These include the TGF-Par6 pathway which stimulates cells 
to undergo EMT [2, 3], as well as various MAPK pathways including p38 MAPK 
signalling which can stimulate epithelial cells to undergo apoptosis [4-6]. Understanding 
the factors that contribute to the regulation of the trafficking and signalling of the TGF 
pathway are an important area of research.     
In this thesis I examined the role of the aPKC class of proteins in regulating 
TGF signalling processes and outcomes. aPKC has known roles in endocytic 
trafficking, thereby linking it to classical TGF-Smad signal transduction. Furthermore, 
aPKC is a direct binding partner of both Par6 and TRAF6 thereby linking it to both the 
TGF-Par6 pathway as well as the TGF-p38 MAPK pathway (respectively); however, 
the role of aPKC in these pathways was not fully understood. The overall purpose of this 
study was to examine whether aPKC modulates various TGF pathways, while 
characterizing mechanisms and outcomes contributing to these effects. I evaluated 
whether broad pharmacological PKC inhibition altered membrane trafficking patterns of 
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the TGF receptors, and subsequently whether siRNA knockdown of aPKC isoforms 
altered TGF receptor dynamics and signalling patterns. Furthermore, I examined the 
role of aPKC in the TGF-Par6 pathway, and discovered that both aPKC isoforms could 
phosphorylate Par6 to facilitate the EMT of NSCLC cells. Finally, I examined the role of 
aPKC in the initiation of TGF genetic program and discovered that aPKC knockdown 
reduces Smad2 nuclear accumulation through an increased level of SARA mediated 
retention. Furthermore, I also showed that knockdown of aPKC increases TRI-TRAF6 
complexes and enhances p38 MAPK activation upon TGF stimulation leading to 
increased apoptosis. Thus, I have shown that aPKC is intricately linked to TGF 
signalling, and its expression can modulate TGF signalling outcomes. A brief summary 
of the major findings from this thesis is described in Figure 5.1. 
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Figure 5.1.  aPKC affects TGF signalling pathways 
In this thesis I have found that aPKC isoforms affect both Smad-dependent and Smad-
independent TGF signalling pathways. aPKC plays a role in TGF receptor early 
endosome transit, as well as SARA-Smad2-Smad4 binding dynamics. aPKC also 
phosphorylates Par6 to facilitate TGF induced EMT. Finally, aPKC expression regulates 
TRI-TRAF6 complexes to control the ability of TGF to signal to p38 MAPK.  
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5.2 General Discussion and Future Directions 
5.2.1 Regulation of TGF receptor trafficking and signalling by 
atypical protein kinase C 
Although it is now well established that the endocytic itinerary of the TGF 
receptors can influence TGF signalling patterns, the proteins that control these processes 
are less understood. PKC family members are known regulators of intracellular traffic [7] 
but their potential role in TGF signalling was not explored. In chapter 2 of my thesis I 
examined the role of PKC in TGF signalling by examining the trafficking and 
degradation patterns of the TGF receptors with pharmacological inhibition of PKC. We 
discovered that broad inhibition of PKC isoforms shifted the TGF receptors into the 
early endosome, and reduced TGF receptor degradation. Interestingly, we also 
pinpointed that the atypical class of PKCs (aPKCs) was responsible for enhancing 
phospho-Smad2 levels. This is an important finding, because specifying PKC isoforms 
relevant to particular pathways will aid in the development of selective therapeutic 
approaches. Interestingly, when we knocked down aPKC using siRNA, we were able to 
extend TGF induced P-Smad2 levels, which corresponded to a reduced TGF receptor 
degradation. However, in chapter 4, when we examined the transcriptional output of this 
enhanced Smad2 phosphorylation we determined that aPKC knockdown actually reduced 
TGF mediated transcription of several genes. Interestingly, we then found that TGF-
induced Smad2 nuclear accumulation was reduced in aPKC depleted cells, and we 
showed this was due to an enhanced capacity of SARA to retain Smad2 in the 
cytosplasm. This is an interesting finding for a number of reasons. Firstly, it suggests that 
the proper exchange of SARA-Smad2 complexes to Smad2-Smad4 complexes is a 
regulated process that may require more than just phosphorylation of the R-Smad. 
Certainly, it is in line with a previous report that the proper subcellular localization 
through internalization of the receptors is required for SARA to dissociate from Smad2 
upon phosphorylation [8]. This is particularly important, as there has been some 
controversy with respect to SARA, as some reports indicate SARA as being dispensable 
for the phosphorylation of R-Smads [9, 10]. Consistent with the above reports, we show 
that Smad2 still becomes phosphorylated in aPKC knockdown cells, however, 
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dissociation of Smad2 from SARA is severely impaired, which in turn impairs Smad2 
nuclear translocation and transcriptional response. However, many questions still need to 
be answered. For example, how aPKC knockdown impair SARA-Smad2 dissociation still 
needs to be identified. One possibility is a change in trafficking dynamics of the TGF 
receptors and SARA. We have shown that the knockdown of aPKC increases the total 
protein levels of SARA (in chapter 4) and also slows TGF receptor degradation (in 
chapter 2). One possibility is that TGF receptor-SARA complexes are being internalized 
slower in aPKC knockdown cells, and thus are accessing intracellular degradatory 
machinery (such as Smurf1, Smurf2 or other ubiquitin ligases) at a slower rate. This 
could effectively explain why we see increased receptor levels, SARA levels, and 
reduced SARA-Smad2 dissociation, as internalization is required for the degradation of 
these proteins as well as proper Smad2 dissociation and nuclear translocation [1, 8]. 
Furthermore, if this is the case, understanding the mechanisms that control the reduced 
degradation patterns and altered subcellular itinerary of the TGF receptors is also 
needed. Certainly, a recent report implicates SARA in controlling the trafficking patterns 
of the EGFR through the recruitment of the ubiquitination factor RNF11 [11]. 
Importantly, aPKC is a known binding partner of the TGF pathway ubiquitin ligsase 
Smurf1, and has been shown to recruit Smurf1 to degrade substrate proteins such as 
RhoA [12]. It would be interesting to test whether aPKC was facilitating the recruitment 
of Smurf1 to the TGF receptor-SARA complex to control their correct trafficking and 
degradation. If this was the case, presumably in aPKC knockdown cells a lack of Smurf1 
recruitment could lead to an accumulation of both TGF receptors and SARA, as well as 
mislocalized intracellular targeting of the activated complex. Thus, whether the 
ubiquitination status of TGF receptor complexes is altered to change subcellular 
trafficking is an area that requires further investigation. Also, we have not examined 
whether aPKC controls these dynamics through phosphorylation of the TGF receptors. 
Interestingly, aPKC can phosphorylate the EGFR to change its trafficking itinerary from 
degradation to recycling [13]. Whether aPKC can phosphorylate TGF receptor 
complexes is an area that needs to be addressed. Another finding we made in chapter 4 
was that aPKC knockdown increased TGF-receptor-TRAF6 complexes which enhanced 
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p38 MAPK signalling and subsequent apoptotic response. Interestingly, although it is 
well accepted that TGF can activate MAPK pathways, there has been skepticism about 
the physiological importance of TGF-p38 MAPK signalling, particularly because the 
activation does not occur in all cell lines, and many times the activation is much lower 
than classical activators of the p38 MAPK pathway. My data certainly suggests that 
enhanced TGF-TRAF6 receptor complex formation stimulates TGF-p38 MAPK 
signalling; and importantly, this can be controlled by the expression of other proteins, 
such as aPKC. This suggests that the variability seen in TGF-p38 MAPK activation in 
various cell lines and models may be due to differences in the endogenous levels of 
TGF receptor-TRAF6 complexes. How aPKC knockdown is stabilizing TRI-TRAF6 is 
a question that still remains to be answered. Interestingly, some of the ideas mentioned 
above for the SARA-Smad2 pathway, may also hold here. aPKC may be involved in 
recruiting a ubiquitin ligase (such as Smurf1) for the degradation of TRI-TRAF6 
complexes upon internalization. Thus, in aPKC knockdown cells, TRI-TRAF6 is 
degraded less, and thus can activate p38 MAPK to a greater degree. Again, understanding 
whether ubiquitination, or aPKC phosphorylation is involved in this process would be 
interesting areas of study.  
   Although I have identified aPKC as an important player in signalling patterns of 
the TGF receptors, clearly, a more thorough analysis of the internalization patterns of 
the TGF receptors, and the mechanisms that control them is warranted for 
understanding both Smad and non-Smad signalling pathways.  
 
5.2.2 Atypical Protein kinase C phosphorylates Par6 to facilitate EMT  
EMT is an important step in tumour progression, as it signifies that the once 
immobile mass of growing carcinoma cells have escaped the physical constraints of the 
epithelium and are gaining the capacity for independent movement. The TGF-Par6 axis 
was previously shown to be an important pathway in EMT through TRII mediated 
phosphorylation of Par6 [2, 3]. In chapter 3, I showed that both aPKC isoforms ( and ) 
phosphorylate Par6 on S345 to stimulate EMT [14].  Importantly, this was the first time 
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another protein other than TRII was shown to phosphorylate Par6 on this critical 
residue.  Interestingly, I found that aPKC co-localizes with TGF receptors at the leading 
edge of migrating cells, and that aPKC associates with TGF receptors through Par6. 
Furthermore, upon TGF stimulation, which triggers EMT in A549 adenocarcinoma 
cells, aPKC becomes activated as indicated by an increase in its phosphorylation status. 
We found that both aPKC isoforms are able to phosphorylate Par6, and that both the 
association with Par6 and kinase activity of aPKC were important for this 
phosphorylation event. When we silenced aPKC using siRNA we significantly reduced 
the ability of TGF to target RhoA and E-cadherin for degradation and subsequently 
actin stress fibre formation, EMT and migration were reduced (Figure 5.2A). When we 
re-introduced a phospho-mimetic Par6 into aPKC silenced cells, we rescued EMT as 
measured by a restored loss in RhoA and E-cadherin [14].   
 Given the recent important roles reported for both Par6 and aPKC in the 
generation and progression of various cancers, we believe that Par6 phosphorylation by 
aPKC may be central to various extrinsic cues that can lead to the EMT. In addition to 
TGF stimulation, EMT has been shown to occur in response to ErbB2 receptor tyrosine 
kinase activation [15].  Indeed, Aranda and colleagues have shown that activation of 
ErbB2 leads to a complex formation between the ErbB2 receptor and Par6/aPKC and 
disrupts apical-basal polarity and tissue architecture. They further showed that inhibiting 
the interaction of Par6 and aPKC (using a Par6 mutant that does not bind aPKC) was 
required for this ErbB2 induced disruption of acinar formation in mammary epithelial 
cells [15]. Although Par6 S345 phosphorylation was not examined in this report, Par6 
phosphorylation was later shown to be an important event in acinar disruption in murine 
mammary gland cells downstream of TGF[3]. Given the observations that both 
phosphorylation, and aPKC-Par6 interaction are important for acinar disruption and 
tissue organization in mammary gland epithelial cells, it would be interesting to 
investigate whether aPKC induced Par6 phosphorylation is a common theme in other 
tumour promoting pathways.  
It is becoming increasingly clear that aPKC can execute its functions through 
phosphorylation events of interacting partners. Another interesting substrate of aPKC is 
Lgl, a member of the Scribble complex. First identified in D. Melanogaster, Scribble 
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complex proteins (which also include Scrib and Dlg) are localized to the basolateral 
regions of the cell and they help maintain normal junctional complexes and cell polarity 
[16-18]. Loss of Scribble complex proteins through genetic deletion results in a loss of 
cell polarity and growth control [16-18].  Interestingly, expression or mislocalization of 
these proteins is often observed in various carcinomas and all three members of the 
Scribble complex are considered tumour suppressor genes [18-20]. Importantly, active 
aPKC can phosphorylate Lgl to regulate its displacement from the apical domain, and in 
turn, Lgl inhibits aPKC function at the basolateral domain [21-25].  This mutual 
exclusion of aPKC and Lgl is important for tissue homeostasis, as cells overexpressing 
aPKC or depleted of Lgl leads to loss in cell polarity and hyperproliferation [23]. 
Strikingly, Lgl levels are reduced in various human solid tumours including human 
prostate, breast, ovary and lung [26] and reduced Lgl function correlates with reduced 
cell-cell adhesion [27]. Given the roles of both Lgl and Par6 phosphorylation by aPKC in 
cell-cell adhesions, it would be interesting to examine whether aPKC-Par6 
phosphorylation plays a role in Lgl localization and activity during cancer progression – 
as it is likely that there is interplay between polarity complexes during the dissolution of 
tissue structure and tumour development.  
A recent report has highlighted a role for another member of the polarity complex, 
Par3, in protecting against cancer progression [28]. Par3 which is an interacting partner 
of both Par6 and aPKC, as well as an inhibitor of aPKC kinase activity, has been reported 
to be a suppressor of breast cancer metastasis [28]. The authors report a down-regulation 
of Par3 in human breast cancer and that the loss in expression of Par3 inhibits E-cadherin 
junction stability, disrupts actin dynamics, and decreases cell-cell cohesion via a Tiam1-
Rac-GTP pathway in mammary epithelial cells. Interestingly, knockdown of Par3 induces 
metastasis without an overt loss in E-cadherin or an increase in classical EMT phenotype 
(as measured by classical markers of EMT, snail and fibronectin). Instead, the loss of 
Par3 was observed to increase E-cadherin recycling from the membrane, thereby 
reducing the levels of stable and immobile E-cadherin at cell junctions which ultimately 
leads to a decreased cell-cell cohesion [28]. Our own results suggest that knockdown of 
aPKC increases basal E-cadherin levels in lung adenocarcinoma cells (chapter 3), and it 
would be interesting to explore E-cadherin recycling and junctional stability.  
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Interestingly, another report outlines a role for E-cadherin translocation during EMT 
through the endocytic adaptor protein Numb [29]. In epithelial cells, Numb was described 
to stabilize junctional complexes by binding to E-Cadherin and Par3 at adherens 
junctions [29]. However, upon stimulation with the EMT inducing growth factor HGF 
(hepatocyte growth factor), Numb dissociated from E-cadherin, and then sequestered the 
aPKC-Par6 complex to the plasma membrane and the cytosol. Both Par3 and E-cadherin 
were re-localized from the junction, leading to reduced cell-cell adhesion and the 
facilitation of EMT [29, 30]. Interestingly, aPKC has been shown to phosphorylate Numb 
to control integrin endocytosis at the leading edge of migrating cells, outlining an 
important role for aPKC in the normal endocytic function of Numb [31]. Given the 
recently described role for Numb in E-cadherin and Par complex subcellular localization 
and subsequently cell-cell adhesion and EMT, it would be interesting to examine whether 
Par6 phosphorylation directs the function of the endocytic adaptor Numb to control E-
cadherin trafficking and recycling during EMT.  Studying E-cadherin trafficking and 
recycling is particularly interesting since as mentioned earlier, aPKC can alter the 
trafficking, recycling and degradation patterns of membrane receptors [32, 33] and 
furthermore, Par complex proteins have already been implicated in membrane 
endocytosis and vesicular trafficking [34, 35]. Whether other polarity complex proteins 
regulate normal and/or oncogenic cellular processes through vesicular trafficking is a 
promising future area of study.    
Thus, the Par polarity complex is considered to be involved in various cellular 
polarization processes that facilitate directional cell migration, apico-basal polarity and 
embryonic development.  However, recent advances in our understanding of this complex 
reveal that these proteins can have different functions depending on the interacting 
partners, extracellular stimuli, and the cellular context in which the signalling occurs.  
We have described above how the phosphorylation of Par6 leads to EMT, but 
Par6 phosphorylation has also been reported to regulate axon specification in naïve 
neurites [36], and invasive potential of epicardial cells [37]. Thus, the cellular outcomes 
of Par6 phosphorylation may depend on the cell type, subcellular localization, availability 
of binding partners and the combination of various extracellular and intracellular cues. 
How aPKC phosphorylation of Par6 plays a role in these multiple contexts is an area that 
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will require further investigation (Figure 5.2B). Specifically, we will likely require a 
better understanding of the signalling patterns of the Par interactome, and whether aPKC-
Par6 phosphorylation alters the function and activation patterns of downstream effectors 
(and vice versa). Both Par6 and Par3 act as scaffolding nodes for various binding partners 
and effectors that allows this complex to elicit variable signals for multiple pathways. 
The factors that determine the binding and/or activation of specific GTPases, as well as 
the factors that control aPKC activity will likely be important in understanding how Par 
proteins regulate growth, organization, and the maintenance of cellular homeostasis, but 
also on cellular transformation and tumour progression.  
Much work suggests that aPKC may be an attractive clinical target for protecting 
against tumour progression in certain contexts. In support of this idea, the loss of function 
experiments of aPKC in lung cancer cells reduces invasive activity and reduces tumour 
growth and expansion in vivo [38, 39] and a targeted small molecule inhibitor of aPKC-
Par6 signalling is currently in early stage clinical trials for lung cancer [40-42]. Future 
work will uncover the intricacies of Par signalling pathways in normal and oncogenic 
circumstances. These new discoveries will undoubtedly help us further understand how 
polarity proteins control basic biological processes, as well as identify targets to block 
oncogenesis.   
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Figure 5.2 
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Figure 5.2.  Roles for Par6 phosphorylation in EMT and Migration 
(A) Proposed model for aPKC-Par6 induced plasticity.  TGF-dependent Par6 
phosphorylation in epithelial cells leads to junctional complex disassembly through 
Smurf1 mediated ubiquitination and degradation of RhoA. Degradation of RhoA leads to 
the depolymerization of filamentous actin (F-Actin) and loss of structural integrity of the 
cortical actin cytoskeleton, dissolution of junctional complexes, and subsequent reduction 
in cell-cell adhesion. Par6 phosphorylation may also regulate Rho-GTPases at the leading 
edge during cell migration. The aPKC-Par6 complex recruits Smurf1 to degrade RhoA at 
the leading edge to promote protrusive activity. Par6 phosphorylation has also been 
reported to specify axon differentiation, although the role of aPKC isoforms has not been 
defined. 
(B) Major questions surrounding aPKC-Par6 phosphorylation. Understanding Par 
signalling will involve the investigation of the stimuli that control aPKC activation with 
respect to Par6 phosphorylation, how the Par interactome modifies and is modified by 
Par6 phosphorylation, and whether these factors contribute to homeostatic and oncogenic 
processes. 
 
 
 
 
 
 
 
 
236 
 
5.3 Limitations and Future Directions 
The work carried out in this thesis was carried out in established cell lines using 
human recombinant TGF protein, and the majority of it was conducted to gain a 
mechanistic understanding of TGF signalling processes. Using cell lines provides a well 
characterized simplified platform that can be easily evaluated to understand the 
mechanistic biology of the TGF system. However, cell lines may not be fully 
representative of the results one might gather in an in vivo system. It would be interesting 
to test whether aPKC affects TGF induced EMT and apoptotic response using animal 
tumour models. Indeed, in line with our data, others have examined the roles of aPKC 
and Par6 in oncogenesis using mouse models [3, 38, 39] and have reported both aPKC 
and Par6 expression and activity are involved in tumour progression and EMT. However, 
how aPKC drives Par6 and or TGF mediated EMT in an in vivo setting is an area that 
deserves further exploration. Along with this, it would be interesting to examine human 
patient tumour samples and examine whether elevated P-Par6 levels correlate with aPKC 
expression levels. Furthermore, another limitation of our studies is that we have been 
studying these signalling pathways in 2-dimensional cell culture. Although this approach 
is widely used, analysis of EMT and tumour progression in 3D culture would also be a 
natural progression to understand the contributions of components of the ECM in our 
signalling system. It would be extremely interesting to look at epithelial cell acini 
formation and EMT in 3D cultures. Doing this while manipulating levels of aPKC and 
Par6 in the context of TGF signalling would further our understanding of the role of 
polarity protein dynamics in cell-cell junctional dynamics. Important contributions of the 
ECM and integrin signalling have been reported before with respect to aPKC and Par6 
polarization processes [43] and thus it would be exciting to study whether Par6 
phosphorylation by aPKC plays a role in acini formation and or disruption by TGF.  
Another limitation of my studies is that I have not been assigning isoform specific 
functions between PKC and PKC. However, whenever I could, I examined PKC and 
PKC individually to assess their contributions to TGF effects. For example, in chapter 
2, I knocked down each aPKC individually and examine P-Smad2 levels as well as 
receptor degradation, in chapter 3 I overexpressed each aPKC individually and examined 
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Par6 phosphorylation, and in chapter 4 I knocked down each aPKC individually and 
assessed P-p38 MAPK levels. Importantly however, knockdown of PKC alone, resulted 
in compensatory expression of PKC, necessitating the need for a double knockdown. In 
any case, for the most part, knockdown of each aPKC individually yielded similar 
responses in our analyses, and the double knockdown had the most robust effect. For 
example, in chapter 4, knock down of each aPKC individually increased p38 MAPK 
phosphorylation – but the double knockdown enhances p38 phosphorylation to the 
greatest degree. A similar trend was evident for the loss of E-cadherin. Thus, for the 
readouts that we examined, it seemed that both aPKC  and  function redundantly. 
However, this does not mean that each of these PKCs is functionally redundant in a 
normally physiological setting. Although in our cell culture models we find they can 
execute some similar functions, possibly their tissue expression patterns and substrate 
availability may dictate their true individual function in vivo.  
 Another limitation of my studies is that I often use overexpression to study 
protein-protein interactions. The reason I do this is primarily due to a lack of quality 
antibodies for immunoprecipitation of endogenous proteins, this is particularly true for 
the TGF receptors and Par6. In any case, most of the interactions we have studied have 
been reported before. For example, in chapter 3, I showed that the interaction of aPKC 
with the TGF receptors occurs through Par6. A similar interaction has been reported 
before for aPKC[2]. The interaction between aPKC and the TRI scaffolded by Par6 
has been difficult to observe using endogenous proteins partly due to the lack of quality 
reagents, but also possibly related to my finding that aPKC reduces TGF receptor 
complexes. I showed in chapter 2 and 3 that aPKC expression can reduce TGF receptor 
expression, as well as displace Par6 from the complex.  This suggests that aPKC binding 
may be involved in the controlled regulation of TRI-Par6 complexes, making the 
detection of endogenous interactions challenging. Thus, future studies might include 
detecting the endogenous interaction of aPKC with TGF receptors in the presence of a 
proteasome and/or lysosome inhibitor to test if that theory holds true. Furthermore, the 
utilization of I
125
 TGF crosslinked to the receptors (as I utilized in chapter 2 for 
degradation studies) may also increase the sensitivity of the TGF receptor signal 
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following immunoprecipitation of aPKC.  Importantly, whenever possible I attempted to 
immunoprecipitate endogenous proteins (for e.g in chapter 4, I precipitated endogenous 
Smad2 to assess endogenous Smad4 or SARA association).      
 Another area in which I was limited was in the ability to assess TGF receptor 
trafficking in human cells. Our lab used HAT cells (which are mink lung cells stably 
expressing HA tagged TRII) to study TGF receptor trafficking. This is primarily due to 
a lack of antibodies for the TGF receptors sensitive enough to study using 
immunofluorescence microscopy. Because the mink genome has not been sequenced, we 
did not have the resources to knockdown aPKCs as we did in human cells. In the future, 
it would be extremely interesting to conduct a detailed analysis of TGF receptor 
internalization dynamics in aPKC knockdown cells. This may require the generation of 
human cells stably expressing TRII. Another approach would be to use biotinylated-
TGF which would allow for the study of the internalization of activated TGF 
receptors from the cell surface. Coupled with higher resolution confocal microscopy, one 
could analyze receptor dynamics and study the residence time of activated receptors in 
various intracellular compartments in aPKC knockdown cells (caveolae, early and late 
endosome, and lysosomes) (Figure 5.3). This may shed light onto whether Smad2 
dissociation from SARA occurs more efficiently at specific points in the endocytic 
pathway, or whether TRI-TRAF6 complexes are more likely to persist due to an 
increased residence time in one particular intracellular compartment. Interestingly, the 
shuttling ubiquitin binding protein p62 is known to bind both TRAF6 and aPKC to 
control the intracellular trafficking dynamics and signalling potential of various receptors 
[33, 44, 45]. Recent reports indicate that p62 acts as a signalling hub an can recruit and 
oligomerize various signalling molecules to control cell survival, apoptosis, and protein 
degradation and has important roles in cancer progression (reviewed in [46]). Using 
overexpression models, in preliminary analysis I have found that p62 immunoprecipitates 
with the TGF receptors (data not shown). It would be interesting to examine whether 
p62 plays a role in the shuttling dynamics and intracellular itinerary of the TGF 
receptors to control the pathways I have described in this thesis. This remains a 
possibility as p62 is involved in the function of TRAF6 [44], as well as in lysosome 
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targeting of aPKC [33]. Examining whether p62 functions in the TGF pathway deserves 
further exploration.       
 All in all, a thorough and detailed analysis of TGF receptor intracellular 
trafficking dynamics in aPKC knockdown cells would shed light on how aPKC may be 
controlling signalling patterns. Furthermore, it is important to explore some of the 
mechanisms we have identified in an in vivo setting to confirm these findings in a more 
physiologically relevant model.  
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Figure 5.3.  aPKC may control the subcellular itinerary of activated TGF receptor 
complexes to control specific TGF signalling outcomes 
TGF receptors internalize into two distinct endocytic pathways. Clathrin-dependent 
internalization into the early endosome is important for propagating signals, whereas the 
caveolin-1-positive membrane raft compartment is involved in receptor degradation. 
aPKC plays roles in regulating the levels of TGF receptor complexes. This may be 
occurring through a co-ordinated signalling effort between aPKC and binding partners 
such as the late endosome sequestering protein p62, and the polarity protein adaptor Par6. 
Detailed understanding of how aPKC controls the intracellular itinerary of TGF 
receptors is not known (indicated by question marks). An analysis of how/whether aPKC 
controls these dynamic trafficking patterns through these intracellular compartments is 
warranted.     
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5.4 Conclusions 
In conclusion, I have demonstrated that aPKC expression and activity are 
intricately linked to the control of multiple TGF pathways, including Smad2, Par6 and 
p38 MAPK. I have made the novel finding that the modulation of aPKC activity or 
expression alters the way non-small cell lung cancer (NSCLC) cells respond to TGF 
signalling by altering specific TGF-dependent pathways. I have provided mechanistic 
insight into how aPKC is involved in each of the mentioned pathways, as well as 
generated future avenues of research that deserve further exploration.  Given the 
important roles of TGF signalling in developmental processes, cellular homeostasis, as 
well as the progression of cancer, continued understanding of the mechanisms which 
control how cells read TGF signals will further our appreciation of animal physiology in 
both the normal and diseased state.   
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Appendix 
List of Inhibitors Used 
Shown is a list of inhibitors used in these studies alongside some reported IC50 
values. 
 
1. Martiny-Baron, G., et al., Selective inhibition of protein kinase C isozymes by 
the indolocarbazole Go 6976. J Biol Chem, 1993. 268(13): p. 9194-7. 
2. de Laszlo, S.E., et al., Pyrroles and other heterocycles as inhibitors of p38 
kinase. Bioorg Med Chem Lett, 1998. 8(19): p. 2689-94. 
3. Tsubuki, S., et al., Differential inhibition of calpain and proteasome activities 
by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem, 1996. 119(3): p. 
572-6. 
4. Schneider-Poetsch, T., et al., Inhibition of eukaryotic translation elongation by 
cycloheximide and lactimidomycin. Nat Chem Biol, 2010. 6(3): p. 209-217. 
  
 
 
Inhibitor Reported Target and IC50 M Reference 
GF 109203X (GFX) PKC(IC50): (0.008) I(0.018) (0.132) (5.8) [1] 
Gö6976 PKC(IC50): (0.0023) II(0.006) (0.02) [1] 
p38 MAPK Inhibitor p38 MAPK (0.035) [2] 
MG132 Proteasome (0.1) [3] 
Cycloheximide Ribosome/translation (0.532) [4] 
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